oxidopamine has been researched along with Parkinsonian Disorders in 1048 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate etazolate against depression-like behavior and, learning and memory impairment induced by 6- hydroxydopamine (6-OHDA) rat model of Parkinson's disease (PD)." | 7.88 | Beneficial effect of etazolate on depression-like behavior and, learning, and memory impairment in a model of Parkinson's disease. ( Abuirmeileh, AN; Alzoubi, KH; Mokhemer, E, 2018) |
| "In this model of 6-OHDA-induced parkinsonism, Gst treatment in all three doses showed a dose dependent symptomatic improvement in motor imbalance (P < 0." | 5.72 | Post treatment with Gastrodin suppresses oxidative stress and attenuates motor disorders following 6-OHDA induced Parkinson disease. ( Eyvari-Brooshghalan, S; Haddadi, R; Nourouzi, N; Sabahi, M; Sadeghian, Z, 2022) |
| "levodopa is the gold standard for the treatment of Parkinson disease, but prolonged levodopa treatment often leads to the development of abnormal involuntary movements." | 5.56 | Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms. ( Gao, H; Li, W, 2020) |
| "Riluzole was administered prior to and consecutively for ten days following double lesion placement in the left-sided medial forebrain bundle and ipsilateral striatum." | 5.33 | Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). ( Diguet, E; Poewe, W; Puschban, Z; Sather, T; Scherfler, C; Stefanova, N; Tison, F; Wenning, GK, 2005) |
| " Intact male GPR88 KO mice showed diminished tacrine-induced PD-like tremor and spontaneous hyperlocomotion." | 3.96 | Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia. ( Mannoury-la-Cour, C; Mantas, I; Millan, MJ; Svenningsson, P; Yang, Y; Zhang, X, 2020) |
| " Moreover, XE991 decreased apomorphine (APO)-induced contralateral rotations, enhanced balance and coordination, and attenuated muscle rigidity in 6-OHDA-treated rats." | 3.88 | The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease. ( Chen, X; Jia, L; Liu, H; Shi, L; Xie, J, 2018) |
| "The aim of this study was to evaluate etazolate against depression-like behavior and, learning and memory impairment induced by 6- hydroxydopamine (6-OHDA) rat model of Parkinson's disease (PD)." | 3.88 | Beneficial effect of etazolate on depression-like behavior and, learning, and memory impairment in a model of Parkinson's disease. ( Abuirmeileh, AN; Alzoubi, KH; Mokhemer, E, 2018) |
| "The aim of this study was evaluation the effect of Gallic acid on movement disorders and pallidal electrical power in animal model of Parkinson's Disease (PD)." | 3.77 | Motor disorders and impaired electrical power of pallidal EEG improved by gallic acid in animal model of Parkinson's disease. ( Farbood, Y; Mansouri, SM; Sameri, MJ; Sarkaki, A, 2011) |
| "Parkinsonism was induced by 6-hydroxydopamine (6-OHDA, 8 μg/2μl/rat)." | 1.91 | Silibinin chronic treatment in a rat model of Parkinson disease: A comprehensive in-vivo evaluation and in silico molecular modeling. ( Ebadi, SA; Eyvari Brooshghalan, S; Haddadi, R; Mohajjel Nayebi, A; Sabahi, M; Sadeghian, Z, 2023) |
| "PNU reversed motor incoordination and hypokinesia induced via the intrastriatal injection of 6-hydroxydopamine and manifested by lower falling latency in the rotarod test, short ambulation time and low rearing incidence in open field test." | 1.72 | The α7 nAChR allosteric modulator PNU-120596 amends neuroinflammatory and motor consequences of parkinsonism in rats: Role of JAK2/NF-κB/GSk3β/ TNF-α pathway. ( Afify, EA; El-Ganainy, SO; El-Sayed, NS; Gowayed, MA; Matar, NA, 2022) |
| " We then assessed the efficacy of bitopertin on dyskinesia in the context of acute challenge and chronic administration studies." | 1.72 | Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat. ( Bédard, D; Belliveau, S; Bourgeois-Cayer, É; Frouni, I; Hadj-Youssef, S; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Ohlund, L; Sleno, L, 2022) |
| "In this model of 6-OHDA-induced parkinsonism, Gst treatment in all three doses showed a dose dependent symptomatic improvement in motor imbalance (P < 0." | 1.72 | Post treatment with Gastrodin suppresses oxidative stress and attenuates motor disorders following 6-OHDA induced Parkinson disease. ( Eyvari-Brooshghalan, S; Haddadi, R; Nourouzi, N; Sabahi, M; Sadeghian, Z, 2022) |
| "Chronic pain is a common and undertreated nonmotor symptom in Parkinson's disease (PD)." | 1.62 | D2 receptor activation relieves pain hypersensitivity by inhibiting superficial dorsal horn neurons in parkinsonian mice. ( Luan, YW; Tang, DL; Xiao, C; Zhou, CY, 2021) |
| " However, a U-shaped dose-response curve obtained with certain parameters may limit the therapeutic potential of this strategy and require further investigation." | 1.62 | Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat. ( Bédard, D; Frouni, I; Hamadjida, A; Huot, P; Kwan, C, 2021) |
| "Our study suggests that relief of Parkinsonism symptoms and rescue of tyrosine hydroxylase activity in dopaminergic neurons are affected by autophagy enhancing effect of WIN-1001X which the onjisaponin B is one of the major components of activity." | 1.62 | Extract of Polygala tenuifolia, Angelica tenuissima, and Dimocarpus longan Reduces Behavioral Defect and Enhances Autophagy in Experimental Models of Parkinson's Disease. ( Hur, J; Kim, J; Kim, MC; Lee, CH; Li, H; Tran, HNK; Yang, HO, 2021) |
| "Syringic acid (SA) is a polyphenolic compound which has antioxidant and anti-inflammatory properties." | 1.62 | Protective mechanism of Syringic acid in an experimental model of Parkinson's disease. ( Afşar, E; Ağar, A; Aslan, M; Bülbül, M; Güzelad, Ö; Öğüt, E; Özkan, A; Parlak, H; Sinen, O; Yıldırım, FB, 2021) |
| "In Parkinson's disease (PD), long-term administration of L-dopa often leads to L-dopa-induced dyskinesia (LID), a debilitating motor complication." | 1.62 | The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease. ( Liu, Z; Song, L; Yan, A; Yang, S; Zhao, J, 2021) |
| "CBD therapy is effective for parkinsonism-induced orofacial nociception." | 1.62 | Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats. ( Del-Bel, E; Dos-Santos-Pereira, M; Guimaraes, FS; Nascimento, GCD; Vivanco-Estela, AN, 2021) |
| "Ambroxol was administered as 400 mg/kg orally twice a day from D-28 to D-70 after the unilateral intrastriatal injection of 6-hydroxydopamine (6-OHDA) in male rats." | 1.56 | Neurorestorative effects of sub-chronic administration of ambroxol in rodent model of Parkinson's disease. ( Krishnamurthy, S; Mishra, A, 2020) |
| " Importantly, CVL-751 efficacy is observed with less of the concomitant dyskinesia side effect associated with L-DOPA treatment." | 1.56 | D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects. ( Brevard, J; Fonseca, KR; Gray, DL; Kozak, R; Popiolek, M; Trapa, P; Young, D, 2020) |
| "Dopamine replacement therapy using L-3,4-dihydroxyphenylalanine (L-DOPA) is a gold standard treatment in patients with Parkinson's disease (PD); however, chronic administration of L-DOPA causes excessive involuntary movements called L-DOPA-induced dyskinesia." | 1.56 | Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats. ( Arakawa, K; Maehara, S; Yuge, N, 2020) |
| "levodopa is the gold standard for the treatment of Parkinson disease, but prolonged levodopa treatment often leads to the development of abnormal involuntary movements." | 1.56 | Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms. ( Gao, H; Li, W, 2020) |
| "Hydroxysafflor yellow A (HSYA) has been shown to have neuroprotective effects in cerebral infarction." | 1.56 | Protective effect of hydroxysafflor yellow A on dopaminergic neurons against 6-hydroxydopamine, activating anti-apoptotic and anti-neuroinflammatory pathways. ( Chen, L; Li, Y; Nel, D; Sun, B; Wu, J; Xu, M; Yang, X; Zhang, P, 2020) |
| "Parkinson's disease is a progressive neurodegenerative disease characterized by progressive and selective death of dopaminergic neurons." | 1.51 | Induction of cross-tolerance between protective effect of morphine and nicotine in 6-hydroxydopamine-induce neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells. ( Asadi-Shekaari, M; Eftekhar-Vaghefi, SH; Elyasi, L; Esmaeili-Mahani, S, 2019) |
| "In addition, indices of astrogliosis, microgliosis, as well as oxidative stress in the striatum were determined." | 1.51 | Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease. ( Aguilera, J; Limón, ID; Martínez, I; Mendieta, L; Montes, S; Parra, I; Patricio, F; Pérez-Severiano, F; Tizabi, Y, 2019) |
| "Manganese (Mn) is an essential nutrient especially during development, but Mn overexposure (MnOE) produces long-term cognitive deficits." | 1.51 | Effects of Preweaning Manganese in Combination with Adult Striatal Dopamine Lesions on Monoamines, BDNF, TrkB, and Cognitive Function in Sprague-Dawley Rats. ( Bailey, RA; Gutierrez, A; Hemmerle, AM; Hufgard, JR; Kyser, TL; Seroogy, KB; Vorhees, CV; Williams, MT, 2019) |
| " Chronic administration of L-DOPA plus ZNS in PD model mice was shown to increase the duration and severity of LID compared with PD model mice that were treated with L-DOPA alone." | 1.51 | The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice. ( Nambu, A; Sano, H, 2019) |
| "domperidone was administered to both 6-hydroxydopamine Parkinsonism models and regular Wistar rats." | 1.51 | Cardiovascular alterations in rats with Parkinsonism induced by 6-OHDA and treated with Domperidone. ( Britto, LRG; Faber, J; Ferraz, HB; Oliveira, LF; Rodrigues, LD; Scorza, CA; Scorza, FA; Shinoda, L, 2019) |
| " However, its long-term use is limited due to motor complications such as wearing-off and dyskinesia." | 1.48 | Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements. ( Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H, 2018) |
| "Then, catalepsy and motor balance were induced by unilateral infusion of 6-OHDA (8 μg/2 μl/rat) into the SNc." | 1.48 | Gastrodin microinjection suppresses 6-OHDA-induced motor impairments in parkinsonian rats: insights into oxidative balance and microglial activation in SNc. ( Haddadi, R; Nadi, F; Poursina, M; Zeraati, F, 2018) |
| "The present study demonstrates that hemiparkinsonism is associated with a profound reorganization of the hierarchical organization of directed influence patterns among brain areas, perhaps reflecting compensatory processes." | 1.46 | Alterations in Functional Cortical Hierarchy in Hemiparkinsonian Rats. ( Berendse, HW; Bezard, E; Boraud, T; Jávor-Duray, BN; van der Roest, M; Vinck, M; Voorn, P, 2017) |
| "The onset of motor deficits in parkinsonism is thought to result from dopamine (DA) loss-induced corticostriatal disruption and the development of excessive cortico-basal ganglia synchronization." | 1.46 | Frequency-Dependent Corticostriatal Disinhibition Resulting from Chronic Dopamine Depletion: Role of Local Striatal cGMP and GABA-AR Signaling. ( Flores-Barrera, E; Jayasinghe, VR; Tseng, KY; West, AR, 2017) |
| "Optical stimulation did not ameliorate parkinsonism in l-dopa-naïve mice." | 1.46 | Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice. ( Bordia, T; Perez, XA; Quik, M; Zhang, D, 2017) |
| "IP treatment with levodopa also produced contralateral rotation in PD induced rats, and showed anti-Parkinson-like action." | 1.43 | CART modulates the effects of levodopa in rat model of Parkinson's disease. ( Kokare, DM; Shelkar, GP; Subhedar, NK; Upadhya, MA, 2016) |
| "Although dopamine replacement therapy with L-DOPA in Parkinson's disease initially reduces motor symptoms, its chronic use often leads to the development of abnormal involuntary movements known as L-DOPA-induced dyskinesia." | 1.43 | Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats. ( Bishop, C; Conti, MM; Eissa, S; Goldenberg, AA; Kuberka, A; Lindenbach, D; Mohamed, M, 2016) |
| "L-3,4-dihydroxyphenylalanine (L-dopa) remains the most effective therapy for Parkinson's disease (PD), but its long-term administration is associated with the development of debilitating motor complications known as L-dopa-induced dyskinesia (LID)." | 1.43 | Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats. ( Cheng, J; Fan, Q; Gan, J; Hu, R; Li, L; Liu, Z; Song, L; Wu, N; Zhang, Z; Zhou, M, 2016) |
| "Three parkinsonism models using neurotoxin 6-OHDA and pesticides rotenone and paraquat were reproduced in Wistar rats and parameters of astrocyte processes in the striatum (axon number and length, area occupied by them, and axon branching pattern) detected by immunohistochemical reaction for acid glial fibrillary protein were studied by computer morphometry." | 1.43 | Quantitative Evaluation of Changes in the Striatal Astrocyte Axons in Simulated Parkinsonism. ( Dikalova, YV; Khudoerkov, RM; Sheloukhova, LI; Voronkov, DN, 2016) |
| " We used the 6-hydroxydopamine (6-OHDA) rat model of PD treated with a three-week dosing regimen of L-DOPA plus the dopa decarboxylase inhibitor benserazide (4 mg/kg and 7." | 1.43 | Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat. ( Black, MA; Dearden, PK; Duncan, EJ; Gemmell, NJ; Parr-Brownlie, LC; Reynolds, JN; Smith, LM, 2016) |
| "Severity of 6-OHDA-induced Parkinsonism was assessed by conventional behavioural tests." | 1.43 | Pretreatment with potassium channel blockers of 4-aminopyridine and tetraethylammonium attenuates behavioural symptoms of Parkinsonism induced by intrastriatal injection of 6-hydroxydopamine; the role of lipid peroxidation. ( Alipour Heidari, M; Dargahi, T; Faraji, A; Fraidouni, N; Haghdoost-Yazdi, H; Mahmudi, M; Piri, H, 2016) |
| "Depression is a common symptom in Parkinson's disease (PD); however, its pathophysiology is unclear." | 1.43 | Serotonin7 receptors in the lateral habenular nucleus regulate depressive-like behaviors in the hemiparkinsonian rats. ( Du, CX; Han, LN; Liu, J; Sun, YN; Wang, T; Zhang, J; Zhang, L; Zhang, YM, 2016) |
| " In the full lesion model, vehicle dosing or liraglutide treatment was applied for a total of six weeks starting three weeks pre-lesion, or administered for three weeks starting on the lesion day." | 1.43 | Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease. ( Barkholt, P; Fabricius, K; Hansen, HH; Jelsing, J; Knudsen, LB; Mikkelsen, JD; Pyke, C; Vrang, N, 2016) |
| " In this study we investigated the effect of chronic administration of buspirone and fluoxetine on cerebrospinal fluid (CSF) levels of inflammatory cytokines, TNF-α, IL-1β and IL-6 in 6-hydroxydopamine (6-OHDA)-lesioned rats." | 1.42 | Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats. ( Farajnia, S; Haddadi, R; Nayebi, AM; Sharifi, H, 2015) |
| "L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective treatment for Parkinson's disease, but chronic administration is complicated by the development of dyskinesia." | 1.42 | L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. ( Brotchie, JM; Espinosa, MC; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Reyes, MG, 2015) |
| " Levodopa-induced dyskinesias (LID) can be modeled in rats with unilateral 6-OHDA lesions via chronic administration of levodopa, which causes increasingly severe axial, limb, and orofacial abnormal involuntary movements (AIMs) over time." | 1.42 | Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. ( Carta, AR; Cassano, T; Giuffrida, A; Macheda, T; Martinez, AA; Morgese, MG; Paquette, MA; Pisanu, A; Seillier, A, 2015) |
| "Lactacystin is a selective UPS inhibitor recently used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD)." | 1.42 | Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. ( Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P, 2015) |
| " Long-term administration of L-3,4-dihydroxyphenylalanine (L-DOPA) leads to the development of severe motor side effects such as L-DOPA-induced-dyskinesia (LID) in PD." | 1.42 | Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. ( Hwang, BY; Lee, CK; Lee, MK; Park, HJ; Park, KH; Shin, KS; Zhao, TT, 2015) |
| "Rats treated with oleanolic acid 7 days pre- and 1 day post-lesion had more dopamine in the striatum than the non-treated or the 7 days after lesion rats." | 1.42 | Early use of oleanolic acid provides protection against 6-hydroxydopamine induced dopamine neurodegeneration. ( Daniels, WM; Mabandla, MV; Nyoka, M, 2015) |
| "The increase in dyskinesias when parkinsonism becomes bilateral was mostly due to an increase in orolingual dyskinesias associated to a increase in PDyn mRNA expression." | 1.42 | From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms. ( Bonastre, M; Cortés, R; Marin, C; Mengod, G; Rodríguez-Oroz, MC, 2015) |
| "Constipation is extremely common in patients with Parkinson's disease (PD) and has been described in PD animal models." | 1.42 | Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: relevance to gastrointestinal dysfunctions in Parkinson's disease. ( Ambrosi, G; Balestra, B; Blandini, F; Bonizzi, A; Cerri, S; Ferrigno, A; Ghezzi, C; Levandis, G; Pastoris, O; Rizzo, V; Siani, F; Vairetti, M; Vicini, R, 2015) |
| "Gastroparesis is a common non-motor system symptom of Parkinson's disease (PD)." | 1.40 | The role of the vagal pathway and gastric dopamine in the gastroparesis of rats after a 6-hydroxydopamine microinjection in the substantia nigra. ( Chen, CL; Fan, RF; Feng, XY; Li, LS; Ren, QZ; Song, J; Zhang, XL; Zhang, Y; Zheng, LF; Zhu, JX, 2014) |
| "For this purpose, we induced hemi-Parkinsonism by unilateral intranigral injection of 6-hydroxydopamine (6-OHDA, 8 μg/5 μl saline-ascorbate)." | 1.40 | Protective effects of Althaea officinalis L. extract in 6-hydroxydopamine-induced hemi-Parkinsonism model: behavioral, biochemical and histochemical evidence. ( Alirezaei, M; Rezaei, M, 2014) |
| "We hypothesize that parkinsonism-associated electrophysiological changes constitute an increase in neuronal firing pattern disorder and a concomitant decrease in information transmission through the ventral basal ganglia, and that effective DBS alleviates symptoms by decreasing neuronal disorder while simultaneously increasing information transfer through the same regions." | 1.40 | Deep brain stimulation of the subthalamic nucleus reestablishes neuronal information transmission in the 6-OHDA rat model of parkinsonism. ( Dorval, AD; Grill, WM, 2014) |
| " Mitochondrial dysfunction, motor behavior asymmetry, and dopaminergic neuronal cell loss correlated with dosage (1." | 1.40 | 6-Hydroxydopamine impairs mitochondrial function in the rat model of Parkinson's disease: respirometric, histological, and behavioral analyses. ( Debska-Vielhaber, G; Gellerich, FN; Gizatullina, Z; Heinze, HJ; Kupsch, A; Panther, P; Schmidt, W; Schwegler, H; Striggow, F; Vielhaber, S; Voges, J, 2014) |
| "Depression is a common symptom in Parkinson's disease (PD), but its pathophysiology remains unclear." | 1.40 | Activation of prelimbic 5-HT1A receptors produces antidepressant-like effects in a unilateral rat model of Parkinson's disease. ( Chen, L; Guo, Y; Hui, YP; Liu, J; Qiao, HF; Wang, Y; Zhang, L; Zhang, QJ, 2014) |
| "Deferoxamine (DFO) has shown therapeutic promise for the treatment of Parkinson׳s disease (PD) as it has reduced both behavioral and biochemical deficits when injected into the brain of rodent models of PD." | 1.40 | Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease. ( Arneson, LC; Crow, JM; Faltesek, KA; Fine, JM; Forsberg, AC; Frey, WH; Hanson, LR; Mohan, KG; Renner, DB; Wong, JC, 2014) |
| " It is established that the antidyskinetic effect of the injectable dosage form of a new antiparkinsonian drug hemantane (5 mg/kg) after a single intravenous administration is weaker than that of the most effective in clinical practice antidyskinetic drug amantadine (20 mg/kg)." | 1.40 | [Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome]. ( Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA, 2014) |
| " Three or 14 days after lesion, rats were dosed with XPro®1595 (10 mg/kg in saline, subcutaneous) every third day for 35 days." | 1.40 | Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. ( Barnum, CJ; Chang, J; Chen, X; Chung, J; Grigoryan, N; Tansey, MG; Tesi, RJ; Williams, M, 2014) |
| "Melatonin treatment significantly decreased COX, PGE2 and caspase-3 activity, increased Bcl-2 and had no effect on NF-κB levels in experimental PD." | 1.40 | Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease. ( Agar, A; Aslan, M; Dilmac, S; Gemici, B; Kaya, Y; Ogut, E; Ozkan, A; Ozsoy, O; Tanriover, G; Yildirim, FB, 2014) |
| "The effects of berberine on long-term administration of L-DOPA in 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson's disease (PD) were investigated." | 1.39 | Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. ( Choi, HS; Choi, SO; Kwon, IH; Lee, MK; Shin, KS; Suh, KH; Zhao, TT, 2013) |
| "L-DOPA alleviates the motor symptoms of Parkinson's disease, but its long-term use is associated with undesirable dyskinesia." | 1.39 | Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice. ( Aguiar, AS; Córdova, FM; Cunha, RA; Glaser, V; Hoeller, AA; Latini, A; Leal, RB; Moreira, EL; Oliveira, PA; Prediger, RD; Walz, R, 2013) |
| "Then, catalepsy was induced by unilateral infusion of 6-OHDA (8μg/2μl/rat) into the central region of the SNc." | 1.39 | Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats. ( Brooshghalan, SE; Haddadi, R; Mohajjel Nayebi, A, 2013) |
| " Furthermore, the stereological analysis of the SN volume showed that chronic administration of l-DOPA evoked a hypertrophy of the ipsilateral SN when compared to the contralateral side." | 1.39 | Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine. ( Czarnecka, A; Domin, H; Konieczny, J; Lenda, T; Lorenc-Koci, E; Smiałowska, M, 2013) |
| " The long-term use of LD is limited by the development of L-DOPA-induced dyskinesias and dystonia." | 1.39 | The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia. ( Aley-Medina, P; Anaya-Martínez, V; Avila-Costa, MR; Espinosa-Villanueva, J; García-Ruiz, R; Gutiérrez-Valdez, AL; Montiel-Flores, E; Reynoso-Erazo, L; Sánchez-Betancourt, J; Torres-Esquivel, C; Tron-Alvarez, R, 2013) |
| " The injection of 10 nmol of AMG9810 for a single dose (AMG1) and for 2 weeks (AMG14) partially attenuated the hypokinesia shown by these animals in motor function evaluation tests, whereas chronic administration of AMG had destructive effects on learning and memory in 6-OHDA-treated rats." | 1.39 | Pharmacological blockade of TRPV1 receptors modulates the effects of 6-OHDA on motor and cognitive functions in a rat model of Parkinson's disease. ( Allahtavakoli, M; Asadi-Shekaari, M; Esmaeli-Mahani, S; Nazeri, M; Razavinasab, M; Shabani, M; Shamsizadeh, A; Sheibani, V, 2013) |
| "In order to assess whether caffeine and theophylline have the same potency and efficacy to reverse the impairment of motor function caused by acute or chronic interruption of striatal dopamine transmission, a comparison of their dose-response relationship was made in the acute model of haloperidol-induced catalepsy, and the chronic model of unilateral lesion of the dopamine nigrostriatal pathway with 6-hydroxydopamine." | 1.39 | Caffeine has greater potency and efficacy than theophylline to reverse the motor impairment caused by chronic but not acute interruption of striatal dopaminergic transmission in rats. ( Acuña-Lizama, MM; Alvarez-Cervera, FJ; Bata-García, JL; Góngora-Alfaro, JL, 2013) |
| "Treatment with nifedipine could improve the apomorphine-induced rotation behavior in 6-OHDA-lesioned rats." | 1.38 | L-type Cav1.2 calcium channel is involved in 6-hydroxydopamine-induced neurotoxicity in rats. ( Ma, Z; Wang, J; Wang, R; Xie, J, 2012) |
| "Rosmarinic acid (RA) is a naturally occurring polyphenolic compound." | 1.38 | Neurorescue effect of rosmarinic acid on 6-hydroxydopamine-lesioned nigral dopamine neurons in rat model of Parkinson's disease. ( Du, X; Jiang, H; Sun, P; Wang, J; Xie, J; Xu, H, 2012) |
| "Rosiglitazone is a commonly prescribed insulin-sensitizing drug with selective agonistic activity at the peroxisome proliferator-activated receptor-γ (PPARγ)." | 1.38 | Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats. ( Koh, HC; Lee, EY; Lee, JE; Park, JH; Shin, IC, 2012) |
| " Although, using these parameters, re-exposure in the presence of saline did not induce context-dependent AIMs, a strong context-specific component of the sensitised response to l-DOPA was seen; chronic administration of drug produced a significantly stronger behavioural response in animals paired with a particular environment for drug administration than controls." | 1.37 | Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat. ( Daly, CS; Dunnett, SB; Lane, EL; Smith, GA, 2011) |
| "Treatment with sarizotan (1 or 5 mg/kg ip) dose-dependently inhibited the L: -DOPA-induced contraversive turning and AIMs." | 1.37 | Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. ( Bartoszyk, GD; Dean, O; Gerlach, M; Riederer, P; van den Buuse, M, 2011) |
| "The neuropathological hallmark of Parkinson's disease is the loss of dopaminergic neurons in the pars compacta of the substantia nigra (SNc)." | 1.37 | In vivo magnetic resonance imaging characterization of bilateral structural changes in experimental Parkinson's disease: a T2 relaxometry study combined with longitudinal diffusion tensor imaging and manganese-enhanced magnetic resonance imaging in the 6- ( Aguilar, E; Marin, C; Mullol, J; Planas, AM; Soria, G; Tudela, R, 2011) |
| "Magnolol that was administered 30 min before 6-OHDA lesion induction and then applied daily for 14 days significantly ameliorated apomorphine-induced contralateral rotation in 6-OHDA-lesioned mice, and consistently protected the decreased levels of TH protein expression in striatum." | 1.37 | Protective and restorative effects of magnolol on neurotoxicity in mice with 6-hydroxydopamine-induced hemiparkinsonism. ( Chan, MH; Chen, HH; Lin, SC, 2011) |
| "Loss of dopamine neurons in experimental parkinsonism results in altered cyclic nucleotide cAMP and cGMP levels throughout the basal ganglia." | 1.37 | PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology. ( Bernardi, G; Castelli, V; D'Angelo, V; Giorgi, M; Martorana, A; Melchiorri, G; Nuccetelli, V; Sancesario, G; Sorge, R, 2011) |
| "Although levodopa remains the most effective drug in the treatment of Parkinson's disease (PD), chronic administration of levodopa in the treatment of PD usually caused levodopa-induced dyskinesia (LID), the pathogenesis of which is poorly understood." | 1.37 | Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats. ( Cai, Y; Liu, Z; Ren, T; Wu, N; Yang, X; Yuan, W, 2011) |
| " The chronic administration of these drugs together with amantadine (20 mg/kg) accelerates the onset of latency and increases the magnitude of dyskinesia." | 1.37 | [Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome]. ( Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA, 2011) |
| "Catalepsy was induced by the unilateral infusion of 6-OHDA (8 μg/2 μl/rat) into the central region of the SNc." | 1.37 | Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats. ( Babapour, V; Mahmoudi, J; Nayebi, AM; Reyhani-Rad, S; Samini, M, 2011) |
| " However, both acute and chronic administration of S33084 enhanced L-DOPA-induced contralateral turning, suggesting potential antiparkinsonian properties." | 1.36 | The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats. ( Brocco, M; Mela, F; Millan, MJ; Morari, M, 2010) |
| "In Parkinson's disease (PD), the long term use of L-DOPA results in major adverse effects including dyskinesia or abnormal involuntary movements." | 1.36 | The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. ( Buck, K; Ferger, B, 2010) |
| " These results suggest creation of potential pro-toxic environment in the brain due to the long-term administration of L-DOPA, which may get further sensitized by the treatment of monoamine oxidase inhibitors." | 1.36 | L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation. ( Borah, A; Mohanakumar, KP, 2010) |
| "The findings implicated that the anti-parkinsonism effects afforded by octacosanol might be mediated by its neuro-microenvironment improving potency through retrieving the ratios of proNGF:NGF and the respective receptors p75NTR:TrkA in vivo." | 1.36 | Protective effects of octacosanol on 6-hydroxydopamine-induced Parkinsonism in rats via regulation of ProNGF and NGF signaling. ( Liu, YY; Wang, T; Wang, X; Yang, N; Zhu, HB; Zuo, PP, 2010) |
| " It is, therefore, suggested that the use of long-term l-DOPA therapy with isoquinoline derivatives including berberine may need to be examined for the presence of adverse symptoms." | 1.36 | Effects of berberine on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and a rat model of Parkinson's disease. ( Choi, HS; Hwang, BY; Kwon, IH; Lee, BK; Lee, CK; Lee, MK; Lim, SC; Shin, KS, 2010) |
| " In contrast, acute or chronic administration of MPEP (mGlu5 receptor antagonist) has no anticataleptic action." | 1.35 | Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. ( Amalric, M; Brotchie, JM; Johnston, TH; Lopez, S; Neuville, P; Schann, S; Turle-Lorenzo, N, 2008) |
| "Pretreatment with zaprinast reduced the severity of levodopa-induced dyskinesias, and partly prevented the decrease in cyclic nucleotides compared with pretreatment with saline-levodopa." | 1.35 | Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. ( Bernardi, G; D'Angelo, V; Esposito, Z; Giorgi, M; Martorana, A; Nuccetelli, V; Sancesario, G; Sorge, R; Stefani, A, 2008) |
| " We now show that they are associated with the chronic administration of L-DOPA prior to the transplantation surgery." | 1.35 | Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. ( Brundin, P; Cenci, MA; Lane, EL; Vercammen, L, 2009) |
| "Using the rat model of parkinsonism with an additional noradrenergic degeneration induced by the N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) toxin we evaluated whether the circling motor activity and dose-failure episodes induced by levodopa (L-DOPA) differ between single (6-OHDA) and double (6-OHDA + DSP-4) denervated animals challenged with a single daily dose of L-DOPA." | 1.35 | Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats. ( Barbanoj, M; Gich, I; Kulisevsky, J; Pérez, V; Rodríguez-Alvarez, J; Rubio, A; Sosti, V, 2009) |
| "Blocking D1-like receptors during sleep deprivation prevented persistent shortterm memory deficits." | 1.35 | Persistent short-term memory defects following sleep deprivation in a drosophila model of Parkinson disease. ( Galvin, JE; Gottschalk, L; Seugnet, L; Shaw, PJ; Suzuki, Y, 2009) |
| "Melatonin treatment significantly attenuated both the L-DOPA and MPTP-induced increases in the levels of striatal 6-OHDA, and protected against striatal DA depletion caused by the neurotoxin." | 1.35 | Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. ( Borah, A; Mohanakumar, KP, 2009) |
| "Patients with Parkinson's disease develop motor disturbances often accompanied by peripheral autonomic dysfunctions, including gastrointestinal disorders, such as dysphagia, gastric stasis and constipation." | 1.35 | Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. ( Balestra, B; Bazzini, E; Blandini, F; Cervio, M; Clavenzani, P; Colucci, M; De Giorgio, R; Faniglione, M; Greco, R; Levandis, G; Nappi, G; Tassorelli, C; Tonini, M; Vigneri, S, 2009) |
| "Substance P is an important neurotransmitter or neuromodulator in central nervous system." | 1.35 | Effects of substance P on neuronal firing of pallidal neurons in parkinsonian rats. ( Chen, L; Cui, QL; Yung, WH, 2008) |
| "SUN N8075 is a novel antioxidant with neuroprotective properties." | 1.35 | Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease. ( Adachi, T; Hara, H; Izuta, H; Matsunaga, N; Oida, Y; Oyagi, A; Shimazawa, M, 2008) |
| "These behavioural changes reflect parkinsonism in this model." | 1.34 | Effect of ventrolateral thalamic nucleus lesions in the unilateral 6-hydroxydopamine rat model. ( Allbutt, H; Henderson, J; Oehrn, C, 2007) |
| "These findings support the premise that hypokinesia is associated with an increased STN neuronal activity, and that improvements of parkinsonian motor abnormalities are associated with a decrease in STN activity." | 1.34 | Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats. ( Belujon, P; Benazzouz, A; Bezard, E; Bioulac, B; Taupignon, A, 2007) |
| "Riluzole was administered prior to and consecutively for ten days following double lesion placement in the left-sided medial forebrain bundle and ipsilateral striatum." | 1.33 | Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). ( Diguet, E; Poewe, W; Puschban, Z; Sather, T; Scherfler, C; Stefanova, N; Tison, F; Wenning, GK, 2005) |
| " Catechol-O-methyltransferase (COMT) inhibitors increase the half-life and bioavailability of levodopa, providing more continuous dopamine receptor stimulation." | 1.33 | Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. ( Aguilar, E; Bonastre, M; Marin, C; Obeso, JA; Tolosa, E, 2005) |
| " The nicotinic agonists were given acutely and repeatedly either alone or in combination with a dopamine uptake inhibitor, nomifensine." | 1.33 | Comparison of the effects of nicotine and epibatidine given in combination with nomifensine on rotational behaviour in rats. ( Ahtee, L; Janhunen, S; Tuominen, RK, 2005) |
| "Levodopa-unresponsive parkinsonism is present in 80% of MSA cases, and this dominant clinical presentation (MSA-P) is associated with a combined degeneration of the substantia nigra pars compacta and the striatum in anatomically related areas." | 1.33 | In vivo models of multiple system atrophy. ( Diguet, E; Fernagut, PO; Ghorayeb, I; Tison, F, 2005) |
| "Levodopa-induced dyskinesias (LIDs) have been associated with a sequence of events that includes pulsatile stimulation of dopamine receptors." | 1.33 | Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. ( Aguilar, E; Marin, C; Obeso, JA, 2006) |
| " Individual differences in the central bioavailability of L-DOPA may provide a clue to the varying susceptibility to dyskinesia in Parkinson's disease." | 1.33 | Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. ( Carta, M; Cenci, MA; Fadda, F; Lindgren, HS; Lundblad, M; Stancampiano, R, 2006) |
| "Behaviour was evaluated by catalepsy tests and activity box." | 1.32 | Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003) |
| " Acute and chronic administration of U50,488 has been studied to evaluate the possible reversion or prevention of these levodopa effects." | 1.32 | Effect of acute and chronic administration of U50,488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa. ( Bonastre, M; Bové, J; Marin, C; Tolosa, E, 2003) |
| "The frequency of the induction of parkinsonism-like signs was minimal in the first 2 weeks and reached a maximum point 4 weeks after the 6-OHDA injection." | 1.32 | "Hydrocephalus-parkinsonism complex": progressive hydrocephalus as a factor affecting extrapyramidal tract disorder-an experimental study. ( Hidaka, M; Kim, DS; Oi, S, 2004) |
| "The characteristics of the abnormal involuntary movements observed in these animals are similar to L-dopa-induced dyskinesias in parkinsonian patients and might be useful as an experimental model for the study of L-dopa-induced dyskinesia." | 1.32 | Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats. ( Bonastre, M; Bové, J; Jiménez, A; Marin, C; Tolosa, E, 2004) |
| "Treatment with idazoxan counteracted the observed Parkinsonian behaviour in 6-OHDA-lesioned rats and increased the spontaneous open-field activity in control rats." | 1.32 | The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action? ( Schmidt, WJ; Srinivasan, J, 2004) |
| "The modified activity of STN neurons in parkinsonism may thus result in part from complex interactions between glutamatergic hyperactive fibers originating in the thalamus and the pedunculopontine nucleus and hypoactive fibers originating in the cerebral cortex." | 1.31 | Consequences of dopaminergic denervation on the metabolic activity of the cortical neurons projecting to the subthalamic nucleus in the rat. ( Féger, J; François, C; Hirsch, EC; Orieux, G, 2002) |
| " The safer and effective administration of lower doses of CsA combined with enhanced BBB permeability using Cereport, offers a novel way of producing protective effects in the CNS without the toxic liabilities of high-dose CsA." | 1.31 | Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity. ( Bartus, RT; Borlongan, CV; Emerich, DF; Hoffer, BJ, 2002) |
| "Pramipexole treated animals exhibited a 29% and a 27% reduction in striatal dopamine and THir cell counts, respectively." | 1.31 | Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. ( Carvey, PM; Chen, EY; Ling, ZD; Lipton, JW; Ma, SY; Robie, HC; Tong, CW; Vu, TQ, 2000) |
| "When caffeine was removed, tolerance to bromocriptine effects was observed for 1 day only, while no tolerance was observed to pergolide." | 1.31 | Effects of sub-chronic combined treatment with pergolide and caffeine on contralateral rotational behavior in unilateral 6-hydroxydopamine-denervated rats. ( Barbanoj, M; Casas, M; Jané, F; Prat, G; Robledo, P; Rubio, A, 2000) |
| "Levodopa treatment significantly increased the expression of striatal MT-III mRNA in the non-lesioned side, but showed no significant effect in the 6-OHDA-lesioned side." | 1.31 | Expression of metallothionein-III mRNA and its regulation by levodopa in the basal ganglia of hemi-parkinsonian rats. ( Asanuma, M; Higashi, Y; Miyazaki, I; Nakanishi, T; Ogawa, N; Sogawa, CA; Tanaka, KI, 2000) |
| ", was ineffective, suggesting a bell-shaped dose-response relationship which has also been observed in other paradigms." | 1.31 | CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease. ( Hengerer, B; Spooren, WP; Waldmeier, PC, 2000) |
| " The results indicate that SCH 58261 is effective after chronic administration and suggest that SCH 58261 plus L-dopa, differently from Ldopa alone, does not produce alterations in motor responses during the course of the treatment." | 1.31 | Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. ( Morelli, M; Pinna, A, 2001) |
| " Acute and chronic administration of LY293558 was studied to evaluate the possible reversion or prevention of these levodopa effects." | 1.31 | LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. ( Agid, Y; Bonastre, M; Hirsch, EC; Jiménez, A; Marin, C; Tolosa, E; Vila, M, 2001) |
| "Neuroprotective effects of a natural antioxidant tangeretin, a citrus flavonoid, were elucidated in the 6-hydroxydopamine (6-OHDA) lesion rat model of Parkinson's disease (PD), after bioavailability studies." | 1.31 | Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. ( Christidou, M; Datla, KP; Dexter, DT; Rooprai, HK; Widmer, WW, 2001) |
| " When dosed orally, this compound potentiates the effects of L-DOPA in the 6-hydroxydopamine-lesioned rat, a model of Parkinson's disease." | 1.30 | Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists. ( Boxer, PA; Gregory, TF; Meltzer, LT; Serpa, KA; Wise, LD; Wright, JL, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (0.38) | 18.2507 |
| 2000's | 426 (40.65) | 29.6817 |
| 2010's | 523 (49.90) | 24.3611 |
| 2020's | 95 (9.06) | 2.80 |
| Authors | Studies |
|---|---|
| Iyer, V | 1 |
| Venkiteswaran, K | 2 |
| Savaliya, S | 1 |
| Lieu, CA | 2 |
| Handly, E | 1 |
| Gilmour, TP | 1 |
| Kunselman, AR | 2 |
| Subramanian, T | 3 |
| Jiang, W | 2 |
| Zou, W | 2 |
| Hu, M | 2 |
| Tian, Q | 2 |
| Xiao, F | 1 |
| Li, M | 7 |
| Zhang, P | 3 |
| Chen, YJ | 3 |
| Jiang, JM | 1 |
| Hescham, SA | 1 |
| Chiang, PH | 1 |
| Gregurec, D | 1 |
| Moon, J | 2 |
| Christiansen, MG | 1 |
| Jahanshahi, A | 2 |
| Liu, H | 4 |
| Rosenfeld, D | 1 |
| Pralle, A | 1 |
| Anikeeva, P | 1 |
| Temel, Y | 5 |
| Mendes-Pinheiro, B | 1 |
| Soares-Cunha, C | 1 |
| Marote, A | 1 |
| Loureiro-Campos, E | 1 |
| Campos, J | 1 |
| Barata-Antunes, S | 1 |
| Monteiro-Fernandes, D | 1 |
| Santos, D | 1 |
| Duarte-Silva, S | 1 |
| Pinto, L | 1 |
| José Salgado, A | 1 |
| Jiang, X | 4 |
| Liang, P | 1 |
| Wang, K | 3 |
| Jia, J | 4 |
| Wang, X | 18 |
| Jafari, F | 1 |
| Goudarzvand, M | 1 |
| Hajikhani, R | 1 |
| Qorbani, M | 1 |
| Solati, J | 1 |
| Gowayed, MA | 1 |
| El-Sayed, NS | 1 |
| Matar, NA | 1 |
| Afify, EA | 1 |
| El-Ganainy, SO | 1 |
| Frouni, I | 2 |
| Kang, W | 1 |
| Bédard, D | 2 |
| Belliveau, S | 1 |
| Kwan, C | 2 |
| Hadj-Youssef, S | 1 |
| Bourgeois-Cayer, É | 1 |
| Ohlund, L | 1 |
| Sleno, L | 1 |
| Hamadjida, A | 2 |
| Huot, P | 3 |
| Palese, F | 1 |
| Pontis, S | 2 |
| Realini, N | 1 |
| Torrens, A | 1 |
| Ahmed, F | 1 |
| Assogna, F | 1 |
| Pellicano, C | 1 |
| Bossù, P | 1 |
| Spalletta, G | 1 |
| Green, K | 1 |
| Piomelli, D | 1 |
| Calabrese, V | 1 |
| Picconi, B | 17 |
| Heck, N | 1 |
| Campanelli, F | 2 |
| Natale, G | 2 |
| Marino, G | 2 |
| Sciaccaluga, M | 2 |
| Ghiglieri, V | 11 |
| Tozzi, A | 4 |
| Anceaume, E | 1 |
| Cuoc, E | 1 |
| Caboche, J | 1 |
| Conquet, F | 1 |
| Calabresi, P | 17 |
| Charvin, D | 1 |
| Sadeghian, Z | 2 |
| Eyvari-Brooshghalan, S | 1 |
| Sabahi, M | 2 |
| Nourouzi, N | 1 |
| Haddadi, R | 6 |
| Soti, M | 1 |
| Ranjbar, H | 1 |
| Kohlmeier, KA | 1 |
| Razavinasab, M | 2 |
| Masoumi-Ardakani, Y | 1 |
| Shabani, M | 2 |
| Eyvari Brooshghalan, S | 1 |
| Ebadi, SA | 1 |
| Mohajjel Nayebi, A | 2 |
| Ji, YW | 1 |
| Zhang, X | 16 |
| Fan, JP | 1 |
| Gu, WX | 1 |
| Shen, ZL | 1 |
| Wu, HC | 1 |
| Cui, G | 2 |
| Zhou, C | 2 |
| Xiao, C | 2 |
| Liu, K | 1 |
| Song, M | 1 |
| Gao, S | 2 |
| Yao, L | 4 |
| Zhang, L | 17 |
| Feng, J | 3 |
| Wang, L | 2 |
| Gao, R | 2 |
| Wang, Y | 25 |
| de Jager, L | 2 |
| Vidigal, CB | 1 |
| de Campos, BH | 2 |
| Reginato, GS | 2 |
| Fernandes, LM | 1 |
| Ariza, D | 2 |
| Higashi-Mckeown, CM | 1 |
| Bertozzi, MM | 1 |
| Rasquel de Oliveira, FS | 1 |
| Verri, WA | 1 |
| Ceravolo, GS | 1 |
| Crestani, CC | 3 |
| Pinge-Filho, P | 2 |
| Martins-Pinge, MC | 3 |
| Nascimento, GC | 2 |
| Jacob, G | 1 |
| Milan, BA | 1 |
| Leal-Luiz, G | 1 |
| Malzone, BL | 1 |
| Vivanco-Estela, AN | 2 |
| Escobar-Espinal, D | 1 |
| Dias, FJ | 1 |
| Del-Bel, E | 5 |
| Abe, Y | 1 |
| Yagishita, S | 1 |
| Sano, H | 2 |
| Sugiura, Y | 1 |
| Dantsuji, M | 1 |
| Suzuki, T | 2 |
| Mochizuki, A | 1 |
| Yoshimaru, D | 1 |
| Hata, J | 1 |
| Matsumoto, M | 1 |
| Taira, S | 1 |
| Takeuchi, H | 1 |
| Okano, H | 4 |
| Ohno, N | 1 |
| Suematsu, M | 1 |
| Inoue, T | 1 |
| Nambu, A | 2 |
| Watanabe, M | 3 |
| Tanaka, KF | 1 |
| Aristieta, A | 4 |
| Ruiz-Ortega, JA | 3 |
| Morera-Herreras, T | 2 |
| Miguelez, C | 3 |
| Ugedo, L | 4 |
| Minaei, A | 2 |
| Haghdoost-Yazdi, H | 5 |
| Xu, M | 2 |
| Bohlen, JK | 1 |
| Moore, C | 2 |
| Nipper, MA | 1 |
| Finn, DA | 1 |
| Jones, CE | 1 |
| Lim, MM | 1 |
| Meshul, CK | 5 |
| Fine, JM | 2 |
| Stroebel, BM | 1 |
| Faltesek, KA | 2 |
| Terai, K | 1 |
| Haase, L | 1 |
| Knutzen, KE | 1 |
| Kosyakovsky, J | 1 |
| Bowe, TJ | 1 |
| Fuller, AK | 1 |
| Frey, WH | 2 |
| Hanson, LR | 2 |
| Hyland, BI | 1 |
| Seeger-Armbruster, S | 1 |
| Smither, RA | 1 |
| Parr-Brownlie, LC | 2 |
| Pak, ME | 1 |
| Ahn, SM | 1 |
| Jung, DH | 1 |
| Lee, HJ | 2 |
| Ha, KT | 1 |
| Shin, HK | 1 |
| Choi, BT | 1 |
| Mishra, A | 4 |
| Krishnamurthy, S | 2 |
| Mantas, I | 2 |
| Yang, Y | 4 |
| Mannoury-la-Cour, C | 1 |
| Millan, MJ | 4 |
| Svenningsson, P | 5 |
| Rabie, MA | 2 |
| Abd El Fattah, MA | 2 |
| Nassar, NN | 2 |
| Abdallah, DM | 2 |
| El-Abhar, HS | 2 |
| Vaz, RL | 1 |
| Chapela, D | 1 |
| Coelho, JE | 1 |
| Lopes, LV | 1 |
| Ferreira, JJ | 1 |
| Afonso, ND | 1 |
| Sousa, S | 1 |
| Outeiro, TF | 2 |
| Zhong, H | 1 |
| Zhu, C | 2 |
| Minegishi, Y | 1 |
| Richter, F | 2 |
| Zdunowski, S | 1 |
| Roy, RR | 1 |
| Vissel, B | 2 |
| Gad, P | 1 |
| Gerasimenko, Y | 1 |
| Chesselet, MF | 1 |
| Edgerton, VR | 1 |
| Sikora, J | 2 |
| Kieffer, BL | 1 |
| Paoletti, P | 1 |
| Ouagazzal, AM | 2 |
| Isooka, N | 1 |
| Miyazaki, I | 4 |
| Kikuoka, R | 1 |
| Wada, K | 1 |
| Nakayama, E | 1 |
| Shin, K | 1 |
| Yamamoto, D | 1 |
| Kitamura, Y | 5 |
| Asanuma, M | 4 |
| Oliveira, LOD | 1 |
| da Silva, PIC | 1 |
| Filho, RPR | 1 |
| Progênio, RCS | 1 |
| de Oliveira, VDPS | 1 |
| Silva, RC | 1 |
| de Andrade, MC | 1 |
| da Silva Freitas, JJ | 1 |
| Kietzer, KS | 1 |
| Fletcher, EJR | 2 |
| Moon, LDF | 1 |
| Duty, S | 3 |
| Aimé, P | 1 |
| Karuppagounder, SS | 1 |
| Rao, A | 1 |
| Chen, Y | 3 |
| Burke, RE | 5 |
| Ratan, RR | 1 |
| Greene, LA | 4 |
| Young, D | 1 |
| Popiolek, M | 1 |
| Trapa, P | 1 |
| Fonseca, KR | 1 |
| Brevard, J | 1 |
| Gray, DL | 1 |
| Kozak, R | 1 |
| Chitre, NM | 1 |
| Wood, BJ | 1 |
| Ray, A | 1 |
| Moniri, NH | 1 |
| Murnane, KS | 1 |
| Yang, SQ | 1 |
| Li, D | 1 |
| He, SQ | 1 |
| Liu, SY | 1 |
| Tang, XQ | 1 |
| Márquez, I | 1 |
| Muñoz, MF | 1 |
| Ayala, A | 1 |
| López, JC | 1 |
| Vargas, JP | 1 |
| Díaz, E | 1 |
| Bian, G | 1 |
| Liu, J | 25 |
| Guo, Y | 11 |
| Li, L | 7 |
| Qiao, H | 2 |
| Li, W | 4 |
| Xu, T | 1 |
| Zhang, Q | 4 |
| Zhuang, XX | 1 |
| Wang, SF | 1 |
| Tan, Y | 1 |
| Song, JX | 1 |
| Zhu, Z | 2 |
| Wang, ZY | 2 |
| Wu, MY | 1 |
| Cai, CZ | 1 |
| Huang, ZJ | 1 |
| Tan, JQ | 1 |
| Su, HX | 1 |
| Lu, JH | 1 |
| Pisanò, CA | 2 |
| Brugnoli, A | 2 |
| Novello, S | 1 |
| Caccia, C | 2 |
| Keywood, C | 2 |
| Melloni, E | 2 |
| Vailati, S | 2 |
| Padoani, G | 2 |
| Morari, M | 9 |
| Mazzocchetti, P | 1 |
| Bastioli, G | 1 |
| Cardinale, A | 2 |
| Mosci, P | 1 |
| Arakawa, K | 1 |
| Yuge, N | 1 |
| Maehara, S | 1 |
| Ferreira, AFF | 1 |
| Binda, KH | 1 |
| Singulani, MP | 1 |
| Pereira, CPM | 1 |
| Ferrari, GD | 1 |
| Alberici, LC | 1 |
| Real, CC | 3 |
| Britto, LR | 3 |
| Maznychenko, AV | 1 |
| Mankivska, OP | 1 |
| Sokolowska Vereshchaka, IV | 1 |
| Kopyak, BS | 1 |
| Tomiak, T | 1 |
| Bulgakova, NV | 1 |
| Gonchar, OO | 1 |
| Prylutskyy, YI | 1 |
| Ritter, U | 1 |
| Mishchenko, IV | 1 |
| Kostyukov, AI | 1 |
| Crompe, B | 1 |
| Leblois, A | 1 |
| Elsherbiny, S | 1 |
| Boraud, T | 2 |
| Mallet, NP | 1 |
| Sellnow, RC | 1 |
| Steece-Collier, K | 7 |
| Altwal, F | 1 |
| Sandoval, IM | 2 |
| Kordower, JH | 4 |
| Collier, TJ | 11 |
| Sortwell, CE | 6 |
| West, AR | 2 |
| Manfredsson, FP | 4 |
| Anis, E | 1 |
| Zafeer, MF | 1 |
| Firdaus, F | 1 |
| Islam, SN | 1 |
| Khan, AA | 1 |
| Hossain, MM | 1 |
| Valverde, S | 1 |
| Vandecasteele, M | 1 |
| Piette, C | 1 |
| Derousseaux, W | 1 |
| Gangarossa, G | 2 |
| Aristieta Arbelaiz, A | 1 |
| Touboul, J | 1 |
| Degos, B | 1 |
| Venance, L | 1 |
| Jiménez-Urbieta, H | 1 |
| Gago, B | 1 |
| Quiroga-Varela, A | 1 |
| Rodríguez-Chinchilla, T | 1 |
| Merino-Galán, L | 1 |
| Delgado-Alvarado, M | 1 |
| Navalpotro-Gómez, I | 1 |
| Belloso-Iguerategui, A | 1 |
| Marin, C | 14 |
| Rodríguez-Oroz, MC | 2 |
| Sitzia, G | 1 |
| Chergui, K | 4 |
| Park, HW | 1 |
| Park, CG | 1 |
| Park, M | 1 |
| Lee, SH | 1 |
| Park, HR | 1 |
| Lim, J | 2 |
| Paek, SH | 1 |
| Choy, YB | 1 |
| Gao, H | 1 |
| Yang, X | 6 |
| Li, Y | 4 |
| Chen, L | 18 |
| Wu, J | 2 |
| Nel, D | 1 |
| Sun, B | 1 |
| Tang, DL | 1 |
| Luan, YW | 1 |
| Zhou, CY | 1 |
| Duan, WJ | 1 |
| Liang, L | 1 |
| Pan, MH | 1 |
| Lu, DH | 1 |
| Wang, TM | 1 |
| Li, SB | 1 |
| Zhong, HB | 1 |
| Yang, XJ | 1 |
| Cheng, Y | 2 |
| Liu, B | 2 |
| Li, WX | 1 |
| Kurihara, H | 1 |
| Bi, W | 1 |
| Li, YF | 1 |
| He, RR | 1 |
| Pereira, RS | 1 |
| Rezaee, Z | 1 |
| Marandi, SM | 1 |
| Alaei, H | 1 |
| Esfarjani, F | 1 |
| Wasel, O | 1 |
| Freeman, JL | 1 |
| Biolchi, AM | 1 |
| de Oliveira, DGR | 1 |
| Amaral, HO | 1 |
| Campos, GAA | 1 |
| Gonçalves, JC | 1 |
| de Souza, ACB | 1 |
| Lima, MR | 2 |
| Silva, LP | 1 |
| Mortari, MR | 2 |
| Tian, Y | 1 |
| Lu, J | 1 |
| Hao, X | 1 |
| Li, H | 4 |
| Zhang, G | 1 |
| Liu, X | 6 |
| Li, X | 5 |
| Zhao, C | 1 |
| Kuang, W | 1 |
| Chen, D | 3 |
| Zhu, M | 1 |
| Thompson, AM | 1 |
| Farmer, K | 1 |
| Rowe, EM | 1 |
| Hayley, S | 1 |
| Feng, Y | 1 |
| Chen, Z | 3 |
| Zhou, Z | 1 |
| Yuan, J | 1 |
| Li, F | 1 |
| Zhang, Y | 4 |
| Huang, X | 1 |
| Fan, S | 1 |
| Wu, X | 2 |
| Huang, C | 1 |
| Fonseca-Fonseca, LA | 2 |
| da Silva, VDA | 2 |
| Wong-Guerra, M | 1 |
| Ramírez-Sánchez, J | 1 |
| Yaquis, ASP | 1 |
| Ochoa-Rodríguez, E | 2 |
| Verdecia-Reyes, Y | 2 |
| de Araújo, FM | 1 |
| Santana, RC | 1 |
| Costa, SL | 2 |
| Núñez-Figueredo, Y | 2 |
| Güttler, C | 1 |
| Altschüler, J | 3 |
| Tanev, K | 1 |
| Böckmann, S | 1 |
| Haumesser, JK | 2 |
| Nikulin, VV | 1 |
| Kühn, AA | 2 |
| van Riesen, C | 2 |
| Wang, S | 8 |
| Han, QW | 1 |
| Zhou, TT | 1 |
| Zhang, CL | 1 |
| Zhu, CG | 1 |
| Zhou, X | 1 |
| Chen, NH | 1 |
| Yuan, YH | 1 |
| Shi, JG | 1 |
| Zarate, SM | 1 |
| Pandey, G | 1 |
| Chilukuri, S | 1 |
| Garcia, JA | 1 |
| Cude, B | 1 |
| Storey, S | 1 |
| Salem, NA | 1 |
| Bancroft, EA | 1 |
| Hook, M | 1 |
| Srinivasan, R | 1 |
| Kim, J | 2 |
| Tran, HNK | 1 |
| Lee, CH | 3 |
| Hur, J | 1 |
| Kim, MC | 1 |
| Yang, HO | 1 |
| Simorgh, S | 1 |
| Alizadeh, R | 1 |
| Shabani, R | 1 |
| Karimzadeh, F | 1 |
| Seidkhani, E | 1 |
| Majidpoor, J | 1 |
| Moradi, F | 1 |
| Kasbiyan, H | 1 |
| Feyder, M | 1 |
| Plewnia, C | 1 |
| Lieberman, OJ | 1 |
| Spigolon, G | 2 |
| Piccin, A | 1 |
| Urbina, L | 1 |
| Dehay, B | 1 |
| Li, Q | 8 |
| Nilsson, P | 1 |
| Altun, M | 1 |
| Santini, E | 1 |
| Sulzer, D | 3 |
| Bezard, E | 12 |
| Borgkvist, A | 3 |
| Fisone, G | 4 |
| Rivas-Santisteban, R | 1 |
| Lillo, J | 1 |
| Muñoz, A | 3 |
| Rodríguez-Pérez, AI | 1 |
| Labandeira-García, JL | 5 |
| Navarro, G | 2 |
| Franco, R | 3 |
| Iravanpour, F | 1 |
| Dargahi, L | 1 |
| Rezaei, M | 2 |
| Haghani, M | 1 |
| Heidari, R | 1 |
| Valian, N | 1 |
| Ahmadiani, A | 1 |
| Kambey, PA | 1 |
| Chengcheng, M | 1 |
| Xiaoxiao, G | 1 |
| Abdulrahman, AA | 1 |
| Kanwore, K | 1 |
| Nadeem, I | 1 |
| Jiao, W | 1 |
| Gao, D | 2 |
| Gu, L | 1 |
| Yang, HM | 1 |
| Zhang, H | 9 |
| Xie, J | 8 |
| Liu, C | 3 |
| Kan, D | 1 |
| Geng, X | 3 |
| Wei, S | 1 |
| Ye, T | 1 |
| Bartlett, MJ | 1 |
| Sherman, SJ | 1 |
| Falk, T | 1 |
| Cowen, SL | 1 |
| Güzelad, Ö | 1 |
| Özkan, A | 2 |
| Parlak, H | 1 |
| Sinen, O | 1 |
| Afşar, E | 1 |
| Öğüt, E | 2 |
| Yıldırım, FB | 2 |
| Bülbül, M | 1 |
| Ağar, A | 2 |
| Aslan, M | 2 |
| Ferrari, DP | 1 |
| Bortolanza, M | 3 |
| Del Bel, EA | 3 |
| Kucinski, A | 1 |
| Sarter, M | 1 |
| El-Gamal, M | 1 |
| Salama, M | 1 |
| Collins-Praino, LE | 1 |
| Baetu, I | 1 |
| Fathalla, AM | 1 |
| Soliman, AM | 1 |
| Mohamed, W | 1 |
| Moustafa, AA | 1 |
| Sodhi, RK | 1 |
| Bansal, Y | 1 |
| Singh, R | 1 |
| Saroj, P | 1 |
| Bhandari, R | 1 |
| Kumar, B | 1 |
| Kuhad, A | 1 |
| Peters, OM | 1 |
| Weiss, A | 1 |
| Metterville, J | 1 |
| Song, L | 4 |
| Logan, R | 2 |
| Smith, GA | 3 |
| Schwarzschild, MA | 5 |
| Mueller, C | 1 |
| Brown, RH | 1 |
| Freeman, M | 1 |
| Sarookhani, MR | 1 |
| Rajaei, F | 1 |
| Liu, Z | 7 |
| Yan, A | 1 |
| Zhao, J | 1 |
| Yang, S | 1 |
| Yan, T | 1 |
| Mao, Q | 1 |
| Wu, B | 2 |
| Bi, K | 1 |
| He, B | 1 |
| Jia, Y | 1 |
| Brazhnik, E | 2 |
| Novikov, N | 2 |
| McCoy, AJ | 4 |
| Ilieva, NM | 1 |
| Ghraib, MW | 1 |
| Walters, JR | 4 |
| Fauser, M | 1 |
| Ricken, M | 1 |
| Markert, F | 1 |
| Weis, N | 1 |
| Schmitt, O | 3 |
| Gimsa, J | 1 |
| Winter, C | 4 |
| Badstübner-Meeske, K | 1 |
| Storch, A | 2 |
| Kumari, M | 1 |
| Ramdas, P | 1 |
| Radhakrishnan, AK | 1 |
| Kutty, MK | 1 |
| Haleagrahara, N | 1 |
| Andreoli, L | 1 |
| Abbaszadeh, M | 1 |
| Cao, X | 3 |
| Cenci, MA | 17 |
| da Silva, WAB | 1 |
| Ferreira Oliveira, K | 1 |
| Caroline Vitorino, L | 1 |
| Ferreira Romão, L | 1 |
| Allodi, S | 1 |
| Lourenço Correa, C | 1 |
| Lyu, S | 1 |
| Tang, G | 1 |
| Li, R | 2 |
| Yang, J | 8 |
| Ma, C | 1 |
| Zhang, W | 3 |
| Wang, W | 1 |
| Shen, J | 1 |
| Cai, K | 1 |
| Liu, M | 1 |
| Cao, M | 1 |
| Pinna, A | 5 |
| Costa, G | 5 |
| Serra, M | 1 |
| Contu, L | 1 |
| Morelli, M | 7 |
| Dos-Santos-Pereira, M | 2 |
| Guimaraes, FS | 2 |
| Nascimento, GCD | 1 |
| Monge-Fuentes, V | 1 |
| Biolchi Mayer, A | 1 |
| Geraldes, LR | 1 |
| Zanotto, LN | 1 |
| Moreira, KG | 1 |
| Martins, OP | 1 |
| Piva, HL | 1 |
| Felipe, MSS | 1 |
| Amaral, AC | 1 |
| Bocca, AL | 1 |
| Tedesco, AC | 1 |
| Antipova, V | 2 |
| Holzmann, C | 1 |
| Hawlitschka, A | 2 |
| Witt, M | 2 |
| Wree, A | 3 |
| Solís, O | 4 |
| García-Montes, JR | 1 |
| Garcia-Sanz, P | 1 |
| Herranz, AS | 1 |
| Asensio, MJ | 1 |
| Kang, G | 1 |
| Hiroi, N | 1 |
| Moratalla, R | 7 |
| Romero, A | 1 |
| Parada, E | 1 |
| González-Lafuente, L | 1 |
| Farré-Alins, V | 1 |
| Ramos, E | 1 |
| Cacabelos, R | 1 |
| Egea, J | 1 |
| Liu, L | 1 |
| Cacace, F | 3 |
| Mineo, D | 3 |
| Viscomi, MT | 1 |
| Latagliata, EC | 2 |
| Mancini, M | 3 |
| Sasso, V | 1 |
| Vannelli, A | 3 |
| Pascucci, T | 2 |
| Pendolino, V | 6 |
| Marcello, E | 1 |
| Pelucchi, S | 1 |
| Puglisi-Allegra, S | 2 |
| Molinari, M | 1 |
| Pellegrini, C | 2 |
| Antonioli, L | 2 |
| Colucci, R | 2 |
| Tirotta, E | 1 |
| Gentile, D | 1 |
| Ippolito, C | 1 |
| Segnani, C | 1 |
| Levandis, G | 7 |
| Cerri, S | 3 |
| Blandini, F | 10 |
| Barocelli, E | 2 |
| Ballabeni, V | 2 |
| Bernardini, N | 2 |
| Blandizzi, C | 2 |
| Fornai, M | 2 |
| Andrzejewski, K | 2 |
| Budzińska, K | 2 |
| Kaczyńska, K | 2 |
| Dallé, E | 3 |
| Daniels, WMU | 2 |
| Mabandla, MV | 8 |
| Singh, S | 4 |
| Mishra, SK | 2 |
| Shukla, S | 6 |
| Borkar, N | 1 |
| Andersson, DR | 1 |
| Yang, M | 4 |
| Müllertz, A | 1 |
| Holm, R | 1 |
| Mu, H | 1 |
| Dardou, D | 1 |
| Reyrolle, L | 1 |
| Chassain, C | 2 |
| Durif, F | 2 |
| Finkelstein, DI | 3 |
| Billings, JL | 1 |
| Adlard, PA | 1 |
| Ayton, S | 1 |
| Sedjahtera, A | 1 |
| Masters, CL | 1 |
| Wilkins, S | 1 |
| Shackleford, DM | 1 |
| Charman, SA | 1 |
| Bal, W | 1 |
| Zawisza, IA | 1 |
| Kurowska, E | 1 |
| Gundlach, AL | 2 |
| Ma, S | 1 |
| Bush, AI | 2 |
| Hare, DJ | 1 |
| Doble, PA | 1 |
| Crawford, S | 1 |
| Gautier, EC | 1 |
| Parsons, J | 1 |
| Huggins, P | 1 |
| Barnham, KJ | 1 |
| Cherny, RA | 1 |
| Jávor-Duray, BN | 1 |
| Vinck, M | 1 |
| van der Roest, M | 1 |
| Berendse, HW | 1 |
| Voorn, P | 2 |
| Zhang, CW | 1 |
| Tai, YK | 1 |
| Chai, BH | 1 |
| Chew, KCM | 1 |
| Ang, ET | 1 |
| Tsang, F | 1 |
| Tan, BWQ | 1 |
| Hong, ETE | 1 |
| Asad, ABA | 1 |
| Chuang, KH | 1 |
| Lim, KL | 1 |
| Soong, TW | 1 |
| Slominsky, PA | 1 |
| Shadrina, MI | 1 |
| Kolomin, TA | 1 |
| Stavrovskaya, AV | 1 |
| Filatova, EV | 1 |
| Andreeva, LA | 1 |
| Illarioshkin, SN | 1 |
| Myasoedov, NF | 1 |
| Vijayanathan, Y | 1 |
| Lim, FT | 1 |
| Lim, SM | 1 |
| Long, CM | 1 |
| Tan, MP | 1 |
| Majeed, ABA | 1 |
| Ramasamy, K | 1 |
| Guo, Q | 1 |
| You, H | 1 |
| Lin, B | 1 |
| Lu, Z | 1 |
| Zhao, Y | 3 |
| Mao, L | 1 |
| Shen, S | 1 |
| Cheng, H | 1 |
| Zhang, J | 11 |
| Deng, L | 1 |
| Fan, J | 1 |
| Xi, Z | 1 |
| Li, CM | 1 |
| Su, W | 2 |
| Huang, L | 3 |
| Deng, M | 4 |
| Zhang, S | 4 |
| Lu, S | 2 |
| Gui, X | 1 |
| Fang, Y | 5 |
| Stanic, J | 2 |
| Mellone, M | 2 |
| Napolitano, F | 3 |
| Racca, C | 1 |
| Zianni, E | 3 |
| Minocci, D | 1 |
| Thiolat, ML | 1 |
| Longhi, A | 1 |
| De Rosa, A | 1 |
| Di Luca, M | 4 |
| Usiello, A | 4 |
| Gardoni, F | 6 |
| Aono, H | 1 |
| Choudhury, ME | 1 |
| Higaki, H | 1 |
| Miyanishi, K | 1 |
| Kigami, Y | 1 |
| Fujita, K | 1 |
| Akiyama, JI | 1 |
| Takahashi, H | 1 |
| Yano, H | 1 |
| Kubo, M | 1 |
| Nishikawa, N | 1 |
| Nomoto, M | 3 |
| Tanaka, J | 1 |
| Olmedo-Díaz, S | 2 |
| Estévez-Silva, H | 1 |
| Orädd, G | 2 |
| Af Bjerkén, S | 1 |
| Marcellino, D | 1 |
| Virel, A | 2 |
| Frohlich, H | 1 |
| Claes, K | 1 |
| De Wolf, C | 1 |
| Van Damme, X | 1 |
| Michel, A | 1 |
| Gómez-Paz, A | 1 |
| Drucker-Colín, R | 3 |
| Milán-Aldaco, D | 1 |
| Palomero-Rivero, M | 1 |
| Ambriz-Tututi, M | 1 |
| Mamaligas, AA | 1 |
| Ford, CP | 1 |
| Willis, GL | 2 |
| Freelance, CB | 1 |
| Finberg, JPM | 1 |
| Aluf, Y | 1 |
| Loboda, Y | 1 |
| Nakhleh, MK | 1 |
| Jeries, R | 1 |
| Abud-Hawa, M | 1 |
| Zubedat, S | 1 |
| Avital, A | 1 |
| Khatib, S | 1 |
| Vaya, J | 1 |
| Haick, H | 1 |
| Du, CX | 10 |
| Zhang, QJ | 15 |
| Ando, K | 3 |
| Nishime, C | 1 |
| Inoue, R | 1 |
| Nishinaka, E | 1 |
| Kawai, K | 1 |
| Urano, K | 1 |
| Tsutsumi, H | 1 |
| Weilnau, JN | 1 |
| Carcella, MA | 1 |
| Miner, KM | 1 |
| Bhatia, TN | 1 |
| Hutchison, DF | 1 |
| Pant, DB | 1 |
| Nouraei, N | 1 |
| Leak, RK | 2 |
| Shen, D | 1 |
| Tian, X | 1 |
| Zhang, B | 2 |
| Song, R | 1 |
| Jia, L | 1 |
| Chen, X | 5 |
| Shi, L | 1 |
| Johnston, TH | 4 |
| Versi, E | 1 |
| Howson, PA | 1 |
| Ravenscroft, P | 3 |
| Fox, SH | 3 |
| Hill, MP | 1 |
| Reidenberg, BE | 1 |
| Corey, R | 1 |
| Brotchie, JM | 8 |
| Nouhi, M | 1 |
| Yao, N | 1 |
| Tronci, E | 5 |
| Francardo, V | 2 |
| Aparicio-Juárez, A | 1 |
| Duhne, M | 1 |
| Lara-González, E | 1 |
| Ávila-Cascajares, F | 1 |
| Calderón, V | 1 |
| Galarraga, E | 3 |
| Bargas, J | 3 |
| Chen, H | 2 |
| Lei, H | 1 |
| Xu, Q | 2 |
| Sánchez, JR | 1 |
| Guerra, MW | 1 |
| Hernádez, RD | 1 |
| Menezes-Filho, NJ | 1 |
| Costa, TCS | 1 |
| de Santana, WA | 1 |
| Oliveira, JL | 1 |
| Segura-Aguilar, J | 1 |
| Haghparast, E | 1 |
| Esmaeili-Mahani, S | 2 |
| Abbasnejad, M | 1 |
| Sheibani, V | 2 |
| Mercado, G | 1 |
| Castillo, V | 1 |
| Soto, P | 1 |
| López, N | 1 |
| Axten, JM | 1 |
| Sardi, SP | 1 |
| Hoozemans, JJM | 1 |
| Hetz, C | 1 |
| West, TO | 1 |
| Berthouze, L | 1 |
| Halliday, DM | 1 |
| Litvak, V | 2 |
| Sharott, A | 1 |
| Magill, PJ | 6 |
| Farmer, SF | 1 |
| Grospe, GM | 1 |
| Baker, PM | 1 |
| Ragozzino, ME | 1 |
| Huotarinen, A | 1 |
| Penttinen, AM | 2 |
| Bäck, S | 2 |
| Voutilainen, MH | 3 |
| Julku, U | 1 |
| Piepponen, TP | 1 |
| Männistö, PT | 3 |
| Saarma, M | 2 |
| Tuominen, R | 1 |
| Laakso, A | 1 |
| Airavaara, M | 2 |
| Ermine, CM | 1 |
| Wright, JL | 2 |
| Frausin, S | 1 |
| Kauhausen, JA | 1 |
| Parish, CL | 4 |
| Stanic, D | 2 |
| Thompson, LH | 3 |
| Park, SE | 2 |
| Song, KI | 2 |
| Kim, H | 1 |
| Chung, S | 1 |
| Youn, I | 2 |
| Christensen, AB | 1 |
| Sørensen, JCH | 1 |
| Ettrup, KS | 1 |
| Orlowski, D | 1 |
| Bjarkam, CR | 1 |
| Tsunekawa, H | 1 |
| Takahata, K | 1 |
| Okano, M | 1 |
| Ishikawa, T | 1 |
| Satoyoshi, H | 1 |
| Nishimura, T | 2 |
| Hoshino, N | 1 |
| Muraoka, S | 1 |
| Zhang, GJ | 1 |
| Sun, YN | 8 |
| Wang, HS | 2 |
| Kumari, N | 1 |
| Agrawal, S | 1 |
| Kumari, R | 1 |
| Sharma, D | 1 |
| Luthra, PM | 1 |
| Bariotto-Dos-Santos, K | 1 |
| Leite-Panissi, CRA | 1 |
| Del-Bel, EA | 2 |
| Poursina, M | 1 |
| Zeraati, F | 1 |
| Nadi, F | 1 |
| Yu, YW | 1 |
| Hsueh, SC | 1 |
| Lai, JH | 1 |
| Chen, YH | 1 |
| Kang, SJ | 1 |
| Chen, KY | 1 |
| Hsieh, TH | 3 |
| Hoffer, BJ | 5 |
| Greig, NH | 1 |
| Chiang, YH | 3 |
| Zheng, X | 1 |
| Zhu, Y | 2 |
| Chen, S | 2 |
| Chen, T | 1 |
| Huang, Z | 1 |
| Wei, J | 2 |
| Lei, W | 1 |
| Boshoff, EL | 1 |
| Baufreton, J | 2 |
| Milekovic, T | 1 |
| McGuire, S | 1 |
| Moraud, EM | 1 |
| Porras, G | 4 |
| Sun, S | 3 |
| Ko, WKD | 1 |
| Chazalon, M | 1 |
| Morin, S | 1 |
| Normand, E | 1 |
| Farjot, G | 1 |
| Milet, A | 1 |
| Pype, J | 1 |
| Pioli, E | 1 |
| Courtine, G | 1 |
| Bessière, B | 1 |
| Alzoubi, KH | 1 |
| Mokhemer, E | 1 |
| Abuirmeileh, AN | 1 |
| Heckman, PRA | 1 |
| Blokland, A | 2 |
| Van Goethem, NP | 1 |
| Van Hagen, BTJ | 1 |
| Prickaerts, J | 2 |
| Li, LB | 5 |
| Sharma, S | 2 |
| Taliyan, R | 2 |
| de Freitas, CM | 1 |
| Krum, BN | 1 |
| Chiapinotto Ceretta, AP | 1 |
| Schaffer, LF | 1 |
| de Moraes Reis, E | 1 |
| Schwerz, JP | 1 |
| Barbosa, CP | 1 |
| Soares, FAA | 1 |
| Fachinetto, R | 1 |
| Fu-Rong, H | 1 |
| Hai, W | 1 |
| Leino, S | 1 |
| Koski, SK | 1 |
| Hänninen, R | 1 |
| Tapanainen, T | 1 |
| Rannanpää, S | 1 |
| Salminen, O | 1 |
| Elyasi, L | 1 |
| Eftekhar-Vaghefi, SH | 1 |
| Asadi-Shekaari, M | 2 |
| Lv, SX | 3 |
| Ryu, YK | 2 |
| Park, HY | 2 |
| Go, J | 2 |
| Kim, YH | 2 |
| Hwang, JH | 2 |
| Choi, DH | 2 |
| Noh, JR | 1 |
| Rhee, M | 2 |
| Han, PL | 1 |
| Kim, KS | 3 |
| Chandravanshi, LP | 1 |
| Trigun, SK | 1 |
| Choi, YG | 1 |
| Hong, YM | 1 |
| Kim, LH | 1 |
| Yeo, S | 1 |
| Lim, S | 1 |
| Shiying, L | 1 |
| Xinhui, Q | 1 |
| Guanghua, J | 1 |
| Feng, N | 1 |
| Feng, L | 1 |
| Shumei, C | 1 |
| Fan, H | 1 |
| Lima, LAR | 1 |
| Lopes, MJP | 1 |
| Costa, RO | 1 |
| Lima, FAV | 1 |
| Neves, KRT | 1 |
| Calou, IBF | 1 |
| Andrade, GM | 3 |
| Viana, GSB | 1 |
| Lin, L | 1 |
| Yan, M | 1 |
| Lin, R | 2 |
| Zheng, Z | 3 |
| Kamińska, K | 4 |
| Lenda, T | 4 |
| Konieczny, J | 4 |
| Wardas, J | 2 |
| Lorenc-Koci, E | 3 |
| Xi, G | 2 |
| Ikeda-Matsuo, Y | 1 |
| Miyata, H | 1 |
| Mizoguchi, T | 1 |
| Ohama, E | 1 |
| Naito, Y | 1 |
| Uematsu, S | 1 |
| Akira, S | 1 |
| Sasaki, Y | 1 |
| Tanabe, M | 1 |
| Ebrahimi, V | 1 |
| Aliaghaei, A | 1 |
| Piryaei, A | 1 |
| Haghir, H | 1 |
| Abdollahifar, MA | 1 |
| Sadeghi, Y | 1 |
| Yurchenko, EA | 3 |
| Menchinskaya, ES | 2 |
| Pislyagin, EA | 2 |
| Trinh, PTH | 1 |
| Ivanets, EV | 2 |
| Smetanina, OF | 2 |
| Yurchenko, AN | 2 |
| Kolesnikova, SA | 1 |
| Lyakhova, EG | 1 |
| Kalinovsky, AI | 1 |
| Popov, RS | 1 |
| Stonik, VA | 1 |
| Yao, X | 2 |
| Han, H | 3 |
| Gao, Y | 3 |
| Chang, H | 1 |
| Xiang, T | 2 |
| Wang, M | 4 |
| Meadows, SM | 1 |
| Conti, MM | 4 |
| Gross, L | 1 |
| Chambers, NE | 1 |
| Avnor, Y | 1 |
| Ostock, CY | 5 |
| Lanza, K | 1 |
| Bishop, C | 11 |
| Assaf, F | 1 |
| Schiller, Y | 1 |
| Patricio, F | 1 |
| Parra, I | 1 |
| Martínez, I | 1 |
| Pérez-Severiano, F | 1 |
| Montes, S | 1 |
| Aguilera, J | 2 |
| Limón, ID | 3 |
| Tizabi, Y | 1 |
| Mendieta, L | 2 |
| Bailey, RA | 1 |
| Gutierrez, A | 1 |
| Kyser, TL | 1 |
| Hemmerle, AM | 2 |
| Hufgard, JR | 1 |
| Seroogy, KB | 2 |
| Vorhees, CV | 1 |
| Williams, MT | 1 |
| Phan, TTH | 1 |
| Ngo, NTD | 1 |
| Zhuravleva, OI | 1 |
| Rasin, AB | 1 |
| Dyshlovoy, SA | 1 |
| von Amsberg, G | 1 |
| Afiyatullov, SS | 1 |
| Ning, B | 2 |
| Wang, N | 2 |
| Feng, XY | 3 |
| Zhu, J | 1 |
| Ferrazzo, S | 1 |
| Gunduz-Cinar, O | 1 |
| Stefanova, N | 4 |
| Pollack, GA | 1 |
| Holmes, A | 1 |
| Schmuckermair, C | 1 |
| Ferraguti, F | 1 |
| He, F | 1 |
| Gao, G | 1 |
| Menardy, F | 1 |
| Varani, AP | 1 |
| Combes, A | 1 |
| Léna, C | 1 |
| Popa, D | 1 |
| Chen, K | 1 |
| Vincis, R | 1 |
| Fontanini, A | 1 |
| Rentsch, P | 1 |
| Stayte, S | 1 |
| Morris, GP | 1 |
| Guo, M | 1 |
| Jia, Q | 1 |
| Keifman, E | 1 |
| Ruiz-DeDiego, I | 2 |
| Pafundo, DE | 1 |
| Paz, RM | 1 |
| Murer, MG | 11 |
| Wang, T | 13 |
| Xie, W | 2 |
| Stancati, JA | 1 |
| Collier, NJ | 1 |
| Mercado, NM | 1 |
| Yan, Y | 1 |
| Titze-de-Almeida, R | 1 |
| Titze-de-Almeida, SS | 1 |
| Ferreira, NR | 2 |
| Fontanari, C | 1 |
| Faccioli, LH | 1 |
| Del Bel, E | 1 |
| Ge, H | 1 |
| Yan, Z | 1 |
| Zhu, H | 2 |
| Zhao, H | 3 |
| Ogawa, M | 1 |
| Zhou, Y | 2 |
| Tsuji, R | 1 |
| Goto, S | 2 |
| Kasahara, J | 1 |
| Carmo, M | 1 |
| Gonçalves, FQ | 1 |
| Canas, PM | 2 |
| Oses, JP | 1 |
| Fernandes, FD | 1 |
| Duarte, FV | 1 |
| Palmeira, CM | 2 |
| Tomé, AR | 1 |
| Agostinho, P | 1 |
| Cunha, RA | 4 |
| Rodrigues, LD | 1 |
| Oliveira, LF | 1 |
| Shinoda, L | 1 |
| Scorza, CA | 2 |
| Faber, J | 1 |
| Ferraz, HB | 2 |
| Britto, LRG | 1 |
| Scorza, FA | 2 |
| Guimarães Marques, MJ | 1 |
| Victorino, DB | 1 |
| Cavalheiro, EA | 1 |
| Jalali-Nadoushan, M | 1 |
| Roghani, M | 6 |
| Heuer, A | 4 |
| Vinh, NN | 1 |
| Dunnett, SB | 9 |
| López-Huerta, VG | 2 |
| Carrillo-Reid, L | 1 |
| Tapia, D | 1 |
| Fiordelisio, T | 1 |
| Shin, KS | 3 |
| Choi, HS | 2 |
| Zhao, TT | 2 |
| Suh, KH | 1 |
| Kwon, IH | 2 |
| Choi, SO | 1 |
| Lee, MK | 3 |
| Chaudhry, ZL | 1 |
| Ahmed, BY | 1 |
| Bonito-Oliva, A | 2 |
| Pignatelli, M | 1 |
| Yoshitake, T | 1 |
| Seiler, S | 2 |
| Longo, F | 1 |
| Piccinin, S | 1 |
| Kehr, J | 1 |
| Mercuri, NB | 1 |
| Nisticò, R | 1 |
| Aguiar, AS | 3 |
| Moreira, EL | 1 |
| Hoeller, AA | 1 |
| Oliveira, PA | 1 |
| Córdova, FM | 1 |
| Glaser, V | 1 |
| Walz, R | 3 |
| Leal, RB | 1 |
| Latini, A | 2 |
| Prediger, RD | 5 |
| Carvalho, MM | 1 |
| Campos, FL | 1 |
| Coimbra, B | 1 |
| Pêgo, JM | 1 |
| Rodrigues, C | 1 |
| Lima, R | 1 |
| Rodrigues, AJ | 1 |
| Sousa, N | 1 |
| Salgado, AJ | 1 |
| Liao, CH | 1 |
| Chen, SY | 1 |
| Kuo, JS | 1 |
| Pang, CY | 1 |
| Díaz-Martínez, NE | 1 |
| Tamariz, E | 1 |
| Díaz, NF | 1 |
| García-Peña, CM | 1 |
| Varela-Echavarría, A | 1 |
| Velasco, I | 1 |
| Fu, W | 1 |
| Zhuang, W | 2 |
| Sun, X | 1 |
| Suárez, LM | 1 |
| Caramés, JM | 1 |
| Taravini, IR | 3 |
| Solís, JM | 1 |
| Diaz-Corrales, FJ | 2 |
| Higashi, Y | 3 |
| Namba, M | 1 |
| Ogawa, N | 4 |
| Sun, XR | 1 |
| Chen, WF | 2 |
| Xue, Y | 4 |
| Yung, WH | 6 |
| McFarland, K | 1 |
| Price, DL | 1 |
| Davis, CN | 1 |
| Ma, JN | 1 |
| Bonhaus, DW | 1 |
| Burstein, ES | 1 |
| Olsson, R | 1 |
| Gupta, SP | 1 |
| Yadav, S | 1 |
| Singhal, NK | 1 |
| Tiwari, MN | 1 |
| Singh, MP | 1 |
| Fu, RH | 1 |
| Wang, YC | 2 |
| Chen, CS | 1 |
| Tsai, RT | 1 |
| Liu, SP | 1 |
| Chang, WL | 1 |
| Lin, HL | 1 |
| Lu, CH | 1 |
| Wei, JR | 1 |
| Wang, ZW | 1 |
| Shyu, WC | 2 |
| Lin, SZ | 3 |
| Dickerson, JW | 1 |
| Herman, JP | 1 |
| Lisci, C | 1 |
| Stancampiano, R | 3 |
| Fidalgo, C | 2 |
| Collu, M | 1 |
| Devoto, P | 1 |
| Carta, M | 7 |
| Brooshghalan, SE | 1 |
| Chang, YJ | 1 |
| Ho, TY | 1 |
| Wu, ML | 1 |
| Hwang, SM | 1 |
| Chiou, TW | 1 |
| Tsai, MS | 1 |
| Chaves-Kirsten, GP | 1 |
| Mazucanti, CH | 1 |
| Souza, BM | 1 |
| Torrão, AS | 1 |
| Czarnecka, A | 4 |
| Domin, H | 2 |
| Smiałowska, M | 2 |
| Liu, Y | 2 |
| Peng, M | 1 |
| Zang, D | 1 |
| Gonzalez-Aparicio, R | 1 |
| Blanco, E | 1 |
| Serrano, A | 1 |
| Pavon, FJ | 1 |
| Parsons, LH | 1 |
| Maldonado, R | 1 |
| Robledo, P | 2 |
| Fernandez-Espejo, E | 2 |
| de Fonseca, FR | 1 |
| Han, LN | 4 |
| Valencia, M | 1 |
| Chavez, M | 1 |
| Artieda, J | 1 |
| Bolam, JP | 2 |
| Mena-Segovia, J | 1 |
| Gutiérrez-Valdez, AL | 1 |
| García-Ruiz, R | 1 |
| Anaya-Martínez, V | 1 |
| Torres-Esquivel, C | 1 |
| Espinosa-Villanueva, J | 1 |
| Reynoso-Erazo, L | 1 |
| Tron-Alvarez, R | 1 |
| Aley-Medina, P | 1 |
| Sánchez-Betancourt, J | 1 |
| Montiel-Flores, E | 1 |
| Avila-Costa, MR | 1 |
| Dagda, RK | 1 |
| Das Banerjee, T | 1 |
| Janda, E | 1 |
| Landers, MR | 1 |
| Kinney, JW | 1 |
| van Breukelen, F | 1 |
| Chiu, WH | 2 |
| Carlsson, T | 4 |
| Depboylu, C | 2 |
| Höglinger, GU | 3 |
| Oertel, WH | 3 |
| Ries, V | 4 |
| Lou, H | 3 |
| Jing, X | 2 |
| Wei, X | 4 |
| Shi, H | 4 |
| Ren, D | 1 |
| Effenberg, A | 1 |
| Klein, A | 3 |
| Gibb, R | 1 |
| Carroll, C | 1 |
| Baumgärtner, W | 1 |
| Grothe, C | 1 |
| Ratzka, A | 1 |
| Bonastre, M | 10 |
| Mengod, G | 3 |
| Cortés, R | 3 |
| Giralt, A | 1 |
| Obeso, JA | 3 |
| Schapira, AH | 1 |
| Ueno, T | 1 |
| Yamada, J | 1 |
| Nishijima, H | 1 |
| Arai, A | 2 |
| Migita, K | 1 |
| Baba, M | 2 |
| Ueno, S | 1 |
| Tomiyama, M | 2 |
| Kelsey, JE | 1 |
| Neville, C | 1 |
| Salvatore, MF | 1 |
| Zheng, LF | 4 |
| Song, J | 1 |
| Fan, RF | 1 |
| Chen, CL | 1 |
| Ren, QZ | 1 |
| Zhang, XL | 1 |
| Li, LS | 2 |
| Zhu, JX | 5 |
| Bonaventura, J | 1 |
| Farré, D | 2 |
| Sánchez, M | 1 |
| Simola, N | 4 |
| Mallol, J | 2 |
| Lluís, C | 2 |
| Baqi, Y | 1 |
| Müller, CE | 1 |
| Cortés, A | 2 |
| McCormick, P | 1 |
| Canela, EI | 2 |
| Martínez-Pinilla, E | 1 |
| Lanciego, JL | 3 |
| Casadó, V | 2 |
| Armentero, MT | 6 |
| Huang, YZ | 1 |
| Rotenberg, A | 1 |
| Pascual-Leone, A | 1 |
| Wang, JY | 1 |
| Chen, JJ | 2 |
| He, Z | 2 |
| Jiang, Y | 1 |
| Xu, H | 4 |
| Jiang, H | 4 |
| Jia, W | 1 |
| Sun, P | 2 |
| Alirezaei, M | 1 |
| Gan, J | 2 |
| Qi, C | 1 |
| Mao, LM | 1 |
| Feng, ZJ | 2 |
| Carmo, MR | 1 |
| Menezes, AP | 1 |
| Nunes, AC | 1 |
| Pliássova, A | 1 |
| Rolo, AP | 1 |
| Dorval, AD | 2 |
| Grill, WM | 2 |
| Niu, X | 1 |
| Zhang, Z | 5 |
| Zu, J | 1 |
| Hua, F | 1 |
| Shen, X | 1 |
| Kupsch, A | 5 |
| Schmidt, W | 1 |
| Gizatullina, Z | 1 |
| Debska-Vielhaber, G | 1 |
| Voges, J | 1 |
| Striggow, F | 1 |
| Panther, P | 1 |
| Schwegler, H | 1 |
| Heinze, HJ | 1 |
| Vielhaber, S | 1 |
| Gellerich, FN | 1 |
| Thornton, E | 1 |
| Hassall, MM | 1 |
| Corrigan, F | 1 |
| Vink, R | 1 |
| Song, S | 2 |
| Li, J | 2 |
| Liang, T | 1 |
| Doo, AR | 1 |
| Kim, SN | 1 |
| Hahm, DH | 1 |
| Yoo, HH | 1 |
| Park, JY | 2 |
| Lee, H | 2 |
| Jeon, S | 1 |
| Park, SU | 1 |
| Park, HJ | 2 |
| Hui, YP | 4 |
| Qiao, HF | 1 |
| Feng, CW | 1 |
| Wen, ZH | 1 |
| Huang, SY | 1 |
| Hung, HC | 1 |
| Chen, CH | 2 |
| Yang, SN | 1 |
| Chen, NF | 1 |
| Wang, HM | 1 |
| Hsiao, CD | 1 |
| Bez, F | 1 |
| Wieloch, T | 1 |
| Nissbrandt, H | 1 |
| Ruscher, K | 1 |
| Sharifi, H | 1 |
| Nayebi, AM | 3 |
| Farajnia, S | 1 |
| Cerovic, M | 1 |
| Bagetta, V | 6 |
| Fasano, S | 1 |
| Morella, I | 1 |
| Hardingham, N | 1 |
| Papale, A | 1 |
| Marchisella, F | 1 |
| Giampà, C | 3 |
| Brambilla, R | 1 |
| Shah, M | 2 |
| Rajagopalan, S | 1 |
| Xu, L | 3 |
| Voshavar, C | 2 |
| Shurubor, Y | 1 |
| Beal, F | 1 |
| Andersen, JK | 1 |
| Dutta, AK | 3 |
| Mellstrom, B | 1 |
| Vallejo, M | 1 |
| Naranjo, JR | 1 |
| El Arfani, A | 2 |
| Bentea, E | 3 |
| Aourz, N | 1 |
| Ampe, B | 1 |
| De Deurwaerdère, P | 3 |
| Van Eeckhaut, A | 2 |
| Massie, A | 2 |
| Sarre, S | 5 |
| Smolders, I | 2 |
| Michotte, Y | 5 |
| Gubellini, P | 4 |
| Melon, C | 3 |
| Dale, E | 1 |
| Doller, D | 1 |
| Kerkerian-Le Goff, L | 4 |
| Healy-Stoffel, M | 1 |
| Omar Ahmad, S | 1 |
| Stanford, JA | 5 |
| Levant, B | 1 |
| Park, E | 1 |
| Song, I | 1 |
| Jang, DP | 1 |
| Kim, IY | 1 |
| Forsberg, AC | 1 |
| Renner, DB | 1 |
| Mohan, KG | 1 |
| Wong, JC | 1 |
| Arneson, LC | 1 |
| Crow, JM | 1 |
| Chao, OY | 4 |
| Wang, AL | 1 |
| Nikolaus, S | 4 |
| de Souza Silva, MA | 2 |
| Afshin-Majd, S | 1 |
| Khalili, M | 2 |
| Mehranmehr, N | 1 |
| Baluchnejadmojarad, T | 2 |
| Tripathy, D | 2 |
| Verma, P | 1 |
| Nthenge-Ngumbau, DN | 1 |
| Banerjee, M | 1 |
| Mohanakumar, KP | 7 |
| Capozzo, A | 1 |
| Vitale, F | 1 |
| Mattei, C | 1 |
| Mazzone, P | 1 |
| Scarnati, E | 1 |
| Modi, G | 1 |
| Gogoi, S | 1 |
| Antonio, T | 1 |
| Reith, ME | 2 |
| Ko, WK | 1 |
| Martin-Negrier, ML | 1 |
| Crossman, AR | 2 |
| Chen, SS | 2 |
| Yang, C | 3 |
| Hao, F | 2 |
| Li, C | 1 |
| Lu, T | 2 |
| Zhao, LR | 2 |
| Duan, WM | 2 |
| Valle-Leija, P | 1 |
| Kapitsa, IG | 2 |
| Ivanova, EA | 2 |
| Kokshenev, II | 2 |
| Nepoklonov, AV | 2 |
| Val'dman, EA | 2 |
| Voronina, TA | 2 |
| Sgobio, C | 3 |
| Morelli, E | 1 |
| Poggini, S | 1 |
| Branchi, I | 2 |
| Barnum, CJ | 4 |
| Chung, J | 1 |
| Chang, J | 1 |
| Williams, M | 1 |
| Grigoryan, N | 1 |
| Tesi, RJ | 1 |
| Tansey, MG | 2 |
| Cruz, AV | 5 |
| Berg, J | 1 |
| Roch, M | 1 |
| Schwerk, A | 1 |
| Kurtz, A | 1 |
| Steiner, B | 2 |
| Zare, K | 1 |
| Eidi, A | 1 |
| Rohani, AH | 1 |
| Kaminer, J | 1 |
| Thakur, P | 1 |
| Evinger, C | 1 |
| Thiele, SL | 1 |
| Chen, B | 1 |
| Lo, C | 1 |
| Gertler, TS | 1 |
| Warre, R | 1 |
| Surmeier, JD | 1 |
| Nash, JE | 1 |
| Iravani, B | 1 |
| Towhidkhah, F | 1 |
| Nash, KR | 1 |
| Moran, P | 1 |
| Finneran, DJ | 1 |
| Hudson, C | 2 |
| Robinson, J | 1 |
| Morgan, D | 1 |
| Bickford, PC | 4 |
| Bordia, T | 3 |
| McGregor, M | 2 |
| Papke, RL | 1 |
| Decker, MW | 1 |
| McIntosh, JM | 2 |
| Quik, M | 3 |
| Ozsoy, O | 1 |
| Tanriover, G | 1 |
| Kaya, Y | 1 |
| Gemici, B | 1 |
| Dilmac, S | 1 |
| Paumier, KL | 2 |
| Madhavan, L | 4 |
| Terpstra, B | 2 |
| Celano, SL | 1 |
| Green, JJ | 1 |
| Imus, NM | 1 |
| Marckini, N | 1 |
| Daley, B | 1 |
| Toti, L | 1 |
| Travagli, RA | 1 |
| Xu, R | 2 |
| Fang, X | 4 |
| Lu, Y | 1 |
| Deng, X | 1 |
| Li, S | 2 |
| Koprich, JB | 3 |
| Espinosa, MC | 1 |
| Reyes, MG | 1 |
| Dekundy, A | 2 |
| Mela, F | 3 |
| Hofmann, M | 1 |
| Danysz, W | 2 |
| Bałasz, M | 1 |
| Szkilnik, R | 1 |
| Brus, R | 2 |
| Malinowska-Borowska, J | 1 |
| Kasperczyk, S | 1 |
| Nowak, D | 1 |
| Kostrzewa, RM | 3 |
| Nowak, P | 4 |
| Karasawa, H | 1 |
| Pietra, C | 1 |
| Giuliano, C | 1 |
| Garcia-Rubio, S | 1 |
| Xu, X | 1 |
| Yakabi, S | 1 |
| Taché, Y | 1 |
| Moreno, E | 1 |
| Reyes-Resina, I | 1 |
| Canet-Pons, J | 1 |
| Dopeso-Reyes, IG | 1 |
| Rico, AJ | 1 |
| Aidi-Knani, S | 2 |
| Regaya, I | 1 |
| Amalric, M | 5 |
| Mourre, C | 2 |
| Fernández-Dueñas, V | 1 |
| Taura, JJ | 1 |
| Cottet, M | 1 |
| Gómez-Soler, M | 1 |
| López-Cano, M | 1 |
| Ledent, C | 1 |
| Trinquet, E | 1 |
| Pin, JP | 1 |
| Luján, R | 1 |
| Durroux, T | 1 |
| Ciruela, F | 1 |
| Gui, XH | 1 |
| Huang, LP | 1 |
| Deng, MZ | 1 |
| Fang, RM | 1 |
| Ke, XH | 1 |
| He, YP | 1 |
| Fang, YQ | 1 |
| Zhang, C | 1 |
| Ren, M | 2 |
| Han, M | 2 |
| Suzuki, S | 1 |
| Kawamata, J | 1 |
| Iwahara, N | 2 |
| Matsumura, A | 1 |
| Hisahara, S | 1 |
| Matsushita, T | 1 |
| Sasaki, M | 1 |
| Honmou, O | 1 |
| Shimohama, S | 3 |
| Martinez, AA | 2 |
| Morgese, MG | 2 |
| Pisanu, A | 1 |
| Macheda, T | 2 |
| Paquette, MA | 4 |
| Seillier, A | 1 |
| Cassano, T | 2 |
| Carta, AR | 3 |
| Giuffrida, A | 2 |
| Luo, XF | 1 |
| Zhang, BL | 1 |
| Li, JC | 1 |
| Yang, YY | 1 |
| Sun, YF | 1 |
| Haobam, R | 1 |
| Kaidery, NA | 1 |
| Schawkat, K | 1 |
| Di Santo, S | 1 |
| Ducray, AD | 1 |
| Widmer, HR | 1 |
| Lobb, CJ | 1 |
| Jaeger, D | 1 |
| Wong, MY | 2 |
| Choi, SJ | 1 |
| Mosharov, EV | 1 |
| Bamford, NS | 1 |
| Ramírez-García, G | 1 |
| Palafox-Sánchez, V | 1 |
| Zhang, YM | 6 |
| Samata, B | 1 |
| Kikuchi, T | 1 |
| Miyawaki, Y | 1 |
| Morizane, A | 1 |
| Mashimo, T | 1 |
| Nakagawa, M | 1 |
| Okita, K | 1 |
| Takahashi, J | 1 |
| Lin, CM | 2 |
| Lin, YT | 1 |
| Lin, RD | 1 |
| Huang, WJ | 1 |
| Lee, MH | 1 |
| Mitra, R | 1 |
| Aronsson, P | 1 |
| Winder, M | 1 |
| Tobin, G | 1 |
| Bergquist, F | 1 |
| Suh, JK | 1 |
| Hwang, D | 1 |
| Boix, J | 1 |
| Padel, T | 1 |
| Paul, G | 5 |
| Somaa, FA | 1 |
| Bye, CR | 1 |
| Wang, Z | 1 |
| Myers, KG | 1 |
| Heintz, R | 1 |
| Holschneider, DP | 1 |
| Iderberg, H | 1 |
| Maslava, N | 1 |
| Thompson, AD | 1 |
| Bubser, M | 1 |
| Niswender, CM | 1 |
| Hopkins, CR | 1 |
| Lindsley, CW | 1 |
| Conn, PJ | 1 |
| Jones, CK | 1 |
| Zhang, T | 1 |
| Shi, Q | 1 |
| Tang, B | 1 |
| Gut, NK | 1 |
| Winn, P | 1 |
| Drenan, RM | 1 |
| Hallmark, J | 1 |
| Palumbo, N | 1 |
| Bhide, N | 2 |
| Conti, M | 1 |
| George, JA | 3 |
| Liu, CZ | 1 |
| Xu, JD | 1 |
| Haney, MJ | 1 |
| Klyachko, NL | 1 |
| Gupta, R | 1 |
| Plotnikova, EG | 1 |
| Patel, T | 1 |
| Piroyan, A | 1 |
| Sokolsky, M | 1 |
| Kabanov, AV | 1 |
| Batrakova, EV | 1 |
| Hermanns, G | 1 |
| Maurer, L | 1 |
| Windolph, A | 2 |
| Bagga, V | 1 |
| Fricker, RA | 1 |
| Ma, D | 1 |
| Shuler, JM | 1 |
| Raider, KD | 1 |
| Rogers, RS | 1 |
| Wheatley, JL | 1 |
| Geiger, PC | 3 |
| Liu, KC | 1 |
| Li, JY | 1 |
| Tan, HH | 2 |
| Ma, WL | 1 |
| Park, KH | 1 |
| Hwang, BY | 2 |
| Lee, CK | 2 |
| Ferrigno, A | 2 |
| Vairetti, M | 2 |
| Ambrosi, G | 3 |
| Rizzo, V | 2 |
| Richelmi, P | 1 |
| Fuzzati-Armentero, MT | 1 |
| Delaville, C | 3 |
| Gerber, CM | 2 |
| Stasi, MA | 1 |
| Minetti, P | 1 |
| Lombardo, K | 1 |
| Riccioni, T | 1 |
| Caprioli, A | 1 |
| Vertechy, M | 1 |
| Di Serio, S | 1 |
| Pace, S | 1 |
| Borsini, F | 1 |
| Sagot, B | 1 |
| Zhou, FM | 1 |
| Stępkowski, TM | 1 |
| Wasyk, I | 1 |
| Grzelak, A | 1 |
| Kruszewski, M | 1 |
| Zhang, JR | 1 |
| Ge, SN | 1 |
| Wang, JL | 1 |
| Yan, ZQ | 1 |
| Jia, D | 1 |
| Zhu, JL | 1 |
| Gao, GD | 1 |
| Santiago, RM | 1 |
| Tonin, FS | 1 |
| Barbiero, J | 1 |
| Zaminelli, T | 1 |
| Boschen, SL | 1 |
| Andreatini, R | 1 |
| Da Cunha, C | 5 |
| Lima, MM | 1 |
| Vital, MA | 3 |
| Padovan-Neto, FE | 1 |
| Cavalcanti-Kiwiatkoski, R | 1 |
| Dos Santos-Pereira, M | 1 |
| Mitkovski, M | 2 |
| Raisman-Vozari, R | 6 |
| Grant, LM | 1 |
| Barnett, DG | 1 |
| Doll, EJ | 1 |
| Leverson, G | 1 |
| Ciucci, M | 1 |
| Requejo, C | 1 |
| Bengoetxea, H | 1 |
| Garcia-Blanco, A | 1 |
| Herrán, E | 1 |
| Igartua, M | 1 |
| Pedraz, JL | 1 |
| Hernández, RM | 1 |
| Lafuente, JV | 1 |
| Alvarez-Fischer, D | 1 |
| Arias-Carrión, O | 1 |
| Djufri, M | 1 |
| Keber, U | 1 |
| Borta, A | 1 |
| Schwarting, RK | 1 |
| Scheller, D | 1 |
| Gee, LE | 2 |
| Chen, N | 1 |
| Ramirez-Zamora, A | 2 |
| Shin, DS | 3 |
| Pilitsis, JG | 3 |
| Batassini, C | 2 |
| Broetto, N | 1 |
| Tortorelli, LS | 1 |
| Borsoi, M | 1 |
| Zanotto, C | 1 |
| Galland, F | 1 |
| Souza, TM | 1 |
| Leite, MC | 1 |
| Gonçalves, CA | 1 |
| Nyoka, M | 1 |
| Daniels, WM | 6 |
| Jennings, KA | 1 |
| Platt, NJ | 1 |
| Cragg, SJ | 1 |
| Barroso-Flores, J | 1 |
| Herrera-Valdez, MA | 1 |
| de Campos, PS | 1 |
| Hasegawa, K | 1 |
| Kumei, Y | 1 |
| Zeredo, JL | 1 |
| Yang, XY | 1 |
| Zhao, EY | 1 |
| Zhuang, WX | 1 |
| Sun, FX | 1 |
| Han, HL | 1 |
| Han, HR | 1 |
| Lin, ZJ | 1 |
| Pan, ZF | 1 |
| Qu, MH | 1 |
| Zeng, XW | 1 |
| Ding, Y | 1 |
| Albertini, G | 1 |
| Demuyser, T | 1 |
| Furlanetti, LL | 1 |
| Coenen, VA | 1 |
| Aranda, IA | 1 |
| Döbrössy, MD | 1 |
| Navailles, S | 2 |
| Di Giovanni, G | 1 |
| Faggiani, E | 1 |
| Benazzouz, A | 5 |
| Theodore, S | 1 |
| Maragos, W | 1 |
| Anderson, CJ | 1 |
| Sheppard, DT | 1 |
| Huynh, R | 1 |
| Anderson, DN | 1 |
| Polar, CA | 1 |
| Cisbani, G | 1 |
| Drouin-Ouellet, J | 1 |
| Gibrat, C | 1 |
| Saint-Pierre, M | 2 |
| Lagacé, M | 1 |
| Badrinarayanan, S | 1 |
| Lavallée-Bourget, MH | 1 |
| Charest, J | 1 |
| Chabrat, A | 1 |
| Boivin, L | 1 |
| Lebel, M | 1 |
| Bousquet, M | 1 |
| Lévesque, M | 1 |
| Cicchetti, F | 2 |
| Rehnmark, A | 1 |
| Faergemann, E | 1 |
| Strömberg, I | 1 |
| Nie, S | 1 |
| Xu, Y | 2 |
| Chen, G | 1 |
| Ma, K | 1 |
| Han, C | 1 |
| Guo, Z | 1 |
| Ye, K | 2 |
| Ba, Q | 1 |
| Cui, C | 1 |
| Wen, L | 1 |
| Feng, S | 1 |
| Zhou, J | 4 |
| Yang, K | 1 |
| Ip, CW | 1 |
| Beck, SK | 1 |
| Volkmann, J | 1 |
| Chattopadhyaya, I | 1 |
| Gupta, S | 1 |
| Mohammed, A | 1 |
| Mushtaq, N | 1 |
| Chauhan, S | 3 |
| Ghosh, S | 2 |
| Petri, D | 1 |
| Schnitzler, A | 1 |
| Huston, JP | 3 |
| Duzzioni, M | 1 |
| Remor, AP | 1 |
| Tristão, FS | 2 |
| Matheus, FC | 3 |
| Avegno, EM | 1 |
| Kheirbek, MA | 1 |
| Sonders, MS | 1 |
| Hen, R | 1 |
| Lindenbach, D | 4 |
| Dupre, KB | 5 |
| Lazzarini, M | 1 |
| Martin, S | 1 |
| Amar, M | 1 |
| Stühmer, W | 2 |
| Kirchhoff, F | 1 |
| Gomes, LA | 1 |
| Lanfumey, L | 1 |
| Sepulveda, JE | 1 |
| Lopes, FNC | 1 |
| Balestra, B | 2 |
| Siani, F | 1 |
| Ghezzi, C | 2 |
| Bonizzi, A | 1 |
| Vicini, R | 1 |
| Pastoris, O | 1 |
| Ndlovu, BC | 1 |
| Alvarsson, A | 1 |
| Stan, TL | 1 |
| Schintu, N | 2 |
| Kadkhodaei, B | 1 |
| Perlmann, T | 1 |
| Niu, XL | 1 |
| Jayasinghe, VR | 1 |
| Flores-Barrera, E | 2 |
| Tseng, KY | 2 |
| Tsuchioka, A | 1 |
| Oana, F | 1 |
| Yamauchi, Y | 1 |
| Ijiro, T | 1 |
| Kaidoh, K | 1 |
| Hiratochi, M | 1 |
| Eyring, KW | 1 |
| Reinhart, F | 1 |
| Massri, NE | 1 |
| Chabrol, C | 1 |
| Cretallaz, C | 1 |
| Johnstone, DM | 1 |
| Torres, N | 1 |
| Darlot, F | 1 |
| Costecalde, T | 1 |
| Stone, J | 1 |
| Mitrofanis, J | 5 |
| Benabid, AL | 5 |
| Moro, C | 1 |
| Berghauzen-Maciejewska, K | 1 |
| Kosmowska, B | 1 |
| Głowacka, U | 1 |
| Ossowska, K | 1 |
| di Maio, A | 1 |
| Kwak, C | 1 |
| Lim, CS | 1 |
| Kaang, BK | 1 |
| Rial, D | 1 |
| Real, JI | 1 |
| Lemos, C | 1 |
| Ben, J | 1 |
| Guaita, GO | 1 |
| Pita, IR | 1 |
| Sequeira, AC | 1 |
| Pereira, FC | 1 |
| Takahashi, RN | 1 |
| Bertoglio, LJ | 1 |
| Guzman, M | 1 |
| Prado, VF | 1 |
| Prado, MA | 1 |
| Daumas, S | 1 |
| El Mestikawy, S | 1 |
| Valjent, E | 1 |
| Jin, X | 1 |
| Schwabe, K | 3 |
| Krauss, JK | 3 |
| Alam, M | 1 |
| Hou, L | 1 |
| Ju, C | 1 |
| Lv, Y | 1 |
| O'Connor, KA | 1 |
| Feustel, PJ | 1 |
| Molho, E | 1 |
| Suleymanova, I | 1 |
| Albert, K | 1 |
| Anttila, J | 1 |
| Tao, K | 2 |
| Wang, B | 2 |
| Feng, D | 1 |
| Lu, F | 1 |
| Lai, J | 1 |
| Nie, T | 1 |
| Yang, Q | 2 |
| Upadhya, MA | 1 |
| Shelkar, GP | 1 |
| Subhedar, NK | 1 |
| Kokare, DM | 1 |
| McCreary, AC | 2 |
| Varney, MA | 1 |
| Newman-Tancredi, A | 1 |
| Goldenberg, AA | 2 |
| Kuberka, A | 1 |
| Mohamed, M | 1 |
| Eissa, S | 1 |
| Parker, PR | 1 |
| Lalive, AL | 1 |
| Kreitzer, AC | 1 |
| Kumar, A | 2 |
| Dudhal, S | 1 |
| Sundari T, A | 1 |
| Sunkara, M | 1 |
| Usman, H | 1 |
| Varshney, A | 1 |
| Mukhopadhyay, A | 1 |
| Park, TS | 1 |
| Hu, R | 1 |
| Cheng, J | 1 |
| Fan, Q | 1 |
| Wu, N | 3 |
| Zhou, M | 1 |
| Ayadi, AE | 1 |
| Zigmond, MJ | 5 |
| Smith, AD | 4 |
| Voronkov, DN | 1 |
| Khudoerkov, RM | 1 |
| Dikalova, YV | 1 |
| Sheloukhova, LI | 1 |
| Nie, Q | 1 |
| Li, Z | 3 |
| Du, G | 2 |
| McConnell, GC | 1 |
| So, RQ | 1 |
| Smith, LM | 1 |
| Duncan, EJ | 1 |
| Black, MA | 1 |
| Gemmell, NJ | 1 |
| Dearden, PK | 1 |
| Reynolds, JN | 1 |
| He, Y | 4 |
| Ma, R | 1 |
| Wu, C | 2 |
| Fan, G | 1 |
| Yu, G | 1 |
| Xie, CL | 1 |
| Lin, JY | 1 |
| Wang, MH | 1 |
| Zhang, SF | 1 |
| Wang, XJ | 2 |
| Liu, ZG | 1 |
| Luo, D | 1 |
| Shi, Y | 1 |
| Wang, J | 4 |
| Lin, Q | 1 |
| Sun, Y | 1 |
| Yan, Q | 1 |
| Kneynsberg, A | 1 |
| Kanaan, NM | 1 |
| Piri, H | 1 |
| Faraji, A | 3 |
| Fraidouni, N | 2 |
| Dargahi, T | 1 |
| Mahmudi, M | 1 |
| Alipour Heidari, M | 1 |
| Aldrin-Kirk, P | 1 |
| Wang, G | 1 |
| Mattsson, B | 1 |
| Lundblad, M | 6 |
| Parmar, M | 1 |
| Björklund, T | 2 |
| Lian, H | 1 |
| Zhou, L | 1 |
| Cai, QQ | 1 |
| Holtz, NA | 1 |
| Tedford, SE | 1 |
| Persons, AL | 1 |
| Grasso, SA | 1 |
| Napier, TC | 1 |
| Kheradmand, A | 1 |
| Jorjani, M | 1 |
| Khalifeh, S | 1 |
| Yang, PH | 1 |
| Huang, YD | 1 |
| Zhang, XY | 1 |
| Lei, P | 1 |
| Xiang, Q | 1 |
| Su, ZJ | 1 |
| Zhang, QH | 1 |
| Hansen, HH | 1 |
| Fabricius, K | 1 |
| Barkholt, P | 1 |
| Mikkelsen, JD | 1 |
| Jelsing, J | 1 |
| Pyke, C | 1 |
| Knudsen, LB | 1 |
| Vrang, N | 1 |
| Betancourt, E | 1 |
| Wachtel, J | 1 |
| Michaelos, M | 1 |
| Haggerty, M | 1 |
| Conforti, J | 1 |
| Kritzer, MF | 1 |
| Qu, Q | 1 |
| He, T | 1 |
| Song, Z | 1 |
| Chen, F | 2 |
| Lei, C | 1 |
| Hou, Y | 1 |
| da-Silva, CA | 1 |
| Jia, YJ | 1 |
| Deng, JH | 1 |
| Zhang, WZ | 1 |
| Sun, ZL | 1 |
| Yu, Y | 5 |
| Gong, XL | 1 |
| Wang, XM | 2 |
| Yu, SQ | 1 |
| Ying, Z | 1 |
| Pan, C | 1 |
| Huang, S | 1 |
| Dai, M | 1 |
| Yan, B | 1 |
| Westphal, R | 1 |
| Sumiyoshi, A | 1 |
| Simmons, C | 1 |
| Mesquita, M | 1 |
| Wood, TC | 1 |
| Williams, SC | 1 |
| Vernon, AC | 3 |
| Cash, D | 1 |
| Tubert, C | 1 |
| Taravini, IRE | 1 |
| Sánchez, GM | 1 |
| Prost, MA | 1 |
| Avale, ME | 1 |
| Rela, L | 2 |
| Gudasheva, TA | 2 |
| Koliasnikova, KN | 1 |
| Antipova, TA | 1 |
| Seredenin, SB | 2 |
| Souza, RB | 1 |
| Frota, AF | 1 |
| Sousa, RS | 1 |
| Cezario, NA | 1 |
| Santos, TB | 1 |
| Souza, LM | 1 |
| Coura, CO | 1 |
| Monteiro, VS | 1 |
| Cristino Filho, G | 1 |
| Vasconcelos, SM | 1 |
| da Cunha, RM | 1 |
| Aguiar, LM | 1 |
| Benevides, NM | 1 |
| Melikhov-Sosin, M | 1 |
| Nuss, EE | 1 |
| Wąsik, A | 1 |
| Polak, D | 1 |
| Romańska, I | 1 |
| Michaluk, J | 1 |
| Antkiewicz-Michaluk, L | 2 |
| Kang, NH | 1 |
| Carriere, CH | 1 |
| Bahna, SG | 1 |
| Niles, LP | 1 |
| Beck, MH | 1 |
| Kühn, J | 1 |
| Knutelska, J | 1 |
| Zygmunt, M | 1 |
| Dudek, M | 1 |
| Zhu, YC | 1 |
| Diao, HL | 1 |
| Liu, HY | 1 |
| Han, XH | 1 |
| Manrique, C | 1 |
| Camon, J | 1 |
| Deltheil, T | 1 |
| Turle-Lorenzo, N | 2 |
| Guiraudie-Capraz, G | 1 |
| Perez, RG | 2 |
| Falquetto, B | 1 |
| Tuppy, M | 1 |
| Potje, SR | 1 |
| Moreira, TS | 1 |
| Antoniali, C | 1 |
| Takakura, AC | 1 |
| Srivastava, N | 2 |
| Kaszuba, BC | 1 |
| Walling, I | 1 |
| Cheng, L | 1 |
| Yuan, Z | 1 |
| Wu, Y | 1 |
| Ren, Z | 1 |
| Yang, H | 3 |
| Zhou, T | 1 |
| Yuan, L | 1 |
| Duan, Y | 1 |
| Fjodorova, M | 1 |
| Torres, EM | 3 |
| Wang, YY | 1 |
| Zhou, W | 1 |
| Hao, Q | 1 |
| Hoffer, B | 1 |
| Xu, QY | 2 |
| Leikas, JV | 1 |
| Kääriäinen, TM | 2 |
| Jalkanen, AJ | 1 |
| Lehtonen, M | 1 |
| Rantamäki, T | 1 |
| Forsberg, MM | 1 |
| Russ, K | 1 |
| Flores, J | 1 |
| Brudek, T | 1 |
| Doudet, DJ | 3 |
| Schwarz, SC | 1 |
| Lee, HS | 1 |
| Kang, JM | 1 |
| Lee, YE | 1 |
| Kim, B | 1 |
| Sung, MY | 1 |
| Höglinger, G | 1 |
| Wegner, F | 1 |
| Kim, JS | 2 |
| Chung, HM | 1 |
| Chang, SW | 1 |
| Cha, KY | 1 |
| Schwarz, J | 1 |
| Jalewa, J | 1 |
| Sharma, MK | 1 |
| Gengler, S | 1 |
| Hölscher, C | 1 |
| Yue, P | 1 |
| Gao, L | 1 |
| Ding, X | 1 |
| Teng, J | 1 |
| Mao, Z | 1 |
| Ji, S | 1 |
| Ye, H | 1 |
| Xue, Z | 1 |
| Perez, XA | 1 |
| Zhang, D | 1 |
| A Figge, D | 1 |
| Standaert, DG | 1 |
| Kannari, K | 1 |
| Kimura, T | 1 |
| Suzuki, C | 1 |
| Kawarabayashi, T | 1 |
| Shen, H | 1 |
| Shoji, M | 1 |
| Kaya, AH | 1 |
| Vlamings, R | 3 |
| Tan, S | 1 |
| Lim, LW | 1 |
| Steinbusch, HW | 3 |
| Visser-Vandewalle, V | 3 |
| Sharp, T | 1 |
| Reyes, S | 1 |
| Rangel-Barajas, C | 2 |
| Silva, I | 2 |
| García-Ramírez, M | 1 |
| Sánchez-Lemus, E | 1 |
| Floran, L | 1 |
| Aceves, J | 3 |
| Erlij, D | 3 |
| Florán, B | 3 |
| Abin-Carriquiry, JA | 3 |
| Urbanavicius, J | 3 |
| Cassels, BK | 1 |
| Rebolledo-Fuentes, M | 1 |
| Wonnacott, S | 2 |
| Dajas, F | 3 |
| Kirik, D | 5 |
| Björklund, A | 6 |
| Pienaar, IS | 1 |
| Kellaway, LA | 3 |
| Russell, VA | 5 |
| Stein, DJ | 1 |
| Lopez, S | 1 |
| Schann, S | 1 |
| Neuville, P | 1 |
| Larramendy, C | 3 |
| Saborido, MD | 1 |
| Ferrario, JE | 3 |
| Gershanik, OS | 3 |
| Sanchez-Pernaute, R | 3 |
| Patterson, M | 1 |
| Reske-Nielsen, C | 2 |
| Yoshizaki, T | 3 |
| Sonntag, KC | 1 |
| Studer, L | 2 |
| Isacson, O | 4 |
| Eskow, KL | 3 |
| Dupre, K | 1 |
| Blandino, P | 1 |
| Deak, T | 2 |
| Dal Bo, G | 1 |
| Bérubé-Carrière, N | 1 |
| Mendez, JA | 1 |
| Leo, D | 1 |
| Riad, M | 1 |
| Descarries, L | 1 |
| Lévesque, D | 1 |
| Trudeau, LE | 1 |
| Mo, J | 1 |
| Yu, LP | 1 |
| Sun, PH | 1 |
| Jin, GZ | 1 |
| Zhen, X | 1 |
| Giorgi, M | 2 |
| D'Angelo, V | 2 |
| Esposito, Z | 1 |
| Nuccetelli, V | 2 |
| Sorge, R | 2 |
| Martorana, A | 2 |
| Stefani, A | 1 |
| Bernardi, G | 8 |
| Sancesario, G | 2 |
| Glavan, G | 3 |
| Schmidt, WJ | 7 |
| Lebsanft, H | 1 |
| Heindl, M | 1 |
| Gerlach, M | 4 |
| Gruenblatt, E | 1 |
| Riederer, P | 3 |
| Mayerhofer, A | 1 |
| Scheller, DK | 2 |
| Rojas-Mayorquín, AE | 1 |
| Saldaña-Ortega, M | 1 |
| Salum, C | 1 |
| Gomes, MZ | 2 |
| Hunot, S | 1 |
| Talanov, SA | 1 |
| Sahach, VF | 1 |
| Valastro, B | 1 |
| Quack, G | 1 |
| Moghaddamt, HF | 1 |
| Ardestani, MS | 1 |
| Saffari, M | 1 |
| Navidpour, L | 1 |
| Shafiee, A | 1 |
| Rahmim, A | 1 |
| Morris, JK | 2 |
| Gupte, AA | 1 |
| Bomhoff, GL | 2 |
| Wu, ZH | 3 |
| Yan, W | 1 |
| Ali, U | 6 |
| Chung, EK | 1 |
| Chen, LW | 3 |
| Chan, YS | 4 |
| Yung, KK | 5 |
| Marti, M | 6 |
| Trapella, C | 2 |
| Banegas, I | 2 |
| Prieto, I | 2 |
| Vives, F | 2 |
| Alba, F | 2 |
| de Gasparo, M | 2 |
| Duran, R | 2 |
| Luna, Jde D | 1 |
| Segarra, AB | 2 |
| Hermoso, F | 1 |
| Ramírez, M | 2 |
| Silvestrin, RB | 1 |
| de Oliveira, LF | 1 |
| Oliveira, A | 1 |
| e Souza, TM | 1 |
| Di Chiara, G | 2 |
| Schallert, T | 7 |
| Mabrouk, OS | 2 |
| Volta, M | 1 |
| Kadota, T | 3 |
| Shingo, T | 3 |
| Yasuhara, T | 6 |
| Tajiri, N | 4 |
| Kondo, A | 3 |
| Morimoto, T | 1 |
| Yuan, WJ | 2 |
| Wang, F | 4 |
| Baba, T | 3 |
| Tokunaga, K | 1 |
| Miyoshi, Y | 4 |
| Date, I | 6 |
| Mallet, N | 4 |
| Pogosyan, A | 1 |
| Márton, LF | 1 |
| Brown, P | 5 |
| Gu, S | 2 |
| Huang, H | 2 |
| Bi, J | 1 |
| Yao, Y | 1 |
| Wen, T | 2 |
| Krolewski, DM | 1 |
| Walker, PD | 3 |
| Visanji, NP | 1 |
| Johnston, T | 1 |
| Reyes, G | 1 |
| Wessolleck, J | 1 |
| Papazoglou, A | 3 |
| Metz, GA | 5 |
| Nikkhah, G | 7 |
| Krishnamurthi, RV | 1 |
| Mathai, S | 1 |
| Kim, AH | 1 |
| Zhang, R | 1 |
| Guan, J | 1 |
| García-Horsman, JA | 1 |
| Piltonen, M | 1 |
| Whishaw, IQ | 4 |
| Li, K | 2 |
| Whishaw, PA | 2 |
| Gorny, B | 2 |
| El Atifi-Borel, M | 1 |
| Buggia-Prevot, V | 1 |
| Platet, N | 1 |
| Berger, F | 1 |
| Sgambato-Faure, V | 1 |
| Hahn, M | 1 |
| Timmer, M | 1 |
| Li, KW | 1 |
| Peng, HF | 1 |
| Liu, RS | 3 |
| Wang, HJ | 2 |
| Su, CY | 1 |
| Lee, YJ | 2 |
| Fuentes, R | 1 |
| Petersson, P | 1 |
| Siesser, WB | 1 |
| Caron, MG | 1 |
| Nicolelis, MA | 1 |
| Meurers, BH | 1 |
| Dziewczapolski, G | 3 |
| Bittner, A | 1 |
| Shi, T | 1 |
| Kamme, F | 1 |
| Shults, CW | 3 |
| Mu, X | 1 |
| He, G | 1 |
| Xu, B | 1 |
| Sedaghat, K | 1 |
| Ciucci, MR | 1 |
| Ahrens, AM | 1 |
| Ma, ST | 1 |
| Kane, JR | 1 |
| Windham, EB | 1 |
| Woodlee, MT | 3 |
| Ugrumov, MV | 1 |
| Klein, RL | 1 |
| Dayton, RD | 1 |
| Terry, TL | 1 |
| Vascoe, C | 1 |
| Sunderland, JJ | 1 |
| Tainter, KH | 1 |
| Lane, EL | 7 |
| Vercammen, L | 1 |
| Brundin, P | 4 |
| Daley, BF | 2 |
| Pérez, V | 2 |
| Sosti, V | 1 |
| Rubio, A | 2 |
| Barbanoj, M | 2 |
| Gich, I | 1 |
| Rodríguez-Alvarez, J | 1 |
| Kulisevsky, J | 1 |
| Yu, ZQ | 1 |
| Zha, JH | 1 |
| Liu, HM | 1 |
| Ding, YX | 1 |
| Wang, YQ | 1 |
| Gao, DS | 1 |
| Ballion, B | 1 |
| Frenois, F | 1 |
| Zold, CL | 2 |
| Chetrit, J | 1 |
| Gonon, F | 1 |
| Darmopil, S | 1 |
| Martín, AB | 2 |
| De Diego, IR | 1 |
| Ares, S | 1 |
| Averbeck, BB | 2 |
| Gui, ZH | 4 |
| Cheng, B | 1 |
| An, L | 1 |
| Gao, B | 1 |
| Liu, S | 1 |
| Jackson, J | 1 |
| Chapon, C | 1 |
| Jones, W | 1 |
| Hirani, E | 1 |
| Qassim, A | 1 |
| Bhakoo, K | 1 |
| Nandhu, MS | 1 |
| Fabia, ET | 1 |
| Paulose, CS | 1 |
| Lindgren, HS | 3 |
| Ohlin, KE | 1 |
| Lacombe, E | 1 |
| Khaindrava, V | 1 |
| Oueslati, A | 2 |
| Salin, P | 4 |
| Winner, B | 1 |
| Desplats, P | 1 |
| Hagl, C | 1 |
| Klucken, J | 1 |
| Aigner, R | 1 |
| Ploetz, S | 1 |
| Laemke, J | 1 |
| Karl, A | 1 |
| Aigner, L | 1 |
| Masliah, E | 1 |
| Buerger, E | 1 |
| Winkler, J | 1 |
| Gören, B | 1 |
| Mimbay, Z | 1 |
| Bilici, N | 1 |
| Zarifoğlu, M | 1 |
| Oğul, E | 1 |
| Korfali, E | 1 |
| Lehmkuhle, MJ | 1 |
| Bhangoo, SS | 1 |
| Kipke, DR | 1 |
| Jaunarajs, KL | 1 |
| Steiniger, A | 1 |
| Klioueva, A | 1 |
| Moore, A | 1 |
| Kelly, C | 1 |
| Jiménez, A | 5 |
| Aguilar, E | 5 |
| Hall, H | 1 |
| Breysse, N | 3 |
| Soneson, C | 1 |
| Mandel, RJ | 3 |
| Brown, AR | 2 |
| Hu, B | 2 |
| Antle, MC | 2 |
| Teskey, GC | 2 |
| Seugnet, L | 1 |
| Galvin, JE | 1 |
| Suzuki, Y | 1 |
| Gottschalk, L | 1 |
| Shaw, PJ | 1 |
| Salvadori, S | 1 |
| Brocco, M | 1 |
| Kostrzewa, RA | 1 |
| Skaba, D | 1 |
| Akita, H | 1 |
| Honda, Y | 2 |
| Ogata, M | 1 |
| Noda, K | 1 |
| Saji, M | 1 |
| Buck, K | 1 |
| Ferger, B | 1 |
| Nobre, HV | 1 |
| Cunha, GM | 1 |
| de Vasconcelos, LM | 1 |
| Magalhães, HI | 1 |
| Oliveira Neto, RN | 1 |
| Maia, FD | 1 |
| de Moraes, MO | 1 |
| Leal, LK | 1 |
| Viana, GS | 1 |
| Borah, A | 4 |
| Cervio, M | 1 |
| Greco, R | 1 |
| Tassorelli, C | 1 |
| Colucci, M | 1 |
| Faniglione, M | 1 |
| Bazzini, E | 3 |
| Nappi, G | 5 |
| Clavenzani, P | 1 |
| Vigneri, S | 1 |
| De Giorgio, R | 1 |
| Tonini, M | 1 |
| Henry, V | 1 |
| Paillé, V | 2 |
| Lelan, F | 1 |
| Brachet, P | 2 |
| Damier, P | 1 |
| Delattre, AM | 1 |
| Kiss, A | 1 |
| Szawka, RE | 1 |
| Anselmo-Franci, JA | 3 |
| Bagatini, PB | 1 |
| Xavier, LL | 2 |
| Rigon, P | 1 |
| Achaval, M | 3 |
| Iagher, F | 1 |
| de David, C | 1 |
| Marroni, NA | 1 |
| Ferraz, AC | 2 |
| Lin, JW | 1 |
| Shih, CM | 1 |
| Chen, YC | 2 |
| Tsai, JT | 1 |
| Shih, R | 1 |
| Chiu, PL | 1 |
| Hung, KS | 1 |
| Yeh, YS | 1 |
| Wei, L | 1 |
| Chiu, WT | 1 |
| Yang, LY | 1 |
| Korkmaz, OT | 2 |
| Tunçel, N | 3 |
| Tunçel, M | 1 |
| Oncü, EM | 1 |
| Sahintürk, V | 1 |
| Celik, M | 1 |
| Chung, CY | 1 |
| Hallett, PJ | 1 |
| Casteels, C | 2 |
| Lauwers, E | 2 |
| Baitar, A | 1 |
| Bormans, G | 1 |
| Baekelandt, V | 3 |
| Van Laere, K | 2 |
| Zhang, SJ | 1 |
| Wang, H | 3 |
| Sun, W | 2 |
| Sugiyama, K | 4 |
| Yamaguchi, H | 1 |
| Akamine, S | 3 |
| Magata, Y | 1 |
| Namba, H | 4 |
| Yang, XX | 1 |
| Xue, SR | 1 |
| Dong, WL | 1 |
| Kong, Y | 1 |
| Anderson, AM | 1 |
| Lewis, JR | 1 |
| Johnson, SW | 2 |
| Paul Berger, S | 1 |
| Malagelada, C | 2 |
| Jin, ZH | 1 |
| Jackson-Lewis, V | 5 |
| Przedborski, S | 3 |
| Bioulac, B | 3 |
| Gross, C | 2 |
| Walsh, S | 2 |
| Mnich, K | 1 |
| Mackie, K | 1 |
| Gorman, AM | 1 |
| Finn, DP | 2 |
| Dowd, E | 3 |
| Bramanti, P | 2 |
| Garcia, BG | 1 |
| Neely, MD | 1 |
| Deutch, AY | 1 |
| Rauch, F | 1 |
| Tang, W | 1 |
| McDowell, K | 1 |
| Limsam, M | 1 |
| Neerchal, NK | 1 |
| Yarowsky, P | 1 |
| Tasch, U | 1 |
| Khan, MM | 1 |
| Ahmad, A | 1 |
| Ishrat, T | 2 |
| Khan, MB | 2 |
| Hoda, MN | 2 |
| Khuwaja, G | 1 |
| Raza, SS | 1 |
| Khan, A | 1 |
| Javed, H | 1 |
| Vaibhav, K | 1 |
| Islam, F | 3 |
| Van Camp, N | 1 |
| Vreys, R | 1 |
| Beque, D | 1 |
| Verhoye, M | 1 |
| Verbruggen, A | 1 |
| Debyser, Z | 1 |
| Mortelmans, L | 1 |
| Sijbers, J | 1 |
| Nuyts, J | 1 |
| Van der Linden, A | 1 |
| Higashida, T | 1 |
| Jitsuki, S | 1 |
| Kubo, A | 1 |
| Mitsushima, D | 1 |
| Kamiya, Y | 1 |
| Kanno, H | 2 |
| O'Sullivan, DB | 1 |
| Harrison, PT | 1 |
| Sullivan, AM | 1 |
| Faure, A | 1 |
| Leblanc-Veyrac, P | 1 |
| El Massioui, N | 1 |
| Cordeiro, KK | 1 |
| Tenório, SB | 1 |
| Döbrössy, M | 2 |
| Yu, YP | 1 |
| Ju, WP | 1 |
| Li, ZG | 1 |
| Wang, DZ | 1 |
| Xie, AM | 1 |
| Park, B | 2 |
| Yun, N | 1 |
| Choe, KM | 1 |
| Jin, BK | 1 |
| Oh, YJ | 2 |
| Ahmed, MR | 1 |
| Berthet, A | 2 |
| Bychkov, E | 1 |
| Bioulac, BH | 1 |
| Carl, YT | 1 |
| Bloch, B | 1 |
| Kook, S | 1 |
| Aubert, I | 1 |
| Dovero, S | 1 |
| Doudnikoff, E | 2 |
| Gurevich, VV | 1 |
| Gurevich, EV | 1 |
| Silva, C | 1 |
| Fuxe, K | 4 |
| Chadi, G | 1 |
| Fernando, CV | 1 |
| Moses, D | 1 |
| Tomas, D | 2 |
| Drago, J | 1 |
| Horne, MK | 2 |
| Kameda, M | 4 |
| Tayra, JT | 3 |
| Kikuchi, Y | 3 |
| Grandoso, L | 1 |
| Jones, CA | 1 |
| Johnston, LC | 1 |
| Jackson, MJ | 1 |
| Smith, LA | 1 |
| van Scharrenburg, G | 1 |
| Rose, S | 2 |
| Jenner, PG | 1 |
| Kreisler, A | 1 |
| Duhamel, A | 1 |
| Vanbesien-Mailliot, C | 1 |
| Destée, A | 1 |
| Bordet, R | 2 |
| Guan, Q | 2 |
| Jin, L | 2 |
| Zhao, L | 2 |
| Niknam, A | 1 |
| Jalali-Nadoushan, MR | 1 |
| Kiasalari, Z | 1 |
| Manyam, BV | 1 |
| Liu, YY | 1 |
| Yang, N | 2 |
| Zhu, HB | 1 |
| Zuo, PP | 1 |
| Inden, M | 4 |
| Minamino, H | 1 |
| Abe, M | 1 |
| Takata, K | 4 |
| Taniguchi, T | 4 |
| Hu, CH | 1 |
| Deng, C | 1 |
| Mackovski, N | 1 |
| Long, L | 1 |
| Chen, J | 1 |
| Huang, XF | 1 |
| Wang, Q | 2 |
| Fang, C | 1 |
| Yin, J | 1 |
| Xu, Z | 1 |
| Zhou, H | 1 |
| Gao, C | 1 |
| Lopéz-Santiago, LM | 1 |
| Lee, BK | 1 |
| Lim, SC | 1 |
| Black, YD | 1 |
| Xiao, D | 2 |
| Pellegrino, D | 2 |
| Kachroo, A | 1 |
| Brownell, AL | 3 |
| Cui, LB | 1 |
| Li, BW | 1 |
| Jin, XH | 1 |
| Shi, J | 1 |
| Weinreb, O | 1 |
| Bar-Am, O | 1 |
| Prosolovich, K | 1 |
| Amit, T | 1 |
| Youdim, MB | 4 |
| Agari, T | 3 |
| Kuramoto, S | 1 |
| Liang, H | 1 |
| Borlongan, CV | 4 |
| Mix, E | 1 |
| Benecke, R | 2 |
| Foyet, HS | 2 |
| Hritcu, L | 5 |
| Ciobica, A | 4 |
| Stefan, M | 3 |
| Kamtchouing, P | 2 |
| Cojocaru, D | 1 |
| Spinnewyn, B | 2 |
| Charnet, C | 1 |
| Cornet, S | 1 |
| Roubert, V | 1 |
| Chabrier, PE | 2 |
| Auguet, M | 2 |
| Shi, XR | 1 |
| Hong, ZY | 1 |
| Liu, HR | 1 |
| Zhang, YC | 1 |
| Zhu, YZ | 1 |
| Mautino, G | 1 |
| Marin, JG | 1 |
| Rocher, MN | 1 |
| Grandoulier, AS | 1 |
| Ferrandis, E | 1 |
| Palner, M | 1 |
| Kjaerby, C | 1 |
| Knudsen, GM | 1 |
| Cumming, P | 1 |
| Di Filippo, M | 1 |
| Fusco, FR | 1 |
| Peränen, J | 1 |
| Lindholm, P | 1 |
| Raasmaja, A | 1 |
| Tuominen, RK | 3 |
| Grünblatt, E | 4 |
| Daly, CS | 1 |
| Bartoszyk, GD | 1 |
| Dean, O | 1 |
| van den Buuse, M | 1 |
| Kamibayashi, M | 1 |
| Yanagida, T | 2 |
| Shibaike, T | 1 |
| Yasui, H | 1 |
| Yamashita, M | 1 |
| Gambhir, H | 1 |
| Mathur, R | 1 |
| Behari, M | 1 |
| Xiang, B | 1 |
| Fei, X | 1 |
| Qin, Z | 1 |
| Liang, Z | 1 |
| Eskow Jaunarajs, KL | 2 |
| Larisch, R | 2 |
| Vosberg, H | 2 |
| Beu, M | 2 |
| Hautzel, H | 1 |
| Wirrwar, A | 1 |
| Mueller, HW | 1 |
| Antke, C | 1 |
| Soria, G | 1 |
| Tudela, R | 1 |
| Mullol, J | 1 |
| Planas, AM | 1 |
| Chen, LH | 1 |
| Chiang, PT | 1 |
| Lee, HY | 1 |
| Chen, HH | 1 |
| Lin, SC | 1 |
| Chan, MH | 1 |
| Melchiorri, G | 1 |
| Castelli, V | 1 |
| Sanchez, G | 1 |
| Rodriguez, MJ | 1 |
| Pomata, P | 1 |
| Alachkar, A | 1 |
| Jones, OT | 1 |
| García, J | 1 |
| Winkler, C | 4 |
| Dodiya, HB | 1 |
| Kordower, AM | 1 |
| Paumier, K | 1 |
| Sortwell, C | 1 |
| Garbayo, E | 1 |
| Ansorena, E | 1 |
| Blanco-Prieto, MJ | 1 |
| Aymerich, MS | 1 |
| Mihasan, M | 2 |
| Palamiuc, L | 1 |
| Nabeshima, T | 1 |
| Chang, YL | 1 |
| Chen, SJ | 1 |
| Kao, CL | 1 |
| Hung, SC | 1 |
| Ding, DC | 1 |
| Yu, CC | 1 |
| Ku, HH | 1 |
| Lin, CP | 1 |
| Lee, KH | 1 |
| Wang, JJ | 1 |
| Hsu, CC | 1 |
| Chen, LK | 1 |
| Li, HY | 1 |
| Chiou, SH | 1 |
| Melcangi, RC | 1 |
| Caruso, D | 1 |
| Abbiati, F | 1 |
| Liang, HB | 1 |
| Shinko, A | 1 |
| Wakamori, T | 1 |
| Asongalem, AE | 1 |
| Murphy, E | 1 |
| Charron, G | 1 |
| Laux, A | 1 |
| Canron, MH | 1 |
| Barroso-Chinea, P | 1 |
| Qin, C | 1 |
| Nosten-Bertrand, M | 1 |
| Giros, B | 1 |
| Delalande, F | 1 |
| Van Dorsselaer, A | 1 |
| Vital, A | 1 |
| Goumon, Y | 1 |
| Varcin, M | 1 |
| Mertens, B | 1 |
| Haute, CV | 1 |
| Bergstrom, BP | 3 |
| Sanberg, SG | 1 |
| Andersson, M | 3 |
| Mithyantha, J | 1 |
| Carroll, FI | 1 |
| Garris, PA | 3 |
| Jochem, J | 1 |
| Adwent, M | 1 |
| Boroń, D | 1 |
| Brus, H | 1 |
| Gołembiowska, K | 1 |
| Dziubina, A | 1 |
| Ren, T | 1 |
| Cai, Y | 1 |
| Yuan, W | 2 |
| Peng, Y | 1 |
| Yin, SM | 1 |
| Yu, DQ | 1 |
| Dong, FY | 1 |
| Tang, J | 1 |
| Sun, YP | 1 |
| Zhang, WQ | 1 |
| Qi, R | 1 |
| Chen, XY | 1 |
| Wei, HJ | 1 |
| Tekin, N | 1 |
| Şener, E | 1 |
| Akyüz, F | 1 |
| Inal, M | 1 |
| Moran, RJ | 1 |
| Dolan, RJ | 1 |
| Friston, KJ | 1 |
| Saryyeva, A | 1 |
| Nakamura, M | 1 |
| Yamato, M | 1 |
| Shiba, T | 1 |
| Naganuma, T | 1 |
| Ichikawa, K | 1 |
| Utsumi, H | 1 |
| Yamada, K | 2 |
| von Bothmer, A | 1 |
| Pum, ME | 2 |
| Wang, R | 1 |
| Ma, Z | 1 |
| Oh, CK | 1 |
| Choi, WS | 1 |
| Chung, IK | 1 |
| Errico, F | 1 |
| Vitucci, D | 1 |
| Romano, R | 1 |
| Marinucci, S | 1 |
| Seim, NB | 1 |
| Mahmoudi, J | 1 |
| Samini, M | 1 |
| Reyhani-Rad, S | 1 |
| Babapour, V | 1 |
| Antoury, L | 1 |
| Doty, RL | 1 |
| Ryu, SB | 1 |
| Bae, EK | 1 |
| Hwang, YS | 2 |
| Im, C | 1 |
| Chang, JW | 4 |
| Shin, HC | 1 |
| Kim, KH | 1 |
| Olteanu, Z | 1 |
| Padurariu, M | 2 |
| Westin, JE | 3 |
| Janssen, ML | 2 |
| Sager, TN | 1 |
| Gombash, SE | 1 |
| Lipton, JW | 2 |
| Cole-Strauss, A | 1 |
| Terpstra, BT | 1 |
| Spieles-Engemann, AL | 1 |
| Wohlgenant, SL | 1 |
| Thompson, VB | 1 |
| Pardo, LA | 1 |
| Tian, LP | 1 |
| Pan, J | 2 |
| Lu, GQ | 1 |
| Zhang, YJ | 1 |
| Ding, JQ | 1 |
| Chen, SD | 2 |
| Mattern, C | 1 |
| Silva, AM | 1 |
| Wessler, J | 1 |
| Ruocco, LA | 1 |
| Glajch, KE | 1 |
| Fleming, SM | 2 |
| Surmeier, DJ | 2 |
| Osten, P | 1 |
| Du, X | 1 |
| Zwartjes, DG | 1 |
| Tan, SK | 1 |
| Heida, T | 1 |
| Hoogland, G | 1 |
| Ferraro, L | 2 |
| O'Connor, WT | 1 |
| Beggiato, S | 1 |
| Tomasini, MC | 1 |
| Tanganelli, S | 2 |
| Antonelli, T | 1 |
| Dutra, MF | 1 |
| Jaeger, M | 1 |
| Ilha, J | 1 |
| Kalil-Gaspar, PI | 1 |
| Marcuzzo, S | 1 |
| Sameri, MJ | 1 |
| Sarkaki, A | 1 |
| Farbood, Y | 1 |
| Mansouri, SM | 1 |
| Rodríguez, S | 1 |
| Uchida, K | 2 |
| Nakayama, H | 1 |
| Laloux, C | 1 |
| Petrault, M | 1 |
| Lecointe, C | 1 |
| Devos, D | 1 |
| Betts, MJ | 1 |
| O'Neill, MJ | 1 |
| Abuirmeileh, A | 2 |
| Harkavyi, A | 2 |
| Rampersaud, N | 1 |
| Lever, R | 2 |
| Tadross, JA | 1 |
| Bloom, SR | 1 |
| Whitton, PS | 2 |
| Povarnina, PY | 1 |
| Vorontsova, ON | 1 |
| Bondarenko, NA | 1 |
| Sadeghian, M | 1 |
| Marinova-Mutafchieva, L | 1 |
| Broom, L | 1 |
| Davis, JB | 1 |
| Virley, D | 1 |
| Medhurst, AD | 2 |
| Dexter, DT | 6 |
| Korkmaz, O | 1 |
| Ay, H | 1 |
| Ulupinar, E | 1 |
| Rode, F | 1 |
| Munro, G | 1 |
| Holst, D | 1 |
| Nielsen, EØ | 1 |
| Troelsen, KB | 1 |
| Timmermann, DB | 1 |
| Rønn, LC | 1 |
| Grunnet, M | 1 |
| Jahanihashemi, H | 1 |
| Sarookhani, M | 1 |
| Dai, FR | 1 |
| Du, XP | 1 |
| Yang, QD | 1 |
| Sun, SY | 1 |
| An, CN | 1 |
| Pu, XP | 1 |
| Coune, PG | 1 |
| Craveiro, M | 1 |
| Gaugler, MN | 1 |
| Mlynárik, V | 1 |
| Schneider, BL | 2 |
| Aebischer, P | 3 |
| Gruetter, R | 1 |
| Hamidi, GA | 1 |
| Zarmehri, HA | 1 |
| Sharma, N | 1 |
| Gupta, A | 1 |
| Kalonia, H | 1 |
| Mishra, J | 1 |
| Chen, CC | 1 |
| Shih, YY | 1 |
| Chang, C | 1 |
| Lee, EY | 1 |
| Lee, JE | 1 |
| Park, JH | 1 |
| Shin, IC | 1 |
| Koh, HC | 1 |
| Leung, TC | 1 |
| Lui, CN | 1 |
| Berger, SP | 1 |
| Walker, MD | 1 |
| Dinelle, K | 1 |
| Kornelsen, R | 1 |
| McCormick, S | 1 |
| Mah, C | 1 |
| Holden, JE | 2 |
| Farrer, MJ | 1 |
| Stoessl, AJ | 2 |
| Sossi, V | 2 |
| Engeln, M | 1 |
| Ahmed, SH | 1 |
| Vouillac, C | 1 |
| Tison, F | 4 |
| Fernagut, PO | 2 |
| Bautista, E | 1 |
| Sánchez, A | 1 |
| Guevara, J | 1 |
| Herrando-Grabulosa, M | 1 |
| Moran, J | 1 |
| Martínez, R | 1 |
| Hou, C | 1 |
| Xue, L | 1 |
| Tai, CH | 2 |
| Pan, MK | 1 |
| Lin, JJ | 1 |
| Huang, CS | 1 |
| Yang, YC | 1 |
| Kuo, CC | 1 |
| Fan, KY | 1 |
| Chan, CS | 1 |
| Bevan, MD | 1 |
| Choi, JY | 1 |
| Kim, CH | 1 |
| Jeon, TJ | 1 |
| Cho, WG | 1 |
| Lee, JS | 1 |
| Lee, SJ | 1 |
| Choi, TH | 1 |
| Kim, BS | 1 |
| Yi, CH | 1 |
| Seo, Y | 1 |
| Yi, DI | 1 |
| Han, SJ | 1 |
| Lee, M | 1 |
| Kim, DG | 1 |
| Lee, JD | 1 |
| An, G | 1 |
| Ryu, YH | 1 |
| Gittis, A | 1 |
| Kopalli, SR | 1 |
| Noh, SJ | 1 |
| Koppula, S | 1 |
| Suh, YH | 1 |
| Breger, LS | 1 |
| Tan, X | 1 |
| Qin, J | 1 |
| Tian, M | 1 |
| Dong, C | 1 |
| Jin, G | 1 |
| Hong, X | 1 |
| Shamsizadeh, A | 1 |
| Nazeri, M | 1 |
| Allahtavakoli, M | 1 |
| Esmaeli-Mahani, S | 1 |
| Ke, Y | 1 |
| Chan, DC | 1 |
| Qian, ZM | 1 |
| Ko, H | 1 |
| Arbuthnott, GW | 1 |
| Del Papa, G | 1 |
| Burdett, TC | 1 |
| Desjardins, CA | 1 |
| Cipriani, S | 1 |
| Lui, NP | 1 |
| Capper-Loup, C | 1 |
| Frey, CM | 1 |
| Rebell, D | 1 |
| Kaelin-Lang, A | 1 |
| Barros Silva, R | 1 |
| Santos, NA | 1 |
| Martins, NM | 1 |
| Ferreira, DA | 1 |
| Barbosa, F | 1 |
| Oliveira Souza, VC | 1 |
| Kinoshita, A | 1 |
| Baffa, O | 1 |
| Santos, AC | 1 |
| Acuña-Lizama, MM | 1 |
| Bata-García, JL | 1 |
| Alvarez-Cervera, FJ | 1 |
| Góngora-Alfaro, JL | 1 |
| Fiorentini, C | 1 |
| Savoia, P | 1 |
| Savoldi, D | 1 |
| Barbon, A | 1 |
| Missale, C | 1 |
| Asakawa, T | 1 |
| Ito-Yamashita, T | 1 |
| Ahmad, AS | 3 |
| Maruyama, T | 1 |
| Narumiya, S | 1 |
| Doré, S | 1 |
| Pioli, EY | 1 |
| Meissner, W | 4 |
| Harnack, D | 4 |
| Reum, T | 3 |
| Sohr, R | 2 |
| Morgenstern, R | 4 |
| Wang, ZH | 1 |
| Ji, Y | 1 |
| Shan, W | 1 |
| Zeng, B | 1 |
| Raksadawan, N | 1 |
| Pastores, GM | 1 |
| Wisniewski, T | 1 |
| Kolodny, EH | 1 |
| Lie, DC | 2 |
| Willhoite, AR | 1 |
| Kaspar, BK | 1 |
| Gage, FH | 2 |
| Tillerson, JL | 3 |
| Cohen, AD | 1 |
| Caudle, WM | 2 |
| Miller, GW | 2 |
| Bari, M | 2 |
| Battista, N | 2 |
| Centonze, D | 5 |
| Finazzi-Agrò, A | 2 |
| Maccarrone, M | 2 |
| Ostenfeld, T | 1 |
| Tai, YT | 1 |
| Martin, P | 1 |
| Déglon, N | 1 |
| Svendsen, CN | 1 |
| Cho, J | 1 |
| Duke, D | 1 |
| Manzino, L | 1 |
| Sonsalla, PK | 1 |
| West, MO | 1 |
| Kagawa, S | 1 |
| Nakano, T | 1 |
| Inoue, O | 1 |
| Hastings, TG | 2 |
| Napolitano, M | 1 |
| Calce, A | 1 |
| Spiezia, S | 1 |
| Gulino, A | 1 |
| Orieux, G | 3 |
| François, C | 2 |
| Féger, J | 3 |
| Hirsch, EC | 7 |
| Lorigados Pedre, L | 1 |
| Pavón Fuentes, N | 1 |
| Alvarez González, L | 1 |
| McRae, A | 1 |
| Serrano Sánchez, T | 1 |
| Blanco Lescano, L | 1 |
| Macías González, R | 1 |
| Fredriksson, A | 1 |
| Archer, T | 1 |
| Sasai, Y | 1 |
| Luo, J | 1 |
| Kaplitt, MG | 1 |
| Fitzsimons, HL | 1 |
| Zuzga, DS | 1 |
| Oshinsky, ML | 1 |
| During, MJ | 2 |
| Zerris, VA | 1 |
| Noren, G | 1 |
| Sungarian, A | 1 |
| Friehs, GM | 1 |
| Aoyama, S | 3 |
| Koga, K | 2 |
| Mori, A | 2 |
| Miyaji, H | 1 |
| Sekine, S | 1 |
| Kase, H | 4 |
| Uchimura, T | 1 |
| Kobayashi, H | 1 |
| Kuwana, Y | 3 |
| Bianchi, C | 2 |
| Beani, L | 2 |
| Nass, R | 1 |
| Blakely, RD | 1 |
| Olshausen, F | 1 |
| Mazel, T | 1 |
| Vorísek, I | 1 |
| Syková, E | 1 |
| Georgievska, B | 1 |
| Oh, JD | 1 |
| Bibbiani, F | 1 |
| Chase, TN | 3 |
| Mura, A | 1 |
| Mintz, M | 1 |
| Feldon, J | 1 |
| Pisani, A | 1 |
| Battaglia, G | 2 |
| Storto, M | 1 |
| Nicoletti, F | 1 |
| Emerich, DF | 1 |
| Bartus, RT | 2 |
| Chekhonin, VP | 4 |
| Lebedev, SV | 3 |
| Dmitrieva, TB | 4 |
| Blinov, DV | 1 |
| Lazarenko, IP | 2 |
| Savchenko, EA | 3 |
| Volodin, NN | 1 |
| Azzouz, M | 1 |
| Martin-Rendon, E | 1 |
| Barber, RD | 1 |
| Mitrophanous, KA | 1 |
| Carter, EE | 1 |
| Rohll, JB | 1 |
| Kingsman, SM | 1 |
| Kingsman, AJ | 1 |
| Mazarakis, ND | 1 |
| Muriel, MP | 1 |
| Martí, MJ | 2 |
| Saura, J | 2 |
| Tolosa, E | 8 |
| Périer, C | 3 |
| Huang, WS | 3 |
| Ma, KH | 2 |
| Chou, YH | 1 |
| Chen, CY | 1 |
| Liu, JC | 3 |
| El-Khodor, BF | 1 |
| Oo, TF | 2 |
| Kholodilov, N | 3 |
| Love, RM | 1 |
| Branton, RL | 1 |
| Karlsson, J | 1 |
| Clarke, DJ | 1 |
| Vergara-Aragon, P | 1 |
| Gonzalez, CL | 1 |
| Teismann, P | 1 |
| Tieu, K | 1 |
| Cohen, O | 1 |
| Choi, DK | 1 |
| Wu, DC | 1 |
| Marks, D | 1 |
| Vila, M | 3 |
| Datla, KP | 3 |
| Murray, HE | 2 |
| Pillai, AV | 1 |
| Gillies, GE | 2 |
| Vaudano, E | 1 |
| Forutan, F | 1 |
| Müller-Gärtner, HW | 1 |
| Henderson, JM | 4 |
| Watson, S | 1 |
| Halliday, GM | 1 |
| Heinemann, T | 1 |
| Belluscio, MA | 2 |
| Kasanetz, F | 1 |
| Riquelme, LA | 3 |
| Parés, M | 1 |
| Bové, J | 4 |
| Pezzi, S | 1 |
| Alberch, J | 1 |
| Watson, SH | 1 |
| Bentlage, C | 1 |
| Reverón, ME | 1 |
| Orth, M | 1 |
| Tabrizi, SJ | 1 |
| Srinivasan, J | 4 |
| Balcioglu, A | 1 |
| Zhang, K | 2 |
| Tarazi, FI | 2 |
| Yamada, H | 1 |
| Dezawa, M | 1 |
| Shimazu, S | 1 |
| Sawada, H | 1 |
| Kuroiwa, Y | 1 |
| Yamamoto, I | 1 |
| Kemmerer, ES | 1 |
| Desmond, TJ | 1 |
| Albin, RL | 1 |
| Kilbourn, MR | 1 |
| Frey, KA | 1 |
| Hernandes, S | 1 |
| Sulzbach, M | 1 |
| Viola, GG | 1 |
| Yang, JS | 1 |
| Jeon, MF | 2 |
| Lee, BH | 2 |
| Chung, SS | 1 |
| Eslamboli, A | 2 |
| Baker, HF | 1 |
| Ridley, RM | 1 |
| Annett, LE | 1 |
| Ray, J | 1 |
| Ha, Y | 1 |
| Cho, YH | 1 |
| Park, YG | 1 |
| Chaturvedi, RK | 5 |
| Agrawal, AK | 5 |
| Seth, K | 4 |
| Shukla, Y | 3 |
| Sinha, C | 3 |
| Seth, PK | 2 |
| Oi, S | 1 |
| Kim, DS | 1 |
| Hidaka, M | 1 |
| Jollivet, C | 1 |
| Aubert-Pouessel, A | 1 |
| Clavreul, A | 1 |
| Venier-Julienne, MC | 1 |
| Remy, S | 1 |
| Montero-Menei, CN | 1 |
| Benoit, JP | 1 |
| Menei, P | 1 |
| Delfino, MA | 1 |
| Stefano, AV | 1 |
| Zbarsky, V | 2 |
| Douhou, A | 1 |
| Chouvet, G | 1 |
| Urbain, N | 1 |
| Vautrelle, N | 1 |
| Dahan, L | 1 |
| Astier, B | 1 |
| Renaud, B | 1 |
| Chen, JF | 2 |
| Fredduzzi, S | 1 |
| Bastia, E | 2 |
| Yu, L | 1 |
| Ongini, E | 1 |
| Ichimura, M | 1 |
| Ikeda, K | 2 |
| Ishii, A | 1 |
| Kanda, T | 1 |
| Koike, N | 1 |
| Kurokawa, M | 2 |
| Nakamura, J | 1 |
| Nonaka, H | 1 |
| Ochi, M | 3 |
| Saki, M | 1 |
| Shimada, J | 1 |
| Shindou, T | 1 |
| Shiozaki, S | 3 |
| Suzuki, F | 1 |
| Takeda, M | 1 |
| Yanagawa, K | 1 |
| Richardson, PJ | 1 |
| Jenner, P | 5 |
| Bedard, P | 1 |
| Borrelli, E | 1 |
| Hauser, RA | 1 |
| Park, S | 1 |
| Kim, EY | 1 |
| Ghil, GS | 1 |
| Joo, WS | 1 |
| Wang, KC | 1 |
| Kim, YS | 1 |
| Iwata, S | 1 |
| Morioka, H | 1 |
| Miyata, A | 1 |
| Touchon, JC | 1 |
| Frederickson, J | 1 |
| Chalon, S | 1 |
| Mladenović, A | 1 |
| Perović, M | 1 |
| Raicević, N | 1 |
| Kanazir, S | 1 |
| Rakić, L | 1 |
| Ruzdijić, S | 1 |
| Diguet, E | 3 |
| Gross, CE | 1 |
| Wenning, GK | 3 |
| Bacci, JJ | 1 |
| Kachidian, P | 1 |
| Baklaushev, VP | 3 |
| Caraballo, I | 1 |
| Rodriguez de Fonseca, F | 1 |
| Ferrer, B | 1 |
| El Banoua, F | 1 |
| Flores, JA | 1 |
| Galan-Rodriguez, B | 1 |
| Camargo, MD | 1 |
| Pitzer, MR | 2 |
| Betarbet, R | 2 |
| Poisik, O | 1 |
| Sherer, TB | 2 |
| Greenamyre, JT | 3 |
| Löschmann, PA | 1 |
| De Groote, C | 1 |
| Smith, L | 1 |
| Wüllner, U | 1 |
| Fischer, G | 1 |
| Kemp, JA | 1 |
| Klockgether, T | 1 |
| Lai, SK | 1 |
| Ng, TK | 1 |
| Lau, WK | 1 |
| Yang, MS | 1 |
| Wong, CK | 1 |
| Zuch, CL | 2 |
| David, D | 1 |
| Ujhelyi, L | 1 |
| Hudson, JL | 1 |
| Gerhardt, GA | 3 |
| Kaplan, PL | 1 |
| Nandi, D | 1 |
| Jenkinson, E | 1 |
| Miall, C | 1 |
| Stein, JF | 1 |
| Aziz, TZ | 1 |
| Baier, PC | 3 |
| Schindehütte, J | 3 |
| Thinyane, K | 2 |
| Flügge, G | 2 |
| Fuchs, E | 2 |
| Mansouri, A | 2 |
| Paulus, W | 3 |
| Gruss, P | 1 |
| Trenkwalder, C | 4 |
| Mauceri, D | 1 |
| Mabandla, M | 1 |
| Kellaway, L | 1 |
| St Clair Gibson, A | 1 |
| Bartlett, LE | 1 |
| Sadi, D | 6 |
| Lewington, M | 1 |
| Mendez, I | 6 |
| Endepols, H | 1 |
| Schul, J | 1 |
| Gerhardt, HC | 1 |
| Walkowiak, W | 1 |
| Kramer, BC | 1 |
| Mytilineou, C | 1 |
| Hurtado-Lorenzo, A | 1 |
| Millan, E | 1 |
| Gonzalez-Nicolini, V | 1 |
| Suwelack, D | 1 |
| Castro, MG | 2 |
| Lowenstein, PR | 2 |
| Yoo, YM | 1 |
| Kim, YJ | 1 |
| Lee, U | 1 |
| Paik, DJ | 1 |
| Yoo, HT | 1 |
| Park, CW | 1 |
| Kim, YB | 1 |
| Lee, SG | 1 |
| Kim, WK | 1 |
| Yoo, CJ | 1 |
| Khanna, VK | 1 |
| Duan, D | 1 |
| Cooper, O | 1 |
| Schober, A | 1 |
| Reglodi, D | 1 |
| Tamás, A | 1 |
| Lubics, A | 1 |
| Szalontay, L | 1 |
| Lengvári, I | 1 |
| Robertson, AD | 1 |
| Scherfler, C | 1 |
| Sather, T | 1 |
| Puschban, Z | 1 |
| Poewe, W | 2 |
| Lebsanft, HB | 1 |
| Kohles, T | 1 |
| Kovar, KA | 1 |
| Ebert, AD | 2 |
| He, X | 1 |
| Cryns, VL | 1 |
| Bohn, MC | 2 |
| Bielicki, G | 1 |
| Donnat, JP | 1 |
| Renou, JP | 1 |
| Eschalier, A | 1 |
| Asseo-García, AM | 1 |
| Zhao, X | 1 |
| Liu, SJ | 1 |
| Jones, TA | 1 |
| Bando, Y | 1 |
| Katayama, T | 1 |
| Taniguchi, M | 1 |
| Ishibashi, T | 1 |
| Matsuo, N | 1 |
| Ogawa, S | 1 |
| Tohyama, M | 1 |
| Sheng, J | 1 |
| Tang, Z | 3 |
| Guo, H | 2 |
| Shen, Y | 2 |
| Paraoan, L | 1 |
| Kondoh, T | 1 |
| Bannai, M | 1 |
| Nishino, H | 1 |
| Torii, K | 1 |
| Cass, WA | 2 |
| Peters, LE | 1 |
| Smith, MP | 2 |
| Bahat-Stroomza, M | 1 |
| Gilgun-Sherki, Y | 1 |
| Offen, D | 1 |
| Panet, H | 1 |
| Saada, A | 1 |
| Krool-Galron, N | 1 |
| Barzilai, A | 1 |
| Atlas, D | 1 |
| Melamed, E | 1 |
| Ahmad, M | 2 |
| Saleem, S | 2 |
| Yousuf, S | 2 |
| Ansari, MA | 2 |
| Castañeda, E | 1 |
| Fleming, S | 1 |
| Boat, K | 1 |
| Moffett, J | 1 |
| Stachowiak, EK | 1 |
| Bloom, DC | 1 |
| Stachowiak, MK | 1 |
| Janhunen, S | 1 |
| Ahtee, L | 1 |
| Håkansson, K | 1 |
| Wang, PH | 1 |
| McLachlan, C | 1 |
| Wong, PT | 1 |
| Ferro, MM | 2 |
| Bellissimo, MI | 1 |
| Angellucci, ME | 1 |
| Canteras, NS | 2 |
| Monville, C | 1 |
| Taymans, JM | 1 |
| Kia, HK | 1 |
| Groenewegen, HJ | 2 |
| Leysen, JE | 1 |
| Langlois, X | 1 |
| Schleimer, SB | 1 |
| Allbutt, H | 4 |
| Dabholkar, V | 1 |
| Abela, D | 1 |
| Jovic, J | 1 |
| Quinlivan, M | 1 |
| Sindhu, KM | 1 |
| Saravanan, KS | 1 |
| Robichon, R | 1 |
| Jaafar, A | 1 |
| Terqui, M | 1 |
| Peschanski, M | 1 |
| Kim, DH | 1 |
| Qi, M | 1 |
| Yanagisawa, D | 2 |
| Nishimura, K | 2 |
| Tsuchiya, D | 2 |
| Hayashi, K | 2 |
| Yoshimoto, K | 1 |
| Sumi, S | 1 |
| Inoue, K | 1 |
| Ghorayeb, I | 1 |
| Zivin, M | 2 |
| Silva, RM | 1 |
| Yarygina, O | 1 |
| Ryu, EJ | 2 |
| Lu, PD | 1 |
| Marciniak, SJ | 1 |
| Ron, D | 1 |
| Kondo, J | 1 |
| Sugimoto, H | 1 |
| Akaike, A | 1 |
| Pavón, N | 1 |
| Mendialdua, A | 1 |
| Liang, Q | 1 |
| Pan, S | 1 |
| Tyurin, VA | 1 |
| Kagan, VE | 1 |
| Schor, NF | 1 |
| Howells, FM | 1 |
| Ariano, MA | 1 |
| Grissell, AE | 1 |
| Littlejohn, FC | 1 |
| Buchanan, TM | 1 |
| Elsworth, JD | 1 |
| Heise, CE | 3 |
| Teo, ZC | 1 |
| Wallace, BA | 1 |
| Ashkan, K | 1 |
| Nakagawa, T | 1 |
| Yabe, T | 1 |
| Schwartz, JP | 1 |
| Campbell, BM | 1 |
| Kreipke, CW | 1 |
| Fancellu, R | 2 |
| Inaji, M | 2 |
| Okauchi, T | 2 |
| Maeda, J | 2 |
| Nagai, Y | 2 |
| Nariai, T | 2 |
| Ohno, K | 2 |
| Obayashi, S | 2 |
| Higuchi, M | 1 |
| Suhara, T | 2 |
| Sajadi, A | 1 |
| Bensadoun, JC | 1 |
| Lo Bianco, C | 1 |
| Kaji, R | 1 |
| Kuratsu, J | 1 |
| Henderson, J | 2 |
| Doherty, K | 1 |
| Billing, R | 1 |
| Truong, L | 1 |
| Kassiou, M | 1 |
| Branisa, P | 1 |
| Koch, R | 1 |
| Donaldson, AE | 2 |
| Marshall, CE | 2 |
| Suon, S | 2 |
| Iacovitti, L | 2 |
| Serrats, J | 1 |
| Shi, LH | 1 |
| Luo, F | 1 |
| Woodward, DJ | 1 |
| Chang, JY | 1 |
| Fadda, F | 1 |
| Polli, F | 1 |
| Cattabeni, F | 1 |
| Hosmann, K | 1 |
| Konitsiotis, S | 1 |
| Tsironis, C | 1 |
| Quintero, EM | 2 |
| Willis, L | 1 |
| Singleton, R | 1 |
| Harris, N | 1 |
| Huang, P | 1 |
| Bhat, N | 1 |
| Granholm, AC | 4 |
| de Meira Santos Lima, M | 1 |
| Braga Reksidler, A | 1 |
| Marques Zanata, S | 1 |
| Bueno Machado, H | 1 |
| Tufik, S | 2 |
| Kobayashi, K | 1 |
| Muraoka, K | 1 |
| Ji Yuan, W | 1 |
| Hayase, H | 1 |
| Matsui, T | 1 |
| Fenu, S | 3 |
| Baraldi, PG | 1 |
| Tabrizi, MA | 1 |
| Väänänen, AJ | 1 |
| Rauhala, P | 1 |
| Liesi, P | 1 |
| Taylor, JL | 1 |
| Kuhn, DM | 1 |
| Meredith, GE | 1 |
| Kang, UJ | 1 |
| Liu, BF | 1 |
| Gao, EJ | 1 |
| Zeng, XZ | 1 |
| Ji, M | 1 |
| Cai, Q | 1 |
| Lu, Q | 1 |
| Gerfen, CR | 1 |
| Enna, SJ | 1 |
| Reisman, SA | 1 |
| McLeod, M | 1 |
| Hong, M | 2 |
| Mukhida, K | 3 |
| Ulalia, R | 1 |
| McCoy, MK | 1 |
| Martinez, TN | 1 |
| Ruhn, KA | 1 |
| Szymkowski, DE | 1 |
| Smith, CG | 1 |
| Botterman, BR | 1 |
| Tansey, KE | 1 |
| Gardi, J | 1 |
| Nyengaard, JR | 1 |
| Mohapel, P | 1 |
| Holtz, WA | 1 |
| Turetzky, JM | 1 |
| Jong, YJ | 1 |
| O'Malley, KL | 1 |
| Eusebio, A | 1 |
| Biswas, SC | 1 |
| Yamamoto, N | 1 |
| Pierce, RC | 1 |
| Soghomonian, JJ | 2 |
| Biagioni, F | 1 |
| Busceti, CL | 1 |
| Molinaro, G | 1 |
| Giorgi, FS | 1 |
| Ruggieri, S | 1 |
| Fornai, F | 1 |
| McArthur, S | 1 |
| Dhankot, A | 1 |
| Köllensperger, M | 1 |
| Reindl, M | 1 |
| O'Dell, SJ | 1 |
| Gross, NB | 1 |
| Fricks, AN | 1 |
| Casiano, BD | 1 |
| Nguyen, TB | 1 |
| Marshall, JF | 1 |
| Ahmed, R | 1 |
| Sagar, RK | 1 |
| Krishana, B | 1 |
| Sánchez-Iglesias, S | 1 |
| Rey, P | 2 |
| Méndez-Alvarez, E | 2 |
| Soto-Otero, R | 2 |
| Jain, M | 1 |
| Armstrong, RJ | 1 |
| Elneil, S | 1 |
| Barker, RA | 2 |
| Kuan, WL | 1 |
| Tyers, P | 1 |
| Hara, K | 1 |
| Sethi, KD | 1 |
| Morgan, JC | 1 |
| Xu, YH | 1 |
| Benn, CL | 1 |
| Cha, JH | 1 |
| Peterson, TS | 1 |
| García-Arencibia, M | 2 |
| González, S | 1 |
| de Lago, E | 1 |
| Ramos, JA | 1 |
| Mechoulam, R | 1 |
| Fernández-Ruiz, J | 2 |
| Ramsay Croft, N | 1 |
| Haas, SJ | 1 |
| Beckmann, S | 1 |
| Petrov, S | 1 |
| Andressen, C | 1 |
| Katz, J | 1 |
| Dagostino, P | 1 |
| Shim, I | 1 |
| Lee, BB | 1 |
| Henning, J | 1 |
| Koczan, D | 1 |
| Glass, A | 1 |
| Karopka, T | 1 |
| Pahnke, J | 1 |
| Rolfs, A | 1 |
| Gimsa, U | 1 |
| Topping, GJ | 1 |
| Camborde, ML | 1 |
| Kornelsen, RA | 1 |
| McCormick, SE | 1 |
| Greene, J | 1 |
| Studenov, AR | 1 |
| Ruth, TJ | 1 |
| Megyeri, K | 1 |
| Marko, B | 1 |
| Sziray, N | 1 |
| Gacsalyi, I | 1 |
| Juranyi, Z | 1 |
| Levay, G | 1 |
| Harsing, LG | 1 |
| Han, F | 1 |
| Viaro, R | 1 |
| Delfino, M | 1 |
| Kalisch, R | 1 |
| Czisch, M | 1 |
| Ricatti, J | 1 |
| Auer, DP | 1 |
| Zhu, A | 2 |
| Yu, M | 2 |
| Wang, JQ | 1 |
| Alemdar, AY | 1 |
| McAlister, V | 1 |
| Gemma, C | 1 |
| Catlow, B | 1 |
| Cole, M | 1 |
| Samec, A | 1 |
| Shah, N | 1 |
| Vila, J | 1 |
| Bachstetter, A | 1 |
| Liang, ZQ | 1 |
| Li, YL | 1 |
| Zhao, XL | 1 |
| Han, R | 1 |
| Wang, XX | 1 |
| Bennett, MC | 1 |
| Qin, ZH | 1 |
| Limón, DI | 1 |
| Flores-Hernández, J | 1 |
| Flores, G | 1 |
| Anstrom, KK | 1 |
| Shattuck, A | 1 |
| Roberts, DC | 1 |
| Dewar, D | 1 |
| Bentley, D | 1 |
| Barnett, SC | 1 |
| Sun, J | 1 |
| Yang, L | 1 |
| Lu, G | 1 |
| Yew, D | 1 |
| Finberg, JP | 1 |
| Sader-Mazbar, O | 1 |
| Liu, YP | 1 |
| Ferreira, M | 1 |
| Strome, EM | 1 |
| Zis, AP | 1 |
| Jeon, MY | 1 |
| Lee, WY | 2 |
| Kang, HY | 1 |
| Chung, EJ | 1 |
| Gasmi, M | 1 |
| Brandon, EP | 1 |
| Herzog, CD | 1 |
| Wilson, A | 1 |
| Bishop, KM | 1 |
| Hofer, EK | 1 |
| Cunningham, JJ | 1 |
| Printz, MA | 1 |
| Xie, JX | 1 |
| Andren, PE | 2 |
| Oehrn, C | 1 |
| Cannon, JR | 1 |
| Hua, Y | 1 |
| Richardson, RJ | 1 |
| Keep, RF | 1 |
| Koopmans, G | 1 |
| Joosten, EA | 1 |
| Kozan, R | 1 |
| Kaplan, S | 1 |
| Croucher, MJ | 2 |
| Hann, HJ | 1 |
| Belujon, P | 1 |
| Taupignon, A | 1 |
| Nilsson, A | 1 |
| Sköld, K | 1 |
| Sjögren, B | 1 |
| Svensson, M | 1 |
| Pierson, J | 1 |
| Caprioli, RM | 1 |
| Buijs, J | 1 |
| Persson, B | 1 |
| Zhan, Q | 1 |
| Tan, L | 1 |
| Imai, Y | 1 |
| Inoue, H | 1 |
| Kataoka, A | 1 |
| Hua-Qin, W | 1 |
| Masuda, M | 1 |
| Ikeda, T | 1 |
| Tsukita, K | 1 |
| Soda, M | 1 |
| Kodama, T | 1 |
| Fuwa, T | 1 |
| Kaneko, S | 1 |
| Matsumoto, S | 1 |
| Wakamatsu, K | 1 |
| Ito, S | 1 |
| Miura, M | 1 |
| Aosaki, T | 1 |
| Itohara, S | 1 |
| Takahashi, R | 1 |
| Teng, Q | 1 |
| Garrity-Moses, ME | 1 |
| McClelland, S | 1 |
| Federici, T | 1 |
| Carlton, E | 1 |
| Riley, J | 1 |
| Boulis, NM | 1 |
| Zhao, YX | 1 |
| Wang, ZQ | 1 |
| Sun, ZK | 1 |
| Hamann, M | 1 |
| Richter, A | 1 |
| Cui, QL | 1 |
| Breit, S | 1 |
| Martin, A | 1 |
| Lessmann, L | 1 |
| Cerkez, D | 1 |
| Gasser, T | 1 |
| Schulz, JB | 1 |
| Biswas, S | 1 |
| Fernandez, F | 1 |
| Ghosh, B | 1 |
| Zhen, J | 1 |
| Kuzhikandathil, E | 1 |
| Rzhetskaya, M | 1 |
| Kareva, T | 1 |
| Bland, R | 1 |
| Tank, AW | 1 |
| Lee, J | 1 |
| Gomez-Ramirez, J | 1 |
| Visanji, N | 1 |
| Blumensath, S | 1 |
| Shimizu, M | 1 |
| Eslava-Alva, MJ | 1 |
| Cheetham, S | 1 |
| Maeda, T | 1 |
| Nagata, K | 1 |
| Yoshida, Y | 1 |
| Mithal, P | 1 |
| Wietzikoski, EC | 1 |
| Martinez, GR | 1 |
| Hipólide, D | 1 |
| D'Andrea, I | 1 |
| Armida, M | 1 |
| Pèzzola, A | 1 |
| Potenza, RL | 1 |
| Popoli, P | 1 |
| Alleva, E | 1 |
| Lanza, M | 1 |
| Makovec, F | 1 |
| Artusi, R | 1 |
| Caselli, G | 1 |
| Miller, RL | 1 |
| James-Kracke, M | 1 |
| Sun, GY | 1 |
| Sun, AY | 1 |
| Tian, YM | 1 |
| Luo, DZ | 1 |
| Zhang, XH | 1 |
| Xue, H | 1 |
| Bankiewicz, KS | 2 |
| Oiwa, Y | 1 |
| Kohutnicka, M | 1 |
| Cummins, A | 1 |
| Eberling, J | 1 |
| Frau, L | 1 |
| Lucia, F | 1 |
| Annalisa, P | 1 |
| Silvia, P | 1 |
| Nicola, S | 1 |
| Nicoletta, S | 1 |
| Micaela, M | 1 |
| Lindgren, N | 1 |
| Carlson, KM | 1 |
| Oyagi, A | 1 |
| Oida, Y | 1 |
| Hara, H | 2 |
| Izuta, H | 1 |
| Shimazawa, M | 1 |
| Matsunaga, N | 1 |
| Adachi, T | 1 |
| Kingsbury, AE | 1 |
| Biggs, CS | 1 |
| Rodriguez-Pallares, J | 1 |
| Parga, JA | 1 |
| Guerra, MJ | 1 |
| Gregory, TF | 1 |
| Boxer, PA | 1 |
| Meltzer, LT | 1 |
| Serpa, KA | 1 |
| Wise, LD | 1 |
| Cintra, A | 1 |
| Aguirre, JA | 1 |
| Andbjer, B | 1 |
| Finnman, UB | 1 |
| Hagman, M | 1 |
| Agnati, LF | 1 |
| Höglund, C | 1 |
| Möller, A | 1 |
| Tranberg, A | 1 |
| Hilbertson, A | 1 |
| Mandel, S | 3 |
| Fukuzaki, K | 1 |
| Kamenosono, T | 1 |
| Nagata, R | 1 |
| Leasure, JL | 1 |
| Bland, ST | 1 |
| Allen, C | 1 |
| Aoi, M | 1 |
| Tomita, S | 1 |
| Ohmoto, T | 1 |
| Yelnik, J | 1 |
| Ruberg, M | 1 |
| Agid, Y | 3 |
| Sbrenna, S | 1 |
| Rosenblad, C | 1 |
| Vu, TQ | 1 |
| Ling, ZD | 2 |
| Ma, SY | 1 |
| Robie, HC | 1 |
| Tong, CW | 1 |
| Chen, EY | 1 |
| Carvey, PM | 2 |
| Prat, G | 2 |
| Jané, F | 1 |
| Casas, M | 2 |
| Dickson, K | 1 |
| Mogi, M | 1 |
| Togari, A | 1 |
| Tanaka, K | 1 |
| Ichinose, H | 1 |
| Nagatsu, T | 1 |
| Baker, KA | 3 |
| García, JC | 1 |
| Remires, D | 1 |
| Leiva, A | 1 |
| González, R | 1 |
| Baldessarini, RJ | 1 |
| Nordstroem, VK | 1 |
| Briedrick, LA | 1 |
| Hoernig, GR | 1 |
| Sogawa, CA | 1 |
| Tanaka, KI | 1 |
| Nakanishi, T | 1 |
| Jonkers, N | 2 |
| Ebinger, G | 2 |
| Iwata, SI | 1 |
| Fukuda, T | 1 |
| Prikhojan, A | 1 |
| Brannan, T | 1 |
| Yahr, MD | 1 |
| Waldmeier, PC | 1 |
| Spooren, WP | 1 |
| Hengerer, B | 1 |
| Palmer, MR | 1 |
| van Horne, CG | 1 |
| Giardina, KE | 1 |
| Freund, RK | 1 |
| Moorhead, JW | 1 |
| Clarkson, ED | 1 |
| Zawada, WM | 1 |
| Bell, KP | 1 |
| Esplen, JE | 1 |
| Choi, PK | 1 |
| Heidenreich, KA | 1 |
| Freed, CR | 1 |
| Behzadi, G | 1 |
| Kogan, BM | 2 |
| Man'kovskaya, IV | 2 |
| Filatova, TS | 2 |
| Yusupova, IU | 1 |
| Zorec, R | 1 |
| Babic, K | 1 |
| Sket, D | 1 |
| Youdim, M | 1 |
| Rubi, A | 1 |
| Unzeta, M | 1 |
| Tariq, M | 1 |
| Khan, HA | 1 |
| Al Moutaery, K | 1 |
| Al Deeb, S | 1 |
| Ganguly, A | 1 |
| Keefe, KA | 1 |
| Schertz, KE | 1 |
| Weirick, T | 1 |
| Nafziger, B | 1 |
| Takacs, SA | 1 |
| Lopes, KO | 1 |
| Massa, KJ | 1 |
| Walker, QD | 1 |
| Belopasov, VV | 1 |
| Olds, ME | 1 |
| Jacques, DB | 1 |
| Kopyov, O | 1 |
| Ni, ZG | 1 |
| Bouali-Benazzouz, R | 2 |
| Gao, DM | 1 |
| Galvan, A | 1 |
| Sawamoto, K | 1 |
| Nakao, N | 1 |
| Kakishita, K | 1 |
| Ogawa, Y | 1 |
| Toyama, Y | 1 |
| Yamamoto, A | 1 |
| Yamaguchi, M | 1 |
| Mori, K | 1 |
| Goldman, SA | 1 |
| Itakura, T | 1 |
| Guo, X | 1 |
| Dawson, VL | 1 |
| Dawson, TM | 1 |
| Fonck, C | 1 |
| Baudry, M | 1 |
| Appel, S | 1 |
| Le, W | 1 |
| Santiago, M | 1 |
| Machado, A | 1 |
| Cano, J | 1 |
| Carta, A | 1 |
| Acquas, E | 1 |
| Farr, T | 1 |
| Ballermann, M | 1 |
| Cadet, JL | 1 |
| Zhou, FC | 1 |
| Hayashi, T | 1 |
| Su, TP | 1 |
| Major, EO | 1 |
| McKay, RD | 1 |
| Hurley, MJ | 1 |
| Gerard, DJ | 1 |
| Jauniaux, E | 1 |
| Stern, GM | 1 |
| Bradford, HF | 1 |
| McGuire, SO | 1 |
| Ni, Z | 1 |
| Crocker, SJ | 1 |
| Wigle, N | 1 |
| Liston, P | 1 |
| Thompson, CS | 1 |
| Lee, CJ | 1 |
| Xu, D | 1 |
| Roy, S | 1 |
| Nicholson, DW | 1 |
| Park, DS | 1 |
| MacKenzie, A | 1 |
| Korneluk, RG | 1 |
| Robertson, GS | 1 |
| Lee, JI | 1 |
| Shin, HJ | 2 |
| Nam, DH | 1 |
| Hong, SC | 1 |
| Park, K | 1 |
| Eoh, W | 1 |
| Kim, JH | 1 |
| Zeng, BY | 1 |
| Charles, KJ | 1 |
| Gray, J | 1 |
| Reavill, C | 1 |
| Hunter, AJ | 1 |
| Shale, JA | 1 |
| Chen, YK | 1 |
| Wey, SP | 2 |
| Ting, G | 2 |
| Shen, YY | 1 |
| Wan, FJ | 1 |
| Christidou, M | 1 |
| Widmer, WW | 1 |
| Rooprai, HK | 1 |
| Tian, Z | 1 |
| Van De Witte, SV | 1 |
| Pelled, G | 1 |
| Bergman, H | 1 |
| Goelman, G | 1 |
| Daadi, MM | 1 |
| McGregor, R | 1 |
| Ishida, Y | 1 |
| Todaka, K | 1 |
| Hashiguchi, H | 1 |
| Takeda, R | 1 |
| Mitsuyama, Y | 1 |
| Nishimori, T | 1 |
| Lu, JQ | 1 |
| Deumens, R | 1 |
| Purdy, MB | 1 |
| McGrath, J | 1 |
| Lintz, E | 1 |
| Marchionini, D | 1 |
| Potter, EM | 1 |
| Cornfeldt, ML | 1 |
| Wang, SD | 1 |
| Liu, HW | 1 |
| Baunez, C | 1 |
| Spooren, W | 1 |
| Gasparini, F | 1 |
| Hermida-Ameijeiras, A | 1 |
| López-Real, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial for Near Infrared Endoventricular Illumination for Neuroprotection in Very Early Cases of Parkinson's Disease (Ev-NIRT)[NCT04261569] | 14 participants (Anticipated) | Interventional | 2020-12-14 | Recruiting | |||
| STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the Safety and Tolerability of Intraputamenal Transplantation of Human Embryonic Stem Cell Derived Dopaminergic Cells for Parkinson's Disease (STEM-PD Product)[NCT05635409] | Phase 1 | 8 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| Thoracic Dorsal Spinal Cord Stimulation for the Treatment of Gait and Balance Impairments in Parkinson Disease[NCT03079310] | 15 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | |||
| Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease.[NCT03526991] | 10 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | |||
| STIMO-PARKINSON: Study on Feasibility of Targeted Epidural Spinal Stimulation (TESS) to Improve Mobility in Patients With Parkinson's Disease[NCT04956770] | 2 participants (Actual) | Interventional | 2021-06-14 | Active, not recruiting | |||
| Effects of Repetitive Trans Spinal Magnetic Stimulation Associated With Treadmill Gait Training on Gait Disorders in Patients With Parkinson's Disease[NCT05938673] | 76 participants (Anticipated) | Interventional | 2023-11-30 | Recruiting | |||
| Effects of Spinal Cord Stimulation on Gait in Patients With Parkinson´s Disease; a Randomized, Crossover, Double Blinded, Placebo-Controlled Study[NCT05148468] | 12 participants (Anticipated) | Interventional | 2021-11-30 | Active, not recruiting | |||
| Spinal Cord Stimulation for the Treatment of Motor and Nonmotor Symptoms of Parkinson's Disease[NCT02388204] | 20 participants (Anticipated) | Interventional | 2014-06-30 | Recruiting | |||
| Efficacy of Repetitive Trans-spinal Magnetic Stimulation on Gait Abnormalities in Parkinson's Disease Patients: A Double-blinded Randomized Controlled Trial[NCT05271513] | 38 participants (Actual) | Interventional | 2023-01-01 | Completed | |||
| Starving for Energy - A Pilot Study to Test Ketone Derived Energy in Eating Disorders[NCT05507008] | 40 participants (Anticipated) | Interventional | 2022-10-13 | Recruiting | |||
| Mucuna Pruriens Therapy in Parkinson's Disease: a Double-blind, Placebo-controlled, Randomized, Crossover Study.[NCT02680977] | Phase 2 | 18 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Phase I Study of Subthalamic GAD Gene Transfer in Medically Refractory Parkinson's Disease Patients[NCT00195143] | Phase 1 | 12 participants | Interventional | 2003-08-31 | Completed | ||
| Preventing Levodopa Induced Dyskinesia in Parkinson?s Disease With Statins[NCT04064294] | 120 participants (Anticipated) | Observational | 2019-06-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
26 reviews available for oxidopamine and Parkinsonian Disorders
| Article | Year |
|---|---|
Chemical and Genetic Zebrafish Models to Define Mechanisms of and Treatments for Dopaminergic Neurodegeneration.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Gene Knockdown Techniques; Neurotox | 2020 |
Neurotoxin-Induced Rodent Models of Parkinson's Disease: Benefits and Drawbacks.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Humans; Neurotoxins; Oxidopamine; Paraquat; P | 2021 |
Synaptic Zinc: An Emerging Player in Parkinson's Disease.
Topics: Animals; Basal Ganglia; Cation Transport Proteins; Cerebral Cortex; Chelating Agents; Corpus Striatu | 2021 |
Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; | 2018 |
Does restraining nitric oxide biosynthesis rescue from toxins-induced parkinsonism and sporadic Parkinson's disease?
Topics: Animals; Humans; Methamphetamine; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Oxidopamine | 2014 |
How Parkinsonian toxins dysregulate the autophagy machinery.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Autophagy; Humans; Methamphetamine; Mitophagy; MPTP Po | 2013 |
Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence.
Topics: alpha-Synuclein; Animals; Cholecystokinin; Efferent Pathways; Enteric Nervous System; Gastric Emptyi | 2015 |
[Synthesis of monoamines by non-monoaminergic neurons: illusion or reality?].
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain; Corpus Striatum; Dopamine; Humans; Hypothalamu | 2009 |
In vivo imaging neurotransmitter function. The rat 6-hydroxydopamine model and its relevance for human Parkinson's disease.
Topics: Animals; Brain; Disease Models, Animal; Humans; Molecular Imaging; Neurotransmitter Agents; Oxidopam | 2011 |
Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.
Topics: Administration, Intranasal; Animals; Disease Models, Animal; Female; Humans; Male; Metals; Mice; Neu | 2012 |
Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity?
Topics: Animals; Dopamine; Humans; Neurons; Oxidopamine; Parkinsonian Disorders | 2002 |
Generation of dopaminergic neurons from embryonic stem cells.
Topics: Animals; Cell Differentiation; Coculture Techniques; Dopamine; Mice; Nerve Growth Factors; Neurons; | 2002 |
The Caenorhabditis elegans dopaminergic system: opportunities for insights into dopamine transport and neurodegeneration.
Topics: Animals; Biological Transport; Caenorhabditis elegans; Disease Models, Animal; Dopamine; Models, Ani | 2003 |
Pathogenic role of glial cells in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Astrocytes; Dopamine Agent | 2003 |
Models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cells, Cultured; Disease Models, A | 2003 |
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus S | 2003 |
[Modeling Parkinson's disease and objectifying the nigro-striatum system dysfunction].
Topics: Animals; Corpus Striatum; Disease Models, Animal; Oxidopamine; Parkinsonian Disorders; Substantia Ni | 2004 |
Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.
Topics: Animals; Disease Models, Animal; Oxidopamine; Parkinsonian Disorders; Sympatholytics | 2004 |
Marmoset monkey models of Parkinson's disease: which model, when and why?
Topics: alpha-Synuclein; Animals; Callithrix; Disease Models, Animal; Humans; Oxidopamine; Parkinson Disease | 2005 |
Behavioral models of Parkinson's disease in rodents: a new look at an old problem.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Motor Activity; Motor Neurons; Motor | 2006 |
Oxidative and inflammatory pathways in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Herbicides; Humans; Inflammation; Lipopolysac | 2009 |
MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies.
Topics: Animals; Disease Models, Animal; Humans; Nerve Degeneration; Neuroprotective Agents; Oxidopamine; Pa | 2000 |
Molecular neurotoxicological models of Parkinsonism: focus on genetic manipulation of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Humans; Methamphetamine; Mic | 2001 |
Animal models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Oxidopamine; Parkinsonian Disorders; Sub | 2002 |
Involvement of nicotinic acetylcholine receptors in the protection of dopamine terminals in experimental parkinsonism.
Topics: Animals; Cytoprotection; Dopamine; In Vitro Techniques; Nerve Endings; Neuroprotective Agents; Neuro | 2001 |
Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Neural Pathways; Oxidopamine; Parkinsonian Disorde | 2002 |
1022 other studies available for oxidopamine and Parkinsonian Disorders
| Article | Year |
|---|---|
The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Medial Foreb | 2021 |
Hydrogen sulphide attenuates neuronal apoptosis of substantia nigra by re-establishing autophagic flux via promoting leptin signalling in a 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Apoptosis; Autophagosomes; Autophagy; Hydrogen Sulfide; Leptin; Male; Microscopy, Electron, | 2022 |
Magnetothermal nanoparticle technology alleviates parkinsonian-like symptoms in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Deep Brain Stimulation; Dis | 2021 |
Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response.
Topics: Animals; Anxiety; Behavior, Animal; Corpus Striatum; Depressive Disorder; Disease Models, Animal; Fe | 2021 |
Serotonin 1A receptor agonist modulation of motor deficits and cortical oscillations by NMDA receptor interaction in parkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Beta Rhythm; Locomotion; Male; Motor Cortex; Motor | 2022 |
Pycnogenol ameliorates motor function and gene expressions of NF-ƙB and Nrf2 in a 6-hydroxydopamine-induced experimental model of Parkinson's disease in male NMRI mice.
Topics: Animals; Antioxidants; Apomorphine; Dose-Response Relationship, Drug; Flavonoids; Gene Expression Re | 2022 |
The α7 nAChR allosteric modulator PNU-120596 amends neuroinflammatory and motor consequences of parkinsonism in rats: Role of JAK2/NF-κB/GSk3β/ TNF-α pathway.
Topics: Animals; Dopaminergic Neurons; Glycogen Synthase Kinase 3 beta; Hypokinesia; Isoxazoles; Janus Kinas | 2022 |
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine Plasma Membrane Transport Proteins; | 2022 |
Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amidohydrolases; Animals; Disease Models, Animal; Dopa | 2022 |
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Le | 2022 |
Post treatment with Gastrodin suppresses oxidative stress and attenuates motor disorders following 6-OHDA induced Parkinson disease.
Topics: Animals; Disease Models, Animal; Humans; Motor Disorders; Oxidative Stress; Oxidopamine; Parkinson D | 2022 |
Probable role of the hyperpolarization-activated current in the dual effects of CB1R antagonism on behaviors in a Parkinsonism mouse model.
Topics: Animals; Disease Models, Animal; Dopamine; Hyperpolarization-Activated Cyclic Nucleotide-Gated Chann | 2022 |
Silibinin chronic treatment in a rat model of Parkinson disease: A comprehensive in-vivo evaluation and in silico molecular modeling.
Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Interleukin-6; Molecular Docking Simulation; Oxidopa | 2023 |
Differential remodeling of subthalamic projections to basal ganglia output nuclei and locomotor deficits in 6-OHDA-induced hemiparkinsonian mice.
Topics: Animals; Basal Ganglia; Globus Pallidus; Mice; Oxidopamine; Parkinsonian Disorders; Substantia Nigra | 2023 |
The Dynamics of Dopamine D
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Neuron | 2023 |
Role of the iNOS isoform in the cardiovascular dysfunctions of male rats with 6-OHDA-induced Parkinsonism.
Topics: Animals; Cardiovascular System; Dopamine; Enzyme Inhibitors; Male; NG-Nitroarginine Methyl Ester; Ox | 2023 |
Brainstem Modulates Parkinsonism-Induced Orofacial Sensorimotor Dysfunctions.
Topics: Animals; Antiparkinson Agents; Brain Stem; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug | 2023 |
Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; gamma-Aminobut | 2023 |
Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; | 2019 |
Dexmedetomidine attenuates the induction and reverses the progress of 6-hydroxydopamine- induced parkinsonism; involvement of K
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Inflammatory Agents; Dexmedetomidine; Disease Pr | 2019 |
Effects of sleep disruption on stress, nigrostriatal markers, and behavior in a chronic/progressive MPTP male mouse model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Corticosterone; Disease Mode | 2019 |
Intranasal delivery of low-dose insulin ameliorates motor dysfunction and dopaminergic cell death in a 6-OHDA rat model of Parkinson's Disease.
Topics: Administration, Intranasal; Adrenergic Agents; Animals; Cell Survival; Disease Models, Animal; Dopam | 2020 |
Altered Recruitment of Motor Cortex Neuronal Activity During the Grasping Phase of Skilled Reaching in a Chronic Rat Model of Unilateral Parkinsonism.
Topics: Animals; Chronic Disease; Disease Models, Animal; Hand Strength; Male; Motor Cortex; Motor Skills; N | 2019 |
Electroacupuncture Therapy Ameliorates Motor Dysfunction via Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor in a Mouse Model of Parkinson's Disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; Dopaminergic Ne | 2020 |
Neurorestorative effects of sub-chronic administration of ambroxol in rodent model of Parkinson's disease.
Topics: Ambroxol; Animals; Dopaminergic Neurons; Dose-Response Relationship, Drug; Hand Strength; Locomotion | 2020 |
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Corpus Striatum; Dopami | 2020 |
Correlation between angiotensin 1-7-mediated Mas receptor expression with motor improvement, activated STAT3/SOCS3 cascade, and suppressed HMGB-1/RAGE/NF-κB signaling in 6-hydroxydopamine hemiparkinsonian rats.
Topics: Angiotensin I; Animals; Corpus Striatum; Dopaminergic Neurons; Gene Expression; HMGB1 Protein; Male; | 2020 |
Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; M | 2020 |
Epidural Spinal Cord Stimulation Improves Motor Function in Rats With Chemically Induced Parkinsonism.
Topics: Animals; Disease Models, Animal; Epidural Space; Hindlimb; Locomotion; Lumbosacral Region; Male; Oxi | 2019 |
Synaptic zinc contributes to motor and cognitive deficits in 6-hydroxydopamine mouse models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Cation Transport Proteins; Cognition; Corpus Striatum; Disease Models, An | 2020 |
Dopaminergic neuroprotective effects of rotigotine via 5-HT1A receptors: Possibly involvement of metallothionein expression in astrocytes.
Topics: Animals; Astrocytes; Cells, Cultured; Dopamine Agonists; Female; Male; Metallothionein; Mice; Mice, | 2020 |
Prior exercise protects against oxidative stress and motor deficit in a rat model of Parkinson's disease.
Topics: Animals; Male; Motor Skills Disorders; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Physic | 2020 |
Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Death; Chondroitin ABC Lyase; Corpus Striatum; Dopaminergic Neur | 2019 |
The drug adaptaquin blocks ATF4/CHOP-dependent pro-death Trib3 induction and protects in cellular and mouse models of Parkinson's disease.
Topics: Activating Transcription Factor 4; Animals; Cell Cycle Proteins; Cell Death; Cells, Cultured; HEK293 | 2020 |
D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induce | 2020 |
Docosahexaenoic acid protects motor function and increases dopamine synthesis in a rat model of Parkinson's disease via mechanisms associated with increased protein kinase activity in the striatum.
Topics: Animals; Corpus Striatum; Docosahexaenoic Acids; Dopamine; Male; Motor Activity; Neuroprotective Age | 2020 |
Leptin mediates protection of hydrogen sulfide against 6-hydroxydopamine-induced Parkinson's disease: Involving enhancement in Warburg effect.
Topics: Animals; Dose-Response Relationship, Drug; Hydrogen Sulfide; Leptin; Male; Neuroprotective Agents; O | 2020 |
Effects on goal directed behavior and habit in two animal models of Parkinson's disease.
Topics: Animals; Conditioning, Operant; Disease Models, Animal; Extinction, Psychological; Goals; Habits; Li | 2020 |
Kv7.2 subunit-containing M-type potassium channels in the lateral habenula are involved in the regulation of working memory in parkinsonian rats.
Topics: Animals; Habenula; KCNQ2 Potassium Channel; Male; Membrane Transport Modulators; Memory, Short-Term; | 2020 |
Pharmacological enhancement of TFEB-mediated autophagy alleviated neuronal death in oxidative stress-induced Parkinson's disease models.
Topics: Animals; Antiparkinson Agents; Ascorbic Acid; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Trans | 2020 |
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Oxidopamine; | 2020 |
Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Dose-Response Relationship, D | 2020 |
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: Administration, Oral; Amantadine; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; D | 2020 |
Physical exercise protects against mitochondria alterations in the 6-hidroxydopamine rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Gait; Male; Mitochondria; Oxidative Stress; O | 2020 |
C60 fullerenes increase the intensity of rotational movements in non‑anesthetized hemiparkinsonic rats.
Topics: Animals; Antioxidants; Apomorphine; Female; Fullerenes; Motor Activity; Muscle Fatigue; Muscle, Skel | 2020 |
The globus pallidus orchestrates abnormal network dynamics in a model of Parkinsonism.
Topics: Action Potentials; Animals; Basal Ganglia; Beta Rhythm; Disease Models, Animal; Globus Pallidus; Mot | 2020 |
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Topics: Aged; Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nuclear Re | 2020 |
Perillyl Alcohol Mitigates Behavioural Changes and Limits Cell Death and Mitochondrial Changes in Unilateral 6-OHDA Lesion Model of Parkinson's Disease Through Alleviation of Oxidative Stress.
Topics: Animals; bcl-2-Associated X Protein; Behavior, Animal; Caspase 3; DNA Fragmentation; Dynamins; Elect | 2020 |
Deep brain stimulation-guided optogenetic rescue of parkinsonian symptoms.
Topics: Algorithms; Animals; Antiparkinson Agents; Deep Brain Stimulation; Disease Models, Animal; Electroph | 2020 |
Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats.
Topics: Animals; Corpus Striatum; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Ago | 2020 |
NMDA receptors are altered in the substantia nigra pars reticulata and their blockade ameliorates motor deficits in experimental parkinsonism.
Topics: Animals; Excitatory Amino Acid Antagonists; Male; Mice; Mice, Inbred C57BL; Motor Disorders; Oxidopa | 2020 |
Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinson's disease rat model.
Topics: Administration, Oral; Animals; Apomorphine; Corpus Striatum; Dopaminergic Neurons; Dose-Response Rel | 2020 |
Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms.
Topics: Animals; Behavior, Animal; Cistanche; Cornus; Corpus Striatum; Dioscorea; Disease Models, Animal; Do | 2020 |
Protective effect of hydroxysafflor yellow A on dopaminergic neurons against 6-hydroxydopamine, activating anti-apoptotic and anti-neuroinflammatory pathways.
Topics: Animals; Apoptosis; Chalcone; Corpus Striatum; Dopamine; Dopaminergic Neurons; Dose-Response Relatio | 2020 |
D2 receptor activation relieves pain hypersensitivity by inhibiting superficial dorsal horn neurons in parkinsonian mice.
Topics: Action Potentials; Animals; Chronic Pain; Dopamine Agonists; Dopamine Antagonists; Indoles; Male; Mi | 2021 |
Theacrine, a purine alkaloid from kucha, protects against Parkinson's disease through SIRT3 activation.
Topics: Animals; Apoptosis; Behavior, Animal; Camellia; Dopaminergic Neurons; Embryo, Nonmammalian; Humans; | 2020 |
Cardiovascular evaluation of female rats with 6-OHDA-induced parkinsonism: Possible protection by ovarian hormones and participation of nitric oxide.
Topics: Animals; Blood Pressure; Cardiovascular System; Corpus Striatum; Disease Models, Animal; Dopamine; D | 2020 |
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
Topics: Allosteric Regulation; Animals; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; | 2020 |
Exercise-Induced Neuroprotection in the 6-Hydroxydopamine Parkinson's Disease Model.
Topics: Animals; Exercise Test; Male; Neuroprotection; Oxidopamine; Parkinsonian Disorders; Physical Conditi | 2020 |
Fraternine, a Novel Wasp Peptide, Protects against Motor Impairments in 6-OHDA Model of Parkinsonism.
Topics: Animals; Behavior, Animal; Cell Death; Disease Models, Animal; Dopaminergic Neurons; Female; Male; M | 2020 |
FTH1 Inhibits Ferroptosis Through Ferritinophagy in the 6-OHDA Model of Parkinson's Disease.
Topics: Animals; Cell Survival; Ferritins; Ferroptosis; Male; Oxidopamine; Oxidoreductases; Parkinsonian Dis | 2020 |
Erythropoietin modulates striatal antioxidant signalling to reduce neurodegeneration in a toxicant model of Parkinson's disease.
Topics: Animals; Apomorphine; Brain; Cell Shape; Corpus Striatum; Dopamine; Erythropoietin; Humans; Male; Mi | 2020 |
Pepper component 7-ethoxy-4-methylcoumarin, a novel dopamine D2 receptor agonist, ameliorates experimental Parkinson's disease in mice and Caenorhabditis elegans.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Genetically Modified; Behavior, Anim | 2021 |
JM-20 protects against 6-hydroxydopamine-induced neurotoxicity in models of Parkinson's disease: Mitochondrial protection and antioxidant properties.
Topics: Animals; Antioxidants; Benzodiazepines; Brain; Male; Mitochondria; Neuroprotective Agents; Niacin; O | 2021 |
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopami | 2021 |
A bibenzyl compound 20C protects rats against 6-OHDA-induced damage by regulating adaptive immunity associated molecules.
Topics: alpha-Synuclein; Animals; Antioxidants; Bibenzyls; Brain; Cytokines; Disease Models, Animal; Dopamin | 2021 |
Cytisine is neuroprotective in female but not male 6-hydroxydopamine lesioned parkinsonian mice and acts in combination with 17-β-estradiol to inhibit apoptotic endoplasmic reticulum stress in dopaminergic neurons.
Topics: Activating Transcription Factor 6; Alkaloids; Animals; Apoptosis; Azocines; Behavior, Animal; Dopami | 2021 |
Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; G | 2021 |
Extract of Polygala tenuifolia, Angelica tenuissima, and Dimocarpus longan Reduces Behavioral Defect and Enhances Autophagy in Experimental Models of Parkinson's Disease.
Topics: Angelica; Animals; Apomorphine; Autophagy; Cell Line, Tumor; Corpus Striatum; Dopaminergic Neurons; | 2021 |
Olfactory mucosa stem cells delivery via nasal route: a simple way for the treatment of Parkinson disease.
Topics: Administration, Intranasal; Animals; Brain; Brain Chemistry; Cells, Cultured; Male; Olfactory Mucosa | 2021 |
Involvement of Autophagy in Levodopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Autophagy; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug- | 2021 |
Novel Interactions Involving the Mas Receptor Show Potential of the Renin-Angiotensin system in the Regulation of Microglia Activation: Altered Expression in Parkinsonism and Dyskinesia.
Topics: Angiotensin II; Animals; Corpus Striatum; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Male; Mice | 2021 |
Intranasal insulin improves mitochondrial function and attenuates motor deficits in a rat 6-OHDA model of Parkinson's disease.
Topics: Administration, Intranasal; Animals; Humans; Insulin; Male; Mitochondria; Motor Disorders; Oxidopami | 2021 |
The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson's disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway.
Topics: Amodiaquine; Animals; Brain; Enzyme Inhibitors; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agen | 2021 |
Cystic fibrosis transmembrane conductance regulator-associated ligand protects dopaminergic neurons by differentially regulating metabotropic glutamate receptor 5 in the progression of neurotoxin 6-hydroxydopamine-induced Parkinson's disease model.
Topics: Animals; Cell Line; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Dopami | 2021 |
Levodopa affects spike and local field synchronisation in the pedunculopontine nucleus of a rat model of Parkinson's disease.
Topics: Action Potentials; Animals; Disease Models, Animal; Dopaminergic Neurons; Levodopa; Locomotion; Male | 2021 |
Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.
Topics: Analgesics; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induce | 2021 |
Protective mechanism of Syringic acid in an experimental model of Parkinson's disease.
Topics: Animals; Dopamine; Dopaminergic Neurons; Gallic Acid; Male; Motor Activity; Neuroprotective Agents; | 2021 |
Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation Mediators; In | 2021 |
Reduction of falls in a rat model of PD falls by the M1 PAM TAK-071.
Topics: Accidental Falls; Administration, Oral; Allosteric Regulation; Animals; Basal Forebrain; Cholinergic | 2021 |
IDO-1 inhibition protects against neuroinflammation, oxidative stress and mitochondrial dysfunction in 6-OHDA induced murine model of Parkinson's disease.
Topics: Animals; Indoleamine-Pyrrole 2,3,-Dioxygenase; Male; Mice; Mice, Inbred BALB C; Mitochondria; Neurop | 2021 |
Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease.
Topics: Animals; Armadillo Domain Proteins; Axons; Cytoskeletal Proteins; Genetic Variation; Male; Mice; Mic | 2021 |
Hydrogen sulfide attenuates induction and prevents progress of the 6-hydroxydopamine-induced Parkinsonism in rat through activation of ATP-sensitive potassium channels and suppression of ER stress.
Topics: Animals; Disease Progression; Endoplasmic Reticulum Stress; Gasotransmitters; Hydrogen Sulfide; KATP | 2021 |
The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian | 2021 |
Schisandra chinensis protects against dopaminergic neuronal oxidative stress, neuroinflammation and apoptosis
Topics: Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Corpus Striatum; Cytokines; Disease Models, A | 2021 |
Early decreases in cortical mid-gamma peaks coincide with the onset of motor deficits and precede exaggerated beta build-up in rat models for Parkinson's disease.
Topics: Animals; Beta Rhythm; Dopamine D2 Receptor Antagonists; Exercise Test; Gamma Rhythm; Male; Motor Cor | 2021 |
Subthalamic nucleus deep brain stimulation induces sustained neurorestoration in the mesolimbic dopaminergic system in a Parkinson's disease model.
Topics: Animals; Corpus Striatum; Deep Brain Stimulation; Dopaminergic Neurons; Female; Limbic System; Male; | 2021 |
Tocotrienols Ameliorate Neurodegeneration and Motor Deficits in the 6-OHDA-Induced Rat Model of Parkinsonism: Behavioural and Immunohistochemistry Analysis.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Immunohistochemistry; Male; Neuroprotective Agents | 2021 |
Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Benzimida | 2021 |
Physical exercise increases the production of tyrosine hydroxylase and CDNF in the spinal cord of a Parkinson's disease mouse model.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Humans; Male; Mice; Motor Neurons; Nerve Growth Fa | 2021 |
Downregulation of astroglial glutamate transporter GLT-1 in the lateral habenula is associated with depressive-like behaviors in a rat model of Parkinson's disease.
Topics: Animals; Astrocytes; Depression; Disease Models, Animal; Down-Regulation; Excitatory Amino Acid Tran | 2021 |
SKP-SCs transplantation alleviates 6-OHDA-induced dopaminergic neuronal injury by modulating autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Brain; Cell Line, Tumor; Coculture Techniques; Di | 2021 |
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Calcium-Binding Proteins; Caudate | 2021 |
Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats.
Topics: Analgesics; Animals; Anticonvulsants; Cannabidiol; Estrous Cycle; Facial Pain; Female; Hyperalgesia; | 2021 |
Dopamine-loaded nanoparticle systems circumvent the blood-brain barrier restoring motor function in mouse model for Parkinson's Disease.
Topics: Animals; Blood-Brain Barrier; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drug De | 2021 |
Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Behavior, Animal; Botulinum Toxins, Type A | 2021 |
Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.
Topics: Animals; Antiparkinson Agents; Armadillo Domain Proteins; Catechol O-Methyltransferase; Cell Adhesio | 2017 |
Neuroprotective effects of E-PodoFavalin-15999 (Atremorine®).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Cell Line, Tumor; Cell Survival; D | 2017 |
Time course study of fractional anisotropy in the substantia nigra of a parkinsonian rat model induced by 6-OHDA.
Topics: Animals; Apomorphine; Diffusion Tensor Imaging; Disease Progression; Dopamine Agonists; Gliosis; Imm | 2017 |
Intermittent theta-burst stimulation rescues dopamine-dependent corticostriatal synaptic plasticity and motor behavior in experimental parkinsonism: Possible role of glial activity.
Topics: Adrenergic Agents; Animals; Astrocytes; Behavior, Animal; Cerebral Cortex; Corpus Striatum; Dopamine | 2017 |
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
Topics: Acetylcholine; Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Choline O-Acetyltra | 2017 |
Phrenic and hypoglossal nerve activity during respiratory response to hypoxia in 6-OHDA unilateral model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Hypoglossal Nerve; Hypoxia; Male; Oxidopamine; Parkinsonian Disorde | 2017 |
Fluvoxamine maleate effects on dopamine signaling in the prefrontal cortex of stressed Parkinsonian rats: Implications for learning and memory.
Topics: Animals; Corticosterone; Dopamine; Fluvoxamine; Learning; Learning Disabilities; Lipid Peroxidation; | 2017 |
ALCAR promote adult hippocampal neurogenesis by regulating cell-survival and cell death-related signals in rat model of Parkinson's disease like-phenotypes.
Topics: Acetylcarnitine; Animals; Cell Death; Cell Survival; Hippocampus; Male; Neurogenesis; Nootropic Agen | 2017 |
Efficacy of oral lipid-based formulations of apomorphine and its diester in a Parkinson's disease rat model.
Topics: Administration, Oral; Animals; Apomorphine; Chemistry, Pharmaceutical; Delayed-Action Preparations; | 2017 |
Chronic pramipexole treatment induces compulsive behavior in rats with 6-OHDA lesions of the substantia nigra and ventral tegmental area.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Compulsive Behavior; Corpus Striatum; Frontal Lobe; I | 2017 |
The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Cation | 2017 |
Alterations in Functional Cortical Hierarchy in Hemiparkinsonian Rats.
Topics: Animals; Corpus Striatum; Male; Motor Cortex; Nerve Net; Oxidopamine; Parkinsonian Disorders; Rats; | 2017 |
Transgenic Mice Overexpressing the Divalent Metal Transporter 1 Exhibit Iron Accumulation and Enhanced Parkin Expression in the Brain.
Topics: Animals; Cation Transport Proteins; Gene Expression Regulation; Iron; Macaca fascicularis; Manganese | 2017 |
Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism.
Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Disease Models, Animal; Dopaminergic Neurons; Male; O | 2017 |
6-OHDA-Lesioned Adult Zebrafish as a Useful Parkinson's Disease Model for Dopaminergic Neuroregeneration.
Topics: Animals; Brain; Cell Count; Dopaminergic Neurons; Dose-Response Relationship, Drug; Immunohistochemi | 2017 |
Functional single-walled carbon nanotubes 'CAR' for targeting dopamine delivery into the brain of parkinsonian mice.
Topics: Animals; Brain; Corpus Striatum; Dopamine; Drug Carriers; Interleukin-1beta; L-Lactate Dehydrogenase | 2017 |
The effect of electroacupuncture on proteomic changes in the motor cortex of 6-OHDA Parkinsonian rats.
Topics: Animals; Apomorphine; Blotting, Western; Chromatography, High Pressure Liquid; Dopamine Agonists; El | 2017 |
β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antiparkinson Agents; Behavior, Animal; Benserazide; Ca | 2017 |
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Corpus | 2017 |
Microglia may compensate for dopaminergic neuron loss in experimental Parkinsonism through selective elimination of glutamatergic synapses from the subthalamic nucleus.
Topics: Animals; Animals, Newborn; Cells, Cultured; Disease Models, Animal; Dopamine; Dopaminergic Neurons; | 2017 |
An altered blood-brain barrier contributes to brain iron accumulation and neuroinflammation in the 6-OHDA rat model of Parkinson's disease.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apoferritins; Astrocytes; Blood-Br | 2017 |
A Machine Learning Approach to Automated Gait Analysis for the Noldus Catwalk System.
Topics: Animals; Disease Models, Animal; Female; Foot; Gait; Gait Analysis; Machine Learning; Male; Mice; Mi | 2018 |
Intrastriatal Chromospheres' Transplant Reduces Nociception in Hemiparkinsonian Rats.
Topics: Animals; Cells, Cultured; Male; Microinjections; Naltrexone; Nociception; Oxidopamine; Pain Measurem | 2018 |
Revealing a Role for NMDA Receptors in Regulating STN Inputs following the Loss of Dopamine.
Topics: Dopamine; Humans; Oxidopamine; Parkinsonian Disorders; Receptors, N-Methyl-D-Aspartate; Subthalamic | 2017 |
The effect of directed photic stimulation of the pineal on experimental Parkinson's disease.
Topics: Animals; Body Weight; Frontal Lobe; Light; Male; Movement; Oxidopamine; Parkinsonian Disorders; Phot | 2017 |
Altered Volatile Organic Compound Profile in Transgenic Rats Bearing A53T Mutation of Human α-Synuclein: Comparison with Dopaminergic and Serotonergic Denervation.
Topics: 5,7-Dihydroxytryptamine; alpha-Synuclein; Animals; Breath Tests; Corpus Striatum; Discriminant Analy | 2018 |
Lesions of the lateral habenula improve working memory performance in hemiparkinsonian rats.
Topics: Amygdala; Animals; Choice Behavior; Dopamine; Habenula; Hippocampus; Male; Medial Forebrain Bundle; | 2018 |
Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine.
Topics: Animals; Apomorphine; Area Under Curve; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamin | 2017 |
Evidence for cross-hemispheric preconditioning in experimental Parkinson's disease.
Topics: Adrenergic Agents; Animals; Anthraquinones; Corpus Striatum; Disease Models, Animal; Dopamine; Dopam | 2018 |
Mechanistic evaluation of neuroprotective effect of estradiol on rotenone and 6-OHDA induced Parkinson's disease.
Topics: Animals; Antioxidants; Apoptosis; Behavior, Animal; Brain; Cells, Cultured; Estradiol; Flow Cytometr | 2017 |
The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Anthracenes; Apomorphine; Corpus Striatum; Dopamine; Dopamine Agonists; Dopaminergic Neuron | 2018 |
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Topics: Adrenergic Agents; Analgesics, Opioid; Animals; Benzamides; Disease Models, Animal; Dose-Response Re | 2018 |
CIQ, a positive allosteric modulator of GluN2C/D-containing N-methyl-d-aspartate receptors, rescues striatal synaptic plasticity deficit in a mouse model of Parkinson's disease.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Benzimidazoles; Corpus Striatum; Excitatory Am | 2018 |
Cortical stimulation relieves parkinsonian pathological activity in vitro.
Topics: Animals; Corpus Striatum; Dopamine; Levodopa; Mice; Neurons; Oxidopamine; Parkinsonian Disorders | 2019 |
Neuronal activity pattern defects in the striatum in awake mouse model of Parkinson's disease.
Topics: Action Potentials; Animals; Beta Rhythm; Corpus Striatum; Cortical Synchronization; Dopamine; Functi | 2018 |
KM-34, a Novel Antioxidant Compound, Protects against 6-Hydroxydopamine-Induced Mitochondrial Damage and Neurotoxicity.
Topics: Animals; Antioxidants; Catechols; Dose-Response Relationship, Drug; Male; Mitochondria; Neuroprotect | 2019 |
Apelin-13 ameliorates cognitive impairments in 6-hydroxydopamine-induced substantia nigra lesion in rats.
Topics: Animals; Behavior, Animal; Cognitive Dysfunction; Intercellular Signaling Peptides and Proteins; Mal | 2018 |
Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease.
Topics: Adenine; Animals; Disease Models, Animal; eIF-2 Kinase; Female; Humans; Indoles; Male; Mice; Mice, I | 2018 |
Propagation of beta/gamma rhythms in the cortico-basal ganglia circuits of the parkinsonian rat.
Topics: Animals; Basal Ganglia; Beta Rhythm; Cerebral Cortex; Disease Models, Animal; Electroencephalography | 2018 |
Cognitive Flexibility Deficits Following 6-OHDA Lesions of the Rat Dorsomedial Striatum.
Topics: Animals; Cognition Disorders; Corpus Striatum; Discrimination, Psychological; Executive Function; Ma | 2018 |
Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Combined Modality Therapy; Corpus Striatum; Deep Brain S | 2018 |
Angiotensin 1-7 ameliorates 6-hydroxydopamine lesions in hemiparkinsonian rats through activation of MAS receptor/PI3K/Akt/BDNF pathway and inhibition of angiotensin II type-1 receptor/NF-κB axis.
Topics: Angiotensin I; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Corpus Striatum; Male; | 2018 |
Modelling the dopamine and noradrenergic cell loss that occurs in Parkinson's disease and the impact on hippocampal neurogenesis.
Topics: Adrenergic Neurons; Animals; Brain; Bromodeoxyuridine; Cell Death; Dopamine; Dopamine beta-Hydroxyla | 2018 |
Graded 6-OHDA-induced dopamine depletion in the nigrostriatal pathway evokes progressive pathological neuronal activities in the subthalamic nucleus of a hemi-parkinsonian mouse.
Topics: Action Potentials; Animals; Cell Death; Disease Progression; Dopamine; Dopaminergic Neurons; Dose-Re | 2018 |
Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
Topics: Amphetamine; Animals; Apomorphine; Biophysics; Central Nervous System Stimulants; Corpus Striatum; D | 2018 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Ther | 2018 |
Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
Topics: Animals; Antiparkinson Agents; Apomorphine; Arachidonic Acids; Biomarkers; Cannabinoid Receptor Agon | 2018 |
Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H)-yl)urea) in 6-OHDA induced rodent model of hemiparkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Depression; Disease Models, Animal; Male; Neuroprot | 2018 |
Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation; Levodopa; Ma | 2018 |
Gastrodin microinjection suppresses 6-OHDA-induced motor impairments in parkinsonian rats: insights into oxidative balance and microglial activation in SNc.
Topics: Animals; Benzyl Alcohols; Catalepsy; Glucosides; Lipid Peroxidation; Male; Microglia; Microinjection | 2018 |
Glucose-Dependent Insulinotropic Polypeptide Mitigates 6-OHDA-Induced Behavioral Impairments in Parkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Incretins; Locomotion; Male; Oxidopamine; Parkinsonian Disorders; Rat | 2018 |
A Comparative study for striatal-direct and -indirect pathway neurons to DA depletion-induced lesion in a PD rat model.
Topics: Animals; Corpus Striatum; Dopamine; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Random Alloc | 2018 |
Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.
Topics: Animals; Astrocytes; Corpus Striatum; Dopaminergic Neurons; Fibroblast Growth Factors; Male; Neural | 2018 |
Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
Topics: Administration, Inhalation; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Rel | 2018 |
Beneficial effect of etazolate on depression-like behavior and, learning, and memory impairment in a model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Depression; Etazolate; Hippocampus; Learning Disabilities; Male; Memo | 2018 |
The mediating role of phosphodiesterase type 4 in the dopaminergic modulation of motor impulsivity.
Topics: Aminopyridines; Animals; Benzamides; Brain; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropa | 2018 |
Activation and blockade of basolateral amygdala 5-HT
Topics: Animals; Anti-Anxiety Agents; Anxiety; Basolateral Nuclear Complex; Corpus Striatum; Dopamine; gamma | 2018 |
High fat diet feeding induced insulin resistance exacerbates 6-OHDA mediated neurotoxicity and behavioral abnormalities in rats.
Topics: Animals; Corpus Striatum; Diabetes Mellitus, Experimental; Diet, High-Fat; Inflammation; Insulin Res | 2018 |
Silymarin recovers 6-hydroxydopamine-induced motor deficits in mice.
Topics: Animals; Behavior, Animal; Corpus Striatum; Male; Mice; Motor Activity; Neuroprotective Agents; Oxid | 2018 |
[Modulation by desensitized nicotinic receptors on metabolism of DA in striatum derived from the hemiparkinsonian model].
Topics: Animals; Corpus Striatum; Dopamine; Monoamine Oxidase; Nicotine; Oxidopamine; Parkinsonian Disorders | 2016 |
Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain; Central Nervous System Stimulants; Dopamine; Dopa | 2018 |
Induction of cross-tolerance between protective effect of morphine and nicotine in 6-hydroxydopamine-induce neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Dopaminergic Neurons; Drug Tolerance; | 2019 |
Involvement of prelimbic 5-HT
Topics: Animals; Anxiety; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Enzyme Inhibito | 2018 |
Effects of histone acetyltransferase inhibitors on L-DOPA-induced dyskinesia in a murine model of Parkinson's disease.
Topics: Anacardic Acids; Animals; Antiparkinson Agents; Curcumin; Cytoskeletal Proteins; Drug Evaluation, Pr | 2018 |
Ambroxol modulates 6-Hydroxydopamine-induced temporal reduction in Glucocerebrosidase (GCase) enzymatic activity and Parkinson's disease symptoms.
Topics: Ambroxol; Animals; Enzyme Activation; Expectorants; Glucosylceramidase; Locomotion; Male; Microinjec | 2018 |
Moutan Cortex Radicis inhibits the nigrostriatal damage in a 6-OHDA-induced Parkinson's disease model.
Topics: Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Cell Death; Cell Line; Disease Models, Anim | 2018 |
Puerarin promoted proliferation and differentiation of dopamine-producing cells in Parkinson's animal models.
Topics: Animals; Cell Differentiation; Cell Proliferation; Cells, Cultured; Corpus Striatum; Disease Models, | 2018 |
Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Tr | 2018 |
Expression of magnesium transporter SLC41A1 in the striatum of 6-hydroxydopamine-induced parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Cation Transport Proteins; Corpus Striatum; Dopamine Ago | 2018 |
Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Drug Interactions; Levodo | 2018 |
Safranal-promoted differentiation and survival of dopaminergic neurons in an animal model of Parkinson's disease.
Topics: Animals; Cell Differentiation; Cyclohexenes; Disease Models, Animal; Dopamine; Dopamine Plasma Membr | 2018 |
Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Animals; Dopaminergic Neurons; Female; Humans; Male; Mice, Inbred C5 | 2019 |
Nigral injection of 6-hydroxydopamine induces changes in spatial arrangement of striatal neuron and glial cells.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Male; Neuroglia; Neurons; Oxidopamine; Parkinsonia | 2019 |
Neuroprotective Activity of Some Marine Fungal Metabolites in the 6-Hydroxydopamin- and Paraquat-Induced Parkinson's Disease Models.
Topics: Alkaloids; Animals; Antioxidants; Antiparkinson Agents; Aquatic Organisms; Aspergillus; Biological P | 2018 |
Oxysterols from a Marine Sponge
Topics: Animals; Antiparkinson Agents; Cell Line, Tumor; Cell Survival; Mice; Neuroprotective Agents; Oxidop | 2018 |
Altered Local Field Potential Relationship Between the Parafascicular Thalamic Nucleus and Dorsal Striatum in Hemiparkinsonian Rats.
Topics: Animals; Brain Waves; Corpus Striatum; Cortical Synchronization; Dopaminergic Neurons; Electrocortic | 2019 |
Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkepha | 2018 |
A chemogenetic approach for treating experimental Parkinson's disease.
Topics: Animals; Basal Ganglia; Clozapine; Genetic Vectors; Male; Medial Forebrain Bundle; Mice; Motor Activ | 2019 |
Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Antiparkinson Agents; Astrocytes; Co | 2019 |
Effects of Preweaning Manganese in Combination with Adult Striatal Dopamine Lesions on Monoamines, BDNF, TrkB, and Cognitive Function in Sprague-Dawley Rats.
Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Cognition; Cognitive Dysfunction; Dopamine; Femal | 2019 |
Auroglaucin-related neuroprotective compounds from Vietnamese marine sediment-derived fungus
Topics: Animals; Antiparkinson Agents; Aspergillus; Cell Line; Fungi; Geologic Sediments; Humans; Magnetic R | 2020 |
Endoplasmic reticulum stress induced autophagy in 6-OHDA-induced Parkinsonian rats.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Endoplasmic Reticulum; Endop | 2019 |
Effect of 6-OHDA on hypercapnic ventilatory response in the rat model of Parkinson's disease.
Topics: Animals; Hypercapnia; Male; Medial Forebrain Bundle; Oxidopamine; Parkinsonian Disorders; Pulmonary | 2019 |
Gastrointestinal non-motor dysfunction in Parkinson's disease model rats with 6-hydroxydopamine.
Topics: Animals; Gastrointestinal Diseases; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-D | 2019 |
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
Topics: Animals; Anticonvulsants; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopam | 2019 |
Increased anxiety-like behavior following circuit-specific catecholamine denervation in mice.
Topics: Adrenergic Agents; Amygdala; Animals; Anxiety; Catecholamines; Male; Mice; Mice, Inbred C57BL; Oxido | 2019 |
Spike and Local Field Synchronization Between the Pedunculopontine Nucleus and Primary Motor Cortex in a Rat Model of Parkinson's Disease.
Topics: Action Potentials; Animals; Disease Models, Animal; Levodopa; Male; Motor Cortex; Oxidopamine; Parki | 2019 |
Functional Alteration of Cerebello-Cerebral Coupling in an Experimental Mouse Model of Parkinson's Disease.
Topics: Action Potentials; Animals; Cerebellum; Electrocorticography; Mice; Motor Activity; Motor Cortex; Ne | 2019 |
Disruption of Cortical Dopaminergic Modulation Impairs Preparatory Activity and Delays Licking Initiation.
Topics: Action Potentials; Animals; Cues; Dopamine; Dopamine Antagonists; Dopaminergic Neurons; Male; Mice, | 2019 |
Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.
Topics: Activins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Disease Progressio | 2019 |
State-Dependent Spike and Local Field Synchronization between the Thalamic Parafascicular Nucleus and the Dorsal Striatum in a Rat Model of Parkinson's Disease.
Topics: Action Potentials; Animals; Corpus Striatum; Disease Models, Animal; Intralaminar Thalamic Nuclei; M | 2019 |
Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; La | 2019 |
Activation and blockade of serotonin
Topics: Animals; Benzimidazoles; Brain; Bridged Bicyclo Compounds, Heterocyclic; Dopamine; Dose-Response Rel | 2019 |
Dopamine drives binge-like consumption of a palatable food in experimental Parkinsonism.
Topics: Animals; Dopamine Agents; Eating; Feeding Behavior; Food Preferences; Levodopa; Long-Term Potentiati | 2019 |
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Calcium Channels; Disease Models, Animal; Dyskines | 2019 |
Brain state-dependent alterations of corticostriatal synchronized oscillations in awake and anesthetized parkinsonian rats.
Topics: Anesthesia; Animals; Basal Ganglia; Beta Rhythm; Brain; Corpus Striatum; Disease Models, Animal; Lev | 2019 |
Suppressing nNOS Enzyme by Small-Interfering RNAs Protects SH-SY5Y Cells and Nigral Dopaminergic Neurons from 6-OHDA Injury.
Topics: Cell Line, Tumor; Dopaminergic Neurons; Gene Knockdown Techniques; Humans; Nitric Oxide Synthase Typ | 2019 |
MiR-410 exerts neuroprotective effects in a cellular model of Parkinson's disease induced by 6-hydroxydopamine via inhibiting the PTEN/AKT/mTOR signaling pathway.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Gene Expression Regulation; Humans; MicroRNAs; | 2019 |
Video-based assessments of the hind limb stepping in a mouse model of hemi-parkinsonism.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Gait; Hindlimb; Levodopa; Male; Mice; Mice, Inbred | 2020 |
Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A
Topics: 5'-Nucleotidase; Adenosine; Adenosine A2 Receptor Antagonists; Adenosine Diphosphate; Adenosine Trip | 2019 |
Cardiovascular alterations in rats with Parkinsonism induced by 6-OHDA and treated with Domperidone.
Topics: Animals; Behavior, Animal; Cardiovascular Diseases; Disease Models, Animal; Domperidone; Dopamine An | 2019 |
Endogenous protection against the 6-OHDA model of Parkinson's disease in the Amazonian rodent Proechimys.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Exploratory Behavior; Male; Neuroprotection; Oxido | 2019 |
Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; F | 2013 |
Behavioural recovery on simple and complex tasks by means of cell replacement therapy in unilateral 6-hydroxydopamine-lesioned mice.
Topics: Animals; Brain; Choice Behavior; Conditioning, Operant; Male; Mice; Mice, Inbred C57BL; Movement; Ox | 2013 |
The balance of striatal feedback transmission is disrupted in a model of parkinsonism.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Adrenergic Agents; Anesthetics, Local; Anim | 2013 |
Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Berberine; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, | 2013 |
Caspase-2 and caspase-8 trigger caspase-3 activation following 6-OHDA-induced stress in human dopaminergic neurons differentiated from ReNVM stem cells.
Topics: Adrenergic Agents; Apoptosis; Blotting, Western; Caspase 2; Caspase 8; Cell Differentiation; Cystein | 2013 |
Cognitive impairment and dentate gyrus synaptic dysfunction in experimental parkinsonism.
Topics: Animals; CA1 Region, Hippocampal; Cognition Disorders; Corpus Striatum; Dentate Gyrus; Long-Term Pot | 2014 |
Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
Topics: Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dyskinesia, Dr | 2013 |
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion | 2013 |
Reduction of motor disorder in 6-OHDA-induced severe parkinsonism rats by post treatment with granulocyte-colony stimulating factor.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Drug Evaluation, Preclinical | 2013 |
Recovery from experimental parkinsonism by semaphorin-guided axonal growth of grafted dopamine neurons.
Topics: Animals; Axons; Cell Differentiation; Cell Line; Cell- and Tissue-Based Therapy; Corpus Striatum; Do | 2013 |
Neural metabolite changes in corpus striatum after rat multipotent mesenchymal stem cells transplanted in hemiparkinsonian rats by magnetic resonance spectroscopy.
Topics: Animals; Aspartic Acid; Cell Differentiation; Cell Survival; Choline; Corpus Striatum; Creatine; Dis | 2013 |
L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Cerebral | 2014 |
Transplantation of melanocytes obtained from the skin ameliorates apomorphine-induced abnormal behavior in rodent hemi-parkinsonian models.
Topics: Analysis of Variance; Animals; Apomorphine; Corpus Striatum; Dopamine; Immunohistochemistry; Levodop | 2013 |
Electrophysiological and behavioral effects of group III metabotropic glutamate receptors on pallidal neurons in normal and parkinsonian rats.
Topics: Action Potentials; Aminobutyrates; Animals; Globus Pallidus; Glycine; Male; Neurons; Oxidopamine; Pa | 2013 |
AC-186, a selective nonsteroidal estrogen receptor β agonist, shows gender specific neuroprotection in a Parkinson's disease rat model.
Topics: Animals; Corpus Striatum; Cyclohexanes; Cytokines; Drug Evaluation, Preclinical; Estradiol; Estrogen | 2013 |
Acetylcorynoline attenuates dopaminergic neuron degeneration and α-synuclein aggregation in animal models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Appetitive Behavior; | 2014 |
Stress exacerbates experimental Parkinson's disease.
Topics: Animals; Antigens, Nuclear; Cell Count; Cell Survival; Chronic Disease; Depressive Disorder; Dopamin | 2014 |
5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Topics: 5-Hydroxytryptophan; Adrenergic Agents; Animals; Caudate Nucleus; Disease Models, Animal; Dopamine; | 2013 |
Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats.
Topics: Animals; Anti-Inflammatory Agents; Catalepsy; Corpus Striatum; Cytokines; Dose-Response Relationship | 2013 |
Amniotic fluid stem cells with low γ-interferon response showed behavioral improvement in Parkinsonism rat model.
Topics: Amniotic Fluid; Animals; Benzothiazoles; Diamines; DNA Primers; Fluorescent Antibody Technique; Gene | 2013 |
Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats.
Topics: Animals; Basal Ganglia; Calbindins; Globus Pallidus; Immunoblotting; Immunohistochemistry; Male; Neo | 2013 |
Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Blotting, Western; Immunohistochemistry; Levodopa; | 2013 |
Leukemia inhibitory factor promotes nestin-positive cells, and increases gp130 levels in the Parkinson disease mouse model of 6-hydroxydopamine.
Topics: Adrenergic Agents; Animals; Blotting, Western; Brain; Cytokine Receptor gp130; Disease Models, Anima | 2013 |
The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism.
Topics: Animals; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; | 2014 |
The theta-related firing activity of parvalbumin-positive neurons in the medial septum-diagonal band of Broca complex and their response to 5-HT1A receptor stimulation in a rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Apomorphine; Desipramine; Diagon | 2014 |
Abnormal functional connectivity between motor cortex and pedunculopontine nucleus following chronic dopamine depletion.
Topics: Alpha Rhythm; Animals; Cortical Synchronization; Motor Cortex; Oxidopamine; Parkinsonian Disorders; | 2014 |
The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Administration, Oral; Animals; Cannabinoid Receptor Antagonists; Corpus Striatum; Dihydroxyphenylala | 2013 |
Forced exercise before or after induction of 6-OHDA-mediated nigrostriatal insult does not mitigate behavioral asymmetry in a hemiparkinsonian rat model.
Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Forelimb; Function | 2014 |
Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Count; Cell Survival; Dopamine Agents; Dopaminergic Neurons; Hip | 2014 |
Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2/ARE signaling pathway.
Topics: Animals; Antioxidant Response Elements; Apoptosis; Cell Line, Tumor; Corpus Striatum; Dopaminergic N | 2014 |
Adult hemiparkinsonian rats do not benefit from tactile stimulation.
Topics: Adrenergic Agents; Amphetamine; Animals; Corpus Striatum; Dendrites; Disease Models, Animal; Functio | 2014 |
Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Benserazide; Benzothiazoles; Corpus Striatum; Hippocam | 2014 |
Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dendritic Spines; Dyskinesia, Drug-Induced; Excitatory Postsynaptic P | 2014 |
The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.
Topics: Animals; Anti-Bacterial Agents; Antiparkinson Agents; Ceftriaxone; Central Nervous System Agents; Dy | 2014 |
ser31 Tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion.
Topics: Animals; Blotting, Western; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Male; O | 2014 |
The role of the vagal pathway and gastric dopamine in the gastroparesis of rats after a 6-hydroxydopamine microinjection in the substantia nigra.
Topics: Acetylcholine; Animals; Blotting, Western; Disease Models, Animal; Dopamine; Fluorescent Antibody Te | 2014 |
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Cannabinoid Receptor Antagonists; | 2014 |
Functional Dopaminergic Neurons in Substantia Nigra are Required for Transcranial Magnetic Stimulation-Induced Motor Plasticity.
Topics: Animals; Dopaminergic Neurons; Electromyography; Evoked Potentials, Motor; Male; Motor Cortex; Muscl | 2015 |
High frequency stimulation of subthalamic nucleus results in behavioral recovery by increasing striatal dopamine release in 6-hydroxydopamine lesioned rat.
Topics: Animals; Cell Survival; Corpus Striatum; Deep Brain Stimulation; Dopamine; Dopaminergic Neurons; Ext | 2014 |
Protective effects of Althaea officinalis L. extract in 6-hydroxydopamine-induced hemi-Parkinsonism model: behavioral, biochemical and histochemical evidence.
Topics: Althaea; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Disease Models, Animal; Lipid Perox | 2014 |
Changes in surface expression of N-methyl-D-aspartate receptors in the striatum in a rat model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rec | 2014 |
GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: implication for Parkinson's disease.
Topics: Acetylcholine; Action Potentials; Animals; Corpus Striatum; Depression, Chemical; Dopamine; Glutamic | 2014 |
The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis.
Topics: Animals; Avoidance Learning; Brain; Cell Line, Tumor; Disease Models, Animal; Exploratory Behavior; | 2014 |
Deep brain stimulation of the subthalamic nucleus reestablishes neuronal information transmission in the 6-OHDA rat model of parkinsonism.
Topics: Action Potentials; Animals; Deep Brain Stimulation; Entropy; Female; Globus Pallidus; Implantable Ne | 2014 |
Decreased response of interneurons in the medial prefrontal cortex to 5-HT₁A receptor activation in the rat 6-hydroxydopamine Parkinson model.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Dose-Response Relationship, Drug | 2014 |
Intracerebral administration of ultrasound-induced dissolution of lipid-coated GDNF microbubbles provides neuroprotection in a rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Female; Glial Cell Line-Derived Neurotrophic Factor; Microbubbles; | 2014 |
6-Hydroxydopamine impairs mitochondrial function in the rat model of Parkinson's disease: respirometric, histological, and behavioral analyses.
Topics: Animals; Cell Death; Dopaminergic Neurons; Dose-Response Relationship, Drug; Functional Laterality; | 2014 |
The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Dose-Response Relationship, | 2014 |
Neuroprotective effect of curcumin on hippocampal injury in 6-OHDA-induced Parkinson's disease rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Curcumin; Cytopr | 2014 |
Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Gastrodia; Lev | 2014 |
Activation of prelimbic 5-HT1A receptors produces antidepressant-like effects in a unilateral rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Depression; Dietary Sucrose; | 2014 |
Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae.
Topics: Animals; Antiparkinson Agents; Anxiety; Biomarkers; Blotting, Western; Carbidopa; Disease Models, An | 2014 |
Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Explorato | 2014 |
Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats.
Topics: Animals; Buspirone; Cerebrospinal Fluid; Fluoxetine; Interleukin-1beta; Interleukin-6; Male; Oxidopa | 2015 |
Allosteric modulation of GluN2C/GluN2D-containing NMDA receptors bidirectionally modulates dopamine release: implication for Parkinson's disease.
Topics: Allosteric Regulation; Animals; Brain; Dopamine; Interneurons; Isoquinolines; Male; Mice; Mice, Inbr | 2014 |
Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Butadienes; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, D | 2015 |
The high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's disease.
Topics: Animals; Apoptosis; Cell Death; Dopaminergic Neurons; Dose-Response Relationship, Drug; Indoles; Mal | 2014 |
Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
Topics: Acetylation; Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Dynorphins; Dyskines | 2015 |
NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Excitatory Ami | 2014 |
Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action.
Topics: Amino Acid Transport System X-AG; Anilides; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; C | 2014 |
Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat.
Topics: Amphetamine; Animals; Cell Count; Cell Nucleolus; Cell Shape; Cell Size; Central Nervous System Stim | 2014 |
The effect of low frequency stimulation of the pedunculopontine tegmental nucleus on basal ganglia in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Disease Models, Animal; Electric Stimulation; Male; Neurons; Oxidopamine; Pa | 2014 |
Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease.
Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Apomorphine; Deferoxamine; Dopamine Agoni | 2014 |
NK₃ receptor agonism reinstates temporal order memory in the hemiparkinsonian rat.
Topics: Animals; Male; Medial Forebrain Bundle; Memory; Movement; Neuropsychological Tests; Nootropic Agents | 2015 |
Carnosine exerts neuroprotective effect against 6-hydroxydopamine toxicity in hemiparkinsonian rat.
Topics: Animals; Carnosine; Male; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, W | 2015 |
Regenerative therapy in experimental parkinsonism: mixed population of differentiated mouse embryonic stem cells, rather than magnetically sorted and enriched dopaminergic cells provide neuroprotection.
Topics: Adrenergic Agents; Amphetamine; Animals; Apomorphine; Brain; Cell Differentiation; Disease Models, A | 2014 |
Continuous stimulation of the pedunculopontine tegmental nucleus at 40 Hz affects preparative and executive control in a delayed sensorimotor task and reduces rotational movements induced by apomorphine in the 6-OHDA parkinsonian rat.
Topics: Animals; Apomorphine; Deep Brain Stimulation; Disease Models, Animal; Dopamine Agonists; Executive F | 2014 |
Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetul | 2014 |
RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephali | 2014 |
Intrastriatal GDNF gene transfer by inducible lentivirus vectors protects dopaminergic neurons in a rat model of parkinsonism.
Topics: Adrenergic Agents; Animals; Animals, Newborn; Cell Differentiation; Corpus Striatum; Culture Media, | 2014 |
Unilateral olfactory deficit in a hemiparkinson's disease mouse model.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Corpus Striatum; Discrimination, Psychologi | 2014 |
[Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].
Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Ma | 2014 |
l-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via β-adrenergic receptors.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dentate Gyrus; Disease Models, Animal; Dopamine; Dopami | 2014 |
Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.
Topics: Animals; Blood-Brain Barrier; Cell Count; Disease Models, Animal; Dopaminergic Neurons; Encephalitis | 2014 |
Functional correlates of exaggerated oscillatory activity in basal ganglia output in hemiparkinsonian rats.
Topics: Action Potentials; Adrenergic Agents; Animals; Antiparkinson Agents; Basal Ganglia; Brain Waves; Dis | 2014 |
Human adipose-derived mesenchymal stem cells improve motor functions and are neuroprotective in the 6-hydroxydopamine-rat model for Parkinson's disease when cultured in monolayer cultures but suppress hippocampal neurogenesis and hippocampal memory functi
Topics: Adipose Tissue; Adult; Animals; Brain-Derived Neurotrophic Factor; Cell Culture Techniques; Cell Dif | 2015 |
The neuroprotective potential of sinapic acid in the 6-hydroxydopamine-induced hemi-parkinsonian rat.
Topics: Animals; Antioxidants; Apomorphine; Cell Count; Coumaric Acids; Dopaminergic Neurons; Iron; Lipid Pe | 2015 |
Frequency matters: beta-band subthalamic nucleus deep-brain stimulation induces Parkinsonian-like blink abnormalities in normal rats.
Topics: Animals; Beta Rhythm; Blinking; Deep Brain Stimulation; Male; Oxidopamine; Parkinsonian Disorders; R | 2014 |
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.
Topics: Animals; Animals, Newborn; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine A | 2014 |
A new feature extraction method and classification of early stage Parkinsonian rats with and without DBS treatment.
Topics: Algorithms; Animals; Artificial Intelligence; Behavior, Animal; Deep Brain Stimulation; Diagnosis, C | 2014 |
Fractalkine over expression suppresses α-synuclein-mediated neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antigen Presentation; Astroc | 2015 |
The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.
Topics: Adrenergic Agents; alpha7 Nicotinic Acetylcholine Receptor; Animals; Autoradiography; Brain; Indoles | 2015 |
Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease.
Topics: Animals; Antioxidants; Dopaminergic Neurons; Male; Melatonin; Motor Activity; Oxidopamine; Parkinson | 2014 |
Chronic amitriptyline treatment attenuates nigrostriatal degeneration and significantly alters trophic support in a rat model of parkinsonism.
Topics: Adrenergic Agents; Amitriptyline; Analgesics, Non-Narcotic; Animals; Brain-Derived Neurotrophic Fact | 2015 |
Gastric dysregulation induced by microinjection of 6-OHDA in the substantia nigra pars compacta of rats is determined by alterations in the brain-gut axis.
Topics: Animals; Biomarkers; Choline O-Acetyltransferase; Disease Models, Animal; Dopamine Antagonists; Dopa | 2014 |
The possible mechanism of Parkinson's disease progressive damage and the preventive effect of GM1 in the rat model induced by 6-hydroxydopamine.
Topics: Animals; bcl-2-Associated X Protein; Brain; Calcium; Calmodulin; Disease Progression; G(M1) Ganglios | 2014 |
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relations | 2015 |
Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.
Topics: Acetamides; Animals; Brain; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Thera | 2015 |
Perinatal manganese exposure and hydroxyl radical formation in rat brain.
Topics: Animals; Brain; Brain Chemistry; Female; Frontal Lobe; Hippocampus; Hydroxyl Radical; Male; Manganes | 2015 |
New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Constipation; Gastrointestinal Transit; Ghrelin; Immunohistoch | 2014 |
Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Corpus Striatu | 2015 |
Kv4 channel blockade reduces motor and neuropsychiatric symptoms in rodent models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cognition; Corpus Striatum; Dopamine; Dose-Response Relationship, Dru | 2015 |
Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats.
Topics: Animals; Brain; Cell Membrane; Corpus Striatum; Disease Models, Animal; Dopamine; Fluorescence Reson | 2015 |
Neuroprotective Effects of β-Asarone Against 6-Hydroxy Dopamine-Induced Parkinsonism via JNK/Bcl-2/Beclin-1 Pathway.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Be | 2016 |
Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity.
Topics: Animals; Antioxidant Response Elements; Cell Line, Tumor; Cell Survival; Corpus Striatum; Dimethyl F | 2015 |
Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats.
Topics: Animals; Dopaminergic Neurons; Female; Humans; Mesenchymal Stem Cell Transplantation; Methamphetamin | 2015 |
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Ea | 2015 |
Lateral habenula as a link between dopaminergic and serotonergic systems contributes to depressive symptoms in Parkinson's disease.
Topics: Animals; Ascorbic Acid; Depressive Disorder; Dopamine; Electric Stimulation; Electron Transport Comp | 2015 |
Embryonic stem cells derived neuron transplantation recovery in models of parkinsonism in relation to severity of the disorder in rats.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Basal Ganglia; Behavior, Animal; Brain; Cells, Cultured; Disea | 2015 |
Loss of Nogo-A-expressing neurons in a rat model of Parkinson's disease.
Topics: Animals; Antigens, Nuclear; Cell Count; Choline O-Acetyltransferase; Dopamine; Female; Glial Fibrill | 2015 |
Bursting activity of substantia nigra pars reticulata neurons in mouse parkinsonism in awake and anesthetized states.
Topics: Action Potentials; Anesthetics; Animals; Beta Rhythm; Dopamine; Mice, Inbred C57BL; Mice, Transgenic | 2015 |
Dopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dopamine Agents; Levodopa; Mice, Inbred C57BL; | 2015 |
Nitrosative and cognitive effects of chronic L-DOPA administration in rats with intra-nigral 6-OHDA lesion.
Topics: Animals; Antiparkinson Agents; Astrocytes; Carbidopa; Corpus Striatum; Gliosis; Levodopa; Male; Maze | 2015 |
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose | 2015 |
Activation of serotonin(2C) receptors in the lateral habenular nucleus increases the expression of depression-related behaviors in the hemiparkinsonian rat.
Topics: Action Potentials; Adrenergic Agents; Animals; Apomorphine; Depression; Disease Models, Animal; Dopa | 2015 |
X-linked severe combined immunodeficiency (X-SCID) rats for xeno-transplantation and behavioral evaluation.
Topics: Animals; Cell Culture Techniques; Cell Survival; Dopaminergic Neurons; Embryonic Stem Cells; Humans; | 2015 |
Neurocytoprotective Effects of Aliphatic Hydroxamates from Lovastatin, a Secondary Metabolite from Monascus-Fermented Red Mold Rice, in 6-Hydroxydopamine (6-OHDA)-Treated Nerve Growth Factor (NGF)-Differentiated PC12 Cells.
Topics: Animals; Apoptosis; Cell Differentiation; Cell Survival; Lovastatin; Models, Biological; Monascus; N | 2015 |
Local Change in Urinary Bladder Contractility Following CNS Dopamine Denervation in the 6-OHDA Rat Model of Parkinson's Disease.
Topics: Adenosine Triphosphate; Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopaminergic | 2015 |
A time-course study of behavioral and electrophysiological characteristics in a mouse model of different stages of Parkinson's disease using 6-hydroxydopamine.
Topics: Action Potentials; Animals; Body Weight; Disease Progression; Immunohistochemistry; Male; Medial For | 2015 |
A partial lesion model of Parkinson's disease in mice--characterization of a 6-OHDA-induced medial forebrain bundle lesion.
Topics: Amphetamine; Animals; Area Under Curve; Dopamine Agents; Dopaminergic Neurons; Dose-Response Relatio | 2015 |
Meningeal cells influence midbrain development and the engraftment of dopamine progenitors in Parkinsonian mice.
Topics: Adrenergic Agents; Animals; Benzylamines; Cell Differentiation; Cells, Cultured; Cyclams; Disease Mo | 2015 |
Recruitment of the prefrontal cortex and cerebellum in Parkinsonian rats following skilled aerobic exercise.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Autoradiography; Brain Mapping; Cerebellum; Cerebr | 2015 |
Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Catalepsy; Dyskinesia, Drug-Induced; Excitatory Amino | 2015 |
Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; | 2015 |
Activation of 5-HT₁A receptors in the medial subdivision of the central nucleus of the amygdala produces anxiolytic effects in a rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Anti-Anxiety Agents; Anxiety Dis | 2015 |
Deep brain stimulation of different pedunculopontine targets in a novel rodent model of parkinsonism.
Topics: Animals; Cell Survival; Cholinergic Neurons; Deep Brain Stimulation; Disease Models, Animal; Dopamin | 2015 |
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Diseas | 2015 |
Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinso | 2015 |
Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease.
Topics: Adenylyl Cyclase Inhibitors; Adrenergic beta-2 Receptor Antagonists; Animals; Antiparkinson Agents; | 2015 |
Exosomes as drug delivery vehicles for Parkinson's disease therapy.
Topics: Administration, Intranasal; Animals; Anti-Inflammatory Agents; Antioxidants; Antiparkinson Agents; B | 2015 |
Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Anxiety; Benzothiazoles; Depression; Hippocampus; Levodopa; Male; Mic | 2015 |
The 6-OHDA mouse model of Parkinson's disease - Terminal striatal lesions provide a superior measure of neuronal loss and replacement than median forebrain bundle lesions.
Topics: Animals; Apomorphine; Corpus Striatum; Dextroamphetamine; Dopamine Agonists; Dopamine Uptake Inhibit | 2015 |
Effects of discontinuing a high-fat diet on mitochondrial proteins and 6-hydroxydopamine-induced dopamine depletion in rats.
Topics: Animals; Body Weight; Corpus Striatum; Diet, Fat-Restricted; Diet, High-Fat; Dopamine; Glucose; Male | 2015 |
Serotonin₆ receptors in the dorsal hippocampus regulate depressive-like behaviors in unilateral 6-hydroxydopamine-lesioned Parkinson's rats.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Dopamine; Excitatory Amino Acid Transporter 3; | 2015 |
Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskines | 2015 |
Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats.
Topics: Animals; Male; Mitochondria, Liver; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; | 2015 |
Subthalamic nucleus activity in the awake hemiparkinsonian rat: relationships with motor and cognitive networks.
Topics: Action Potentials; Adrenergic Agents; Animals; Antiparkinson Agents; Benzazepines; Cognition Disorde | 2015 |
Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Topics: Adenine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Bas | 2015 |
Similar L-dopa-stimulated motor activity in mice with adult-onset 6-hydroxydopamine-induced symmetric dopamine denervation and in transcription factor Pitx3 null mice with perinatal-onset symmetric dopamine denervation.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Homeodomain Proteins; Levodo | 2015 |
6-OHDA-Induced Changes in Parkinson's Disease-Related Gene Expression are not Affected by the Overexpression of PGAM5 in In Vitro Differentiated Embryonic Mesencephalic Cells.
Topics: Carrier Proteins; Cell Differentiation; Cell Line, Transformed; Gene Expression Regulation; Humans; | 2015 |
Decreased HCN2 expression in STN contributes to abnormal high-voltage spindles in the cortex and globus pallidus of freely moving rats.
Topics: Animals; Antiparkinson Agents; Cardiovascular Agents; Cerebral Cortex; Disease Models, Animal; Down- | 2015 |
The nonsteroidal antiinflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model of Parkinson's disease.
Topics: Anhedonia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Depressive Disor | 2015 |
Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?
Topics: Animals; Calbindins; Cyclooxygenase 2; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Dr | 2015 |
Relationships among rat ultrasonic vocalizations, behavioral measures of striatal dopamine loss, and striatal tyrosine hydroxylase immunoreactivity at acute and chronic time points following unilateral 6-hydroxydopamine-induced dopamine depletion.
Topics: Acute Disease; Animals; Apomorphine; Chronic Disease; Corpus Striatum; Dopamine; Dopamine Agonists; | 2015 |
Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.
Topics: Animals; Corpus Striatum; DNA Replication; Doublecortin Domain Proteins; Doublecortin Protein; Drug | 2015 |
Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain-Derived Neurotrophic Factor; Butyric Acid; Corpus | 2015 |
A new dopaminergic nigro-olfactory projection.
Topics: Animals; Dopamine; Dopamine Agonists; Immunohistochemistry; Male; Neural Pathways; Neural Stem Cells | 2015 |
The effects of subthalamic deep brain stimulation on mechanical and thermal thresholds in 6OHDA-lesioned rats.
Topics: Adrenergic Agents; Animals; Deep Brain Stimulation; Disease Models, Animal; Functional Laterality; H | 2015 |
Striatal Injury with 6-OHDA Transiently Increases Cerebrospinal GFAP and S100B.
Topics: Animals; Astrocytes; Cells, Cultured; Corpus Striatum; Glial Fibrillary Acidic Protein; Male; Motor | 2015 |
Early use of oleanolic acid provides protection against 6-hydroxydopamine induced dopamine neurodegeneration.
Topics: Animals; Antiparkinson Agents; Apoptosis; Corpus Striatum; Dopamine; Forelimb; Functional Laterality | 2015 |
From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; F | 2015 |
The impact of a parkinsonian lesion on dynamic striatal dopamine transmission depends on nicotinic receptor activation.
Topics: Animals; Cocaine; Corpus Striatum; Dopamine; Dopamine Uptake Inhibitors; Male; Mice, Inbred C57BL; O | 2015 |
Diverse Short-Term Dynamics of Inhibitory Synapses Converging on Striatal Projection Neurons: Differential Changes in a Rodent Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; GABAergic Neurons; Male; Models, Neurological; Neostriatum; Neurona | 2015 |
Cineradiographic analysis of respiratory movements in a mouse model for early Parkinson's disease.
Topics: Animals; Behavior, Animal; Cineradiography; Diaphragm; Functional Laterality; Male; Mice, Inbred C57 | 2015 |
LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease.
Topics: Animals; Cell Survival; Central Nervous System Agents; Dopaminergic Neurons; Female; Glial Fibrillar | 2015 |
Alterations in the motor cortical and striatal glutamatergic system and D-serine levels in the bilateral 6-hydroxydopamine rat model for Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Glutamic Acid; Male; Motor Cortex; Oxidopamine; Pa | 2015 |
Chronic deep brain stimulation of the medial forebrain bundle reverses depressive-like behavior in a hemiparkinsonian rodent model.
Topics: Adrenergic Agents; Amphetamine; Animals; Central Nervous System Stimulants; Deep Brain Stimulation; | 2015 |
The 5-HT4 Agonist Prucalopride Stimulates L-DOPA-Induced Dopamine Release in Restricted Brain Regions of the Hemiparkinsonian Rat In Vivo.
Topics: Animals; Benzofurans; Brain; Dopamine; Dopamine Agents; Functional Laterality; Indoles; Levodopa; Mi | 2015 |
The combined depletion of monoamines alters the effectiveness of subthalamic deep brain stimulation.
Topics: Animals; Anxiety Disorders; Benzylamines; Biogenic Monoamines; Catalepsy; Corpus Striatum; Deep Brai | 2015 |
6-Hydroxydopamine as a tool to understand adaptive immune system-induced dopamine neurodegeneration in Parkinson's disease.
Topics: Adaptive Immunity; Animals; B-Lymphocytes; Calcium-Binding Proteins; CD3 Complex; Disease Models, An | 2015 |
Subthalamic deep brain stimulation reduces pathological information transmission to the thalamus in a rat model of parkinsonism.
Topics: Action Potentials; Adrenergic Agents; Animals; Biophysics; Deep Brain Stimulation; Disease Models, A | 2015 |
Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Astrocytes; Cell Line; Cells, Cultured; Corpus Striatum; Cystamine; C | 2015 |
Magnetic resonance imaging as a tool to image neuroinflammation in a rat model of Parkinson's disease--phagocyte influx to the brain is promoted by bilberry-enriched diet.
Topics: Animals; Blood-Brain Barrier; Contrast Media; Disease Models, Animal; Encephalitis; Female; Magnetic | 2015 |
Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopaminergic Neurons; Limoni | 2015 |
Schisandrin B shows neuroprotective effect in 6-OHDA-induced Parkinson's disease via inhibiting the negative modulation of miR-34a on Nrf2 pathway.
Topics: 3' Untranslated Regions; Animals; Behavior, Animal; Binding Sites; Brain; Cell Line, Tumor; Cell Sur | 2015 |
Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Animals; Bone Marrow Transplantation; Corpus Striatum; Disease Progression; Dopaminergic Neurons; Ho | 2015 |
Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats.
Topics: Amantadine; Animals; Dietary Supplements; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorder | 2015 |
Serotonergic interaction between medial prefrontal cortex and mesotelencephalic DA system underlies cognitive and affective deficits in hemiparkinsonian rats.
Topics: Adrenergic Agents; Animals; Cognition Disorders; Disease Models, Animal; Excitatory Amino Acid Agoni | 2015 |
Moderate-Intensity Physical Exercise Protects Against Experimental 6-Hydroxydopamine-Induced Hemiparkinsonism Through Nrf2-Antioxidant Response Element Pathway.
Topics: Animals; Male; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Oxidopamine; Parkinsonian Disorders | 2016 |
Loss of Striatonigral GABAergic Presynaptic Inhibition Enables Motor Sensitization in Parkinsonian Mice.
Topics: Adrenergic Agents; Animals; Bacterial Proteins; Channelrhodopsins; Corpus Striatum; Disease Models, | 2015 |
Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
Topics: AIDS-Related Complex; Animals; Benzazepines; Disease Models, Animal; Dopamine Agents; Dyskinesia, Dr | 2015 |
CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Topics: Administration, Intranasal; Animals; Astrocytes; Corpus Striatum; CX3C Chemokine Receptor 1; Dopamin | 2016 |
Chemoreflex and baroreflex alterations in Parkinsonism induced by 6-OHDA in unanesthetized rats.
Topics: Animals; Baroreflex; Blood Pressure; Chemoreceptor Cells; Heart Rate; Male; Nitroprusside; Oxidopami | 2015 |
Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: relevance to gastrointestinal dysfunctions in Parkinson's disease.
Topics: Animals; Chromatography, High Pressure Liquid; Colon; Constipation; Disease Models, Animal; Dopamine | 2015 |
Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.
Topics: Adrenergic Agents; Age Factors; Animals; Animals, Newborn; Antiparkinson Agents; Catalase; Disease M | 2016 |
Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
Topics: Adrenergic Agents; Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; | 2015 |
Activation and blockade of serotonin7 receptors in the prelimbic cortex regulate depressive-like behaviors in a 6-hydroxydopamine-induced Parkinson's disease rat model.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder; Dietary Sucrose; Dopamine; Dose-Response | 2015 |
Frequency-Dependent Corticostriatal Disinhibition Resulting from Chronic Dopamine Depletion: Role of Local Striatal cGMP and GABA-AR Signaling.
Topics: Animals; Brain Waves; Cerebral Cortex; Corpus Striatum; Cyclic GMP; Dopamine; Forelimb; gamma-Aminob | 2017 |
Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions.
Topics: Animals; Antiparkinson Agents; Apomorphine; Azepines; Benzothiazoles; Cabergoline; Corpus Striatum; | 2015 |
Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzazepines; Disease Models, Animal; Dopamine Agon | 2016 |
Intracranial application of near-infrared light in a hemi-parkinsonian rat model: the impact on behavior and cell survival.
Topics: Animals; Apomorphine; Cell Survival; Dopamine Agonists; Dopaminergic Neurons; Dose-Response Relation | 2016 |
Adaptive down-regulation of the serotonin transporter in the 6-hydroxydopamine-induced rat model of preclinical stages of Parkinson's disease and after chronic pramipexole treatment.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Brain; Disease Models, Animal; Dopamine Plasma Membra | 2016 |
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Sig | 2016 |
Assessments of cognitive abilities in a mouse model of Parkinson's disease with a touch screen test.
Topics: Animals; Cognition; Cognition Disorders; Computers; Conditioning, Operant; Discrimination, Psycholog | 2016 |
Decreased synaptic plasticity in the medial prefrontal cortex underlies short-term memory deficits in 6-OHDA-lesioned rats.
Topics: Animals; Discrimination, Psychological; Double-Blind Method; Long-Term Potentiation; Male; Maze Lear | 2016 |
Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia.
Topics: Amino Acid Transport Systems, Acidic; Animals; Antiparkinson Agents; Cell Count; Cell Size; Choline | 2016 |
Coherence of neuronal firing of the entopeduncular nucleus with motor cortex oscillatory activity in the 6-OHDA rat model of Parkinson's disease with levodopa-induced dyskinesias.
Topics: Action Potentials; Animals; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Motor | 2016 |
Neuroprotection of inositol hexaphosphate and changes of mitochondrion mediated apoptotic pathway and α-synuclein aggregation in 6-OHDA induced parkinson's disease cell model.
Topics: Adrenergic Agents; alpha-Synuclein; Apoptosis; Blotting, Western; Cell Line, Tumor; Flow Cytometry; | 2016 |
Investigation of diazepam efficacy on anxiety-like behavior in hemiparkinsonian rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Diazepam; Exploratory Behavior; Functional Laterali | 2016 |
Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Immunohis | 2016 |
Salidroside Protects Against 6-Hydroxydopamine-Induced Cytotoxicity by Attenuating ER Stress.
Topics: Adrenergic Agents; Animals; Apoptosis; Blotting, Western; Cell Line; Cell Survival; Dopaminergic Neu | 2016 |
CART modulates the effects of levodopa in rat model of Parkinson's disease.
Topics: Animals; Antibodies; Antiparkinson Agents; Apomorphine; Brain; Dopamine Agonists; Dose-Response Rela | 2016 |
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relati | 2016 |
Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Dopamine; Dyskinesias; Levodopa; Male; N | 2016 |
Pathway-Specific Remodeling of Thalamostriatal Synapses in Parkinsonian Mice.
Topics: Adrenergic Agents; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Corpus Striatu | 2016 |
Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats.
Topics: Action Potentials; Animals; Brain; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesia, | 2016 |
Dopaminergic-primed fetal liver mesenchymal stromal-like cells can reverse parkinsonian symptoms in 6-hydroxydopamine-lesioned mice.
Topics: Animals; Cell Transdifferentiation; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopami | 2016 |
Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
Topics: Animals; Antigens, Differentiation; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dy | 2016 |
Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
Topics: Animals; Dyskinesia, Drug-Induced; Female; Levodopa; Nerve Tissue Proteins; Oxidopamine; Parkinsonia | 2016 |
IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases.
Topics: Adrenergic Agents; Animals; Disease Models, Animal; Dopaminergic Neurons; Glycogen Synthase Kinase 3 | 2016 |
Quantitative Evaluation of Changes in the Striatal Astrocyte Axons in Simulated Parkinsonism.
Topics: Animals; Astrocytes; Axons; Corpus Striatum; Glial Fibrillary Acidic Protein; Male; Oxidopamine; Par | 2016 |
Curcumin improves neurofunctions of 6-OHDA-induced parkinsonian rats.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Blotting, Western; Curcumin; Disease Models, Animal; M | 2016 |
Failure to suppress low-frequency neuronal oscillatory activity underlies the reduced effectiveness of random patterns of deep brain stimulation.
Topics: Action Potentials; Animals; Central Nervous System Stimulants; Deep Brain Stimulation; Dopamine D2 R | 2016 |
Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Cytoskeleton; Drug Combinations; Dyskin | 2016 |
β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.
Topics: Allylbenzene Derivatives; Animals; Anisoles; ATP Binding Cassette Transporter, Subfamily B; Blood-Br | 2016 |
Morphologic changes within the cerebellar cortex in the unilateral 6-hydroxydopamine lesioned rat model for Parkinson disease.
Topics: Adrenergic Agents; Animals; Blotting, Western; Cerebellum; Disease Models, Animal; Female; Immunohis | 2016 |
Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Cyclic AMP-Dependent Protein Ki | 2016 |
7,8-dihydroxyflavone protects 6-OHDA and MPTP induced dopaminergic neurons degeneration through activation of TrkB in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopaminergic Neurons; Flavo | 2016 |
Quantitative and semi-quantitative measurements of axonal degeneration in tissue and primary neuron cultures.
Topics: Animals; Axons; Brain; Cells, Cultured; Colchicine; Dependovirus; Disease Models, Animal; Genetic Ve | 2016 |
β-Asarone Inhibits IRE1/XBP1 Endoplasmic Reticulum Stress Pathway in 6-OHDA-Induced Parkinsonian Rats.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Endoplasmic Reticulum Stress; Female; Male; Membrane Pr | 2016 |
Pretreatment with potassium channel blockers of 4-aminopyridine and tetraethylammonium attenuates behavioural symptoms of Parkinsonism induced by intrastriatal injection of 6-hydroxydopamine; the role of lipid peroxidation.
Topics: 4-Aminopyridine; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; D | 2016 |
DREADD Modulation of Transplanted DA Neurons Reveals a Novel Parkinsonian Dyskinesia Mechanism Mediated by the Serotonin 5-HT6 Receptor.
Topics: Animals; Clozapine; Cyclic AMP; Diterpenes; Diterpenes, Clerodane; Dopamine; Dopaminergic Neurons; D | 2016 |
Altered Expression of D1 and D2 Dopamine Receptors in Vagal Neurons Innervating the Gastric Muscularis Externa in a Parkinson's Disease Rat Model.
Topics: Animals; Choline O-Acetyltransferase; Disease Models, Animal; Dopamine; Male; Neuroanatomical Tract- | 2016 |
Serotonin7 receptors in the lateral habenular nucleus regulate depressive-like behaviors in the hemiparkinsonian rats.
Topics: Animals; Depression; Disease Models, Animal; Dopamine; Habenula; Hippocampus; Locomotion; Male; Nore | 2016 |
Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease.
Topics: Animals; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Benzothiazoles; Corpus Striatum; De | 2016 |
Effects of WR1065 on 6-hydroxydopamine-induced motor imbalance: Possible involvement of oxidative stress and inflammatory cytokines.
Topics: Animals; Disease Models, Animal; Glutathione; Inflammation; Interleukin-1beta; Lipid Peroxidation; M | 2016 |
Human Basic Fibroblast Growth Factor Inhibits Tau Phosphorylation via the PI3K/Akt-GSK3β Signaling Pathway in a 6-Hydroxydopamine-Induced Model of Parkinson's Disease.
Topics: Administration, Intranasal; Animals; Brain; Cell Line, Tumor; Corpus Striatum; Disease Models, Anima | 2016 |
Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Body Weight; Disease Models, Animal; Dopamine; Dopamine | 2016 |
The impact of biological sex and sex hormones on cognition in a rat model of early, pre-motor Parkinson's disease.
Topics: Animals; Cognition; Estradiol; Female; Male; Maze Learning; Orchiectomy; Ovariectomy; Oxidopamine; P | 2017 |
Distinct temporal spike and local field potential activities in the thalamic parafascicular nucleus of parkinsonian rats during rest and limb movement.
Topics: Action Potentials; Animals; Dopamine; Functional Laterality; Immunohistochemistry; Intralaminar Thal | 2016 |
Anti-parkinsonian effects of fluvoxamine maleate in maternally separated rats.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Antiparkinson Agents; Anxiety; Disease | 2016 |
Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action.
Topics: Animals; Anti-Dyskinesia Agents; Arachidonic Acids; Brain; Cannabidiol; Capsaicin; Cyclooxygenase 2; | 2016 |
The Role of Group II Metabotropic Glutamate Receptors in the Striatum in Electroacupuncture Treatment of Parkinsonian Rats.
Topics: Analysis of Variance; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models | 2017 |
Activation and blockade of prelimbic 5-HT6 receptors produce different effects on depressive-like behaviors in unilateral 6-hydroxydopamine-induced Parkinson's rats.
Topics: Animals; Depression; Injections, Intraventricular; Male; Methylamines; Oxidopamine; Parkinsonian Dis | 2016 |
A Small Molecule That Protects the Integrity of the Electron Transfer Chain Blocks the Mitochondrial Apoptotic Pathway.
Topics: Animals; Antiparkinson Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associat | 2016 |
Characterization of gray matter atrophy following 6-hydroxydopamine lesion of the nigrostriatal system.
Topics: Animals; Apomorphine; Atrophy; Brain; Dopamine Agonists; Dopaminergic Neurons; Functional Laterality | 2016 |
Decrease of a Current Mediated by Kv1.3 Channels Causes Striatal Cholinergic Interneuron Hyperexcitability in Experimental Parkinsonism.
Topics: Aging; Animals; Cholinergic Agents; Interneurons; Ion Channel Gating; Kv1.3 Potassium Channel; Membr | 2016 |
Fluvoxamine maleate normalizes striatal neuronal inflammatory cytokine activity in a Parkinsonian rat model associated with depression.
Topics: Age Factors; Animals; Animals, Newborn; Anti-Anxiety Agents; Corpus Striatum; Cytokines; Depression; | 2017 |
Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Line; Dose-Response Relationship, Drug; Drug Evalua | 2016 |
Neuroprotective Effects of Sulphated Agaran from Marine Alga Gracilaria cornea in Rat 6-Hydroxydopamine Parkinson's Disease Model: Behavioural, Neurochemical and Transcriptional Alterations.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Behavior, Animal; Biomarkers; Brain; Disease Models | 2017 |
The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, | 2016 |
The impact of 1MeTIQ on the dopaminergic system function in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Dopamine; Dose-Response Relationship, Drug; Male; Motor Activity; Neuroprotective Agents; O | 2016 |
Altered melatonin MT
Topics: Animals; Apomorphine; Blotting, Western; Corpus Striatum; Dopamine Agonists; Dopaminergic Neurons; F | 2016 |
Short- and long-term dopamine depletion causes enhanced beta oscillations in the cortico-basal ganglia loop of parkinsonian rats.
Topics: Analysis of Variance; Animals; Basal Ganglia; Beta Rhythm; Cerebral Cortex; Disease Models, Animal; | 2016 |
Contribution of the nitric oxide donor molsidomine and the antiparkinsonian drug l-DOPA to the modulation of the blood pressure in unilaterally 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Blood Pressure; Levodopa; Male; Molsidomine; Nitric Oxide Donors; Oxi | 2017 |
Direct modulation of firing activity by dopamine D
Topics: Animals; Disease Models, Animal; Dopamine; Globus Pallidus; Male; Neurons; Oxidopamine; Parkinsonian | 2016 |
Changes in SK channel expression in the basal ganglia after partial nigrostriatal dopamine lesions in rats: Functional consequences.
Topics: Animals; Apamin; Basal Ganglia; Corpus Striatum; Dopamine; Gene Expression; Male; Oxidopamine; Parki | 2017 |
The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA.
Topics: Acetylcysteine; Amphetamine; Animals; Apomorphine; Benzazepines; Central Nervous System Stimulants; | 2017 |
FTY720 Attenuates 6-OHDA-Associated Dopaminergic Degeneration in Cellular and Mouse Parkinsonian Models.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Fingolimod | 2017 |
Cardiovascular dysfunction associated with neurodegeneration in an experimental model of Parkinson's disease.
Topics: Acetylcholine; Animals; Autonomic Nervous System; Baroreflex; Blood Pressure; Bradycardia; Brain Ste | 2017 |
MK-801 (Dizocilpine) Regulates Multiple Steps of Adult Hippocampal Neurogenesis and Alters Psychological Symptoms via Wnt/β-Catenin Signaling in Parkinsonian Rats.
Topics: Adaptation, Ocular; Animals; beta Catenin; Cell Proliferation; Disease Models, Animal; Dizocilpine M | 2017 |
Effects of subthalamic deep brain stimulation with duloxetine on mechanical and thermal thresholds in 6OHDA lesioned rats.
Topics: Analgesics; Animals; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Duloxe | 2017 |
Tetramethylpyrazine Analogue CXC195 Protects Against Dopaminergic Neuronal Apoptosis via Activation of PI3K/Akt/GSK3β Signaling Pathway in 6-OHDA-Induced Parkinson's Disease Mice.
Topics: Animals; Apoptosis; Dopaminergic Neurons; Dose-Response Relationship, Drug; Glycogen Synthase Kinase | 2017 |
Iron accumulation and microglia activation contribute to substantia nigra hyperechogenicity in the 6-OHDA-induced rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Iron; Male; Microglia; Oxidopamine; Parkinsonian Disorders; Random | 2017 |
Involvement of lateral habenula α1 subunit-containing GABA
Topics: Action Potentials; Animals; Apomorphine; Depression; Dopamine Agonists; GABA Antagonists; GABA-A Rec | 2017 |
Transplantation site influences the phenotypic differentiation of dopamine neurons in ventral mesencephalic grafts in Parkinsonian rats.
Topics: Adrenergic Agents; Amphetamine; Animals; Brain Tissue Transplantation; Disease Models, Animal; Dopam | 2017 |
Long-term protective effects of AAV9-mesencephalic astrocyte-derived neurotrophic factor gene transfer in parkinsonian rats.
Topics: Adenoviridae; Adrenergic Agents; Amphetamine; Animals; Cells, Cultured; Disease Models, Animal; Dopa | 2017 |
Combined ipsilateral limb use score as an index of motor deficits and neurorestoration in parkinsonian rats.
Topics: Animals; Behavior, Animal; Brain; Dopamine Antagonists; Dose-Response Relationship, Drug; Male; Moto | 2017 |
Differential behavioral outcomes following neonatal versus fetal human retinal pigment epithelial cell striatal implants in parkinsonian rats.
Topics: Amphetamine; Animals; Cell Survival; Cell Transplantation; Cellular Senescence; Central Nervous Syst | 2017 |
Preclinical Analysis of Fetal Human Mesencephalic Neural Progenitor Cell Lines: Characterization and Safety In Vitro and In Vivo.
Topics: Animals; Biomarkers; Cell Culture Techniques; Cell Line; Cell Proliferation; Disease Models, Animal; | 2017 |
A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Beclin-1; Cyclic AMP Response Element-Binding Protein; Dopaminergic N | 2017 |
Intranasal Administration of GDNF Protects Against Neural Apoptosis in a Rat Model of Parkinson's Disease Through PI3K/Akt/GSK3β Pathway.
Topics: Administration, Intranasal; Animals; Apoptosis; Glial Cell Line-Derived Neurotrophic Factor; Glycoge | 2017 |
The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson's Disease in Rats.
Topics: Animals; Inflammasomes; Male; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidopamine; Parkinsoni | 2017 |
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
Topics: Animals; Antiparkinson Agents; Channelrhodopsins; Cocaine; Corpus Striatum; Disease Models, Animal; | 2017 |
Dysregulation of BET proteins in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Azepines; Chromatin Immunoprecipitation; Corpus Striatum; Disease Mod | 2017 |
Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter.
Topics: Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Denervation; Desipramine; Disease Models | 2008 |
Increased electrical and metabolic activity in the dorsal raphe nucleus of Parkinsonian rats.
Topics: Action Potentials; Animals; Denervation; Dopamine; Electron Transport Complex IV; Energy Metabolism; | 2008 |
Patterns of FOS expression in the spinal cord and periaqueductal grey matter of 6OHDA-lesioned rats.
Topics: Animals; Disease Models, Animal; Functional Laterality; Immunohistochemistry; Lumbar Vertebrae; Male | 2008 |
6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.
Topics: 1-Methyl-3-isobutylxanthine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; | 2008 |
In vivo modulation of dopaminergic nigrostriatal pathways by cytisine derivatives: implications for Parkinson's Disease.
Topics: Alkaloids; Animals; Antiparkinson Agents; Azocines; Bridged-Ring Compounds; Disease Models, Animal; | 2008 |
Non-dopaminergic neurons in ventral mesencephalic transplants make widespread axonal connections in the host brain.
Topics: Animals; Animals, Newborn; Brain; Brain Tissue Transplantation; Cells, Cultured; Dopamine; Female; g | 2008 |
Maternal separation exaggerates the toxic effects of 6-hydroxydopamine in rats: implications for neurodegenerative disorders.
Topics: Animals; Behavior, Animal; Corpus Striatum; Female; Maternal Deprivation; Neurodegenerative Diseases | 2008 |
Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Catalepsy; Cyclopentanes; Disease Mode | 2008 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease M | 2008 |
Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease.
Topics: Animals; Cell Differentiation; Cell Line; Cell Survival; Dopamine; Embryonic Stem Cells; Female; Fib | 2008 |
Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
Topics: Animals; Anti-Inflammatory Agents; Corpus Striatum; Corticosterone; Disease Models, Animal; Dose-Res | 2008 |
Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Dopamine; Glutamic Acid; Male; Mesencephalon; Ner | 2008 |
L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Antipsy | 2010 |
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
Topics: Animals; Animals, Newborn; Brain; Cerebral Cortex; Cyclic AMP; Cyclic GMP; Dopamine; Dopamine Agents | 2008 |
Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; | 2008 |
Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements.
Topics: Adrenergic Agents; Animals; Dopamine Agonists; Dyskinesia, Drug-Induced; Dyskinesias; Male; Oxidopam | 2008 |
Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Mode | 2008 |
[Antioxidants prevent experimental hemiparkinsonism in rats].
Topics: Animals; Antioxidants; Behavior, Animal; Chromans; Disease Models, Animal; Dopamine; Male; Melatonin | 2008 |
Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Creatine; Dietary Supplements; Disease Models, | 2009 |
Dopaminergic but not glutamatergic neurotransmission is increased in the striatum after selective cyclooxygenase-2 inhibition in normal and hemiparkinsonian rats.
Topics: Animals; Celecoxib; Corpus Striatum; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2008 |
Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Basal Ganglia; Blotting, Western; Chromatography, High Pressure Liquid; | 2008 |
The firing activity of presumed cholinergic and non-cholinergic neurons of the pedunculopontine nucleus in 6-hydroxydopamine-lesioned rats: an in vivo electrophysiological study.
Topics: Acetylcholine; Action Potentials; Animals; Basal Ganglia; Cholinergic Fibers; Disease Models, Animal | 2008 |
Downregulation of glial glutamate transporters after dopamine denervation in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Amino Acid Transport System X-AG; Animals; Blotting, Western; Corpus Striatum; De | 2008 |
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, D | 2008 |
Asymmetrical response of aminopeptidase A and nitric oxide in plasma of normotensive and hypertensive rats with experimental hemiparkinsonism.
Topics: Animals; Blood Pressure; Corpus Striatum; Functional Laterality; Glutamyl Aminopeptidase; Hypertensi | 2009 |
The footfault test as a screening tool in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Behavioral Sciences; Disease Models, Animal; Dopamine; Dopamine Agonists; | 2009 |
Priming of rotational behavior by a dopamine receptor agonist in Hemiparkinsonian rats: movement-dependent induction.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphi | 2009 |
Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzamides; Bicuculline; Bridged Bicyclo Compounds, | 2008 |
Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis.
Topics: Animals; Behavior, Animal; Brain; Bromodeoxyuridine; Disease Models, Animal; Dopamine; Erythropoieti | 2009 |
Parkinsonian beta oscillations in the external globus pallidus and their relationship with subthalamic nucleus activity.
Topics: Action Potentials; Animals; Beta Rhythm; Biological Clocks; Disease Models, Animal; Globus Pallidus; | 2008 |
Combined treatment of neurotrophin-3 gene and neural stem cells is ameliorative to behavior recovery of Parkinson's disease rat model.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Movement; Cells, Cultured; Disease Models, Animal; Dopa | 2009 |
Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; | 2009 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix | 2009 |
Walking pattern analysis after unilateral 6-OHDA lesion and transplantation of foetal dopaminergic progenitor cells in rats.
Topics: Animals; Brain Tissue Transplantation; Corpus Striatum; Dopamine; Female; Fetal Tissue Transplantati | 2009 |
Subthalamic neurons show increased firing to 5-HT2C receptor activation in 6-hydroxydopamine-lesioned rats.
Topics: Action Potentials; Aminopyridines; Analysis of Variance; Animals; Immunohistochemistry; Indoles; Mal | 2009 |
A novel diketopiperazine improves functional recovery given after the onset of 6-OHDA-induced motor deficit in rats.
Topics: Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Diketopiperazines; | 2009 |
L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
Topics: Animals; Brain; Brain Chemistry; Corpus Striatum; Dopamine Agents; Drug Interactions; Dyskinesia, Dr | 2009 |
Firing activity of locus coeruleus noradrenergic neurons increases in a rodent model of Parkinsonism.
Topics: Action Potentials; Animals; Disease Models, Animal; Locus Coeruleus; Male; Neurons; Norepinephrine; | 2009 |
Use of rotorod as a method for the qualitative analysis of walking in rat.
Topics: Animals; Disease Models, Animal; Dopamine; Motor Skills; Oxidopamine; Parkinsonian Disorders; Rats; | 2008 |
De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat.
Topics: Animals; Cell Proliferation; Corpus Striatum; Dopamine Agents; Drug Administration Schedule; Gene Ex | 2009 |
Survival and early functional integration of dopaminergic progenitor cells following transplantation in a rat model of Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Cell Communication; Cell Differentiation; Denervation; Diseas | 2009 |
Induction of GAP-43 modulates neuroplasticity in PBSC (CD34+) implanted-Parkinson's model.
Topics: Animals; Antigens, CD34; Biomarkers; Brain-Derived Neurotrophic Factor; Cell Survival; Corpus Striat | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Dopamine depletion induced up-regulation of HCN3 enhances rebound excitability of basal ganglia output neurons.
Topics: Animals; Basal Ganglia; Cyclic Nucleotide-Gated Cation Channels; Disease Models, Animal; Dopamine; G | 2009 |
Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro.
Topics: Animals; Apoptosis; Brain; Cell Line; Cell Survival; Flavanones; Glial Fibrillary Acidic Protein; Hu | 2009 |
Effect of unilateral lesion of the nigrostriatal dopamine pathway on survival and neurochemistry of parafascicular nucleus neurons in the rat--evaluation of time-course and LGR8 expression.
Topics: Animals; Cell Death; Cell Survival; Corpus Striatum; Disease Models, Animal; Functional Laterality; | 2009 |
Reduction of dopamine synaptic activity: degradation of 50-kHz ultrasonic vocalization in rats.
Topics: Analysis of Variance; Animals; Chloroquinolinols; Corpus Striatum; Disease Models, Animal; Dopamine; | 2009 |
PET imaging in rats to discern temporal onset differences between 6-hydroxydopamine and tau gene vector neurodegeneration models.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Fluorine Radioisotopes; Genetic Vectors; Male; Ner | 2009 |
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Sti | 2009 |
Transplantation of subventricular zone neural precursors induces an endogenous precursor cell response in a rat model of Parkinson's disease.
Topics: Animals; Biomarkers; Brain; Brain Tissue Transplantation; Cell Differentiation; Cell Movement; Cell | 2009 |
Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benzylamines; Brain; Disease Models, Animal; Dopamine; Dose-Response | 2009 |
Effect of intranigral injection of GDNF and EGF on the survival and possible differentiation fate of progenitors and immature neurons in 6-OHDA-lesioned rats.
Topics: Animals; Behavior, Animal; Cell Differentiation; Epidermal Growth Factor; Glial Cell Line-Derived Ne | 2009 |
D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Antiparkinso | 2009 |
Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Topics: Acetylation; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; | 2009 |
Effects of dopamine depletion on network entropy in the external globus pallidus.
Topics: Action Potentials; Adrenergic Agents; Analysis of Variance; Animals; Dopamine; Globus Pallidus; Logi | 2009 |
Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.
Topics: Animals; Apomorphine; Dopamine; Dopamine Agonists; Electrophysiology; Excitatory Amino Acid Antagoni | 2009 |
Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Brain; Brain Chemistry; Chromatography, | 2009 |
In vivo multimodal imaging of stem cell transplantation in a rodent model of Parkinson's disease.
Topics: Adult Stem Cells; Animals; Antipsychotic Agents; Carbon Isotopes; Diagnostic Imaging; Disease Models | 2009 |
Dopamine D1 receptor gene expression studies in unilateral 6-hydroxydopamine-lesioned Parkinson's rat: effect of 5-HT, GABA, and bone marrow cell supplementation.
Topics: Adrenergic Agents; Animals; Bone Marrow Transplantation; Brain; Dopamine; gamma-Aminobutyric Acid; M | 2010 |
Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aminoacetonitrile; Animals; Antiparkinso | 2009 |
Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-I | 2009 |
Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model.
Topics: Animals; Benzothiazoles; Bromodeoxyuridine; Cell Proliferation; Cells, Cultured; Disease Models, Ani | 2009 |
Investigation of neuroprotective effects of cyclooxygenase inhibitors in the 6-hydroxydopamine induced rat Parkinson model.
Topics: Amphetamines; Animals; Antiparkinson Agents; Apomorphine; Aspirin; Behavior, Animal; Cyclooxygenase | 2009 |
The electrocorticogram signal can be modulated with deep brain stimulation of the subthalamic nucleus in the hemiparkinsonian rat.
Topics: Animals; Biophysics; Brain Mapping; Deep Brain Stimulation; Disease Models, Animal; Electrodes, Impl | 2009 |
Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Benzazepines; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Mal | 2009 |
Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dose-Respo | 2009 |
Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats.
Topics: Animals; Biopterins; Corpus Striatum; Dependovirus; Dihydroxyphenylalanine; Dopamine; Female; Geneti | 2009 |
Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopam | 2009 |
Persistent short-term memory defects following sleep deprivation in a drosophila model of Parkinson disease.
Topics: Age Factors; alpha-Synuclein; Animals; Animals, Genetically Modified; Avoidance Learning; Choice Beh | 2009 |
The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway.
Topics: Amino Acids; Animals; Antiparkinson Agents; Benzimidazoles; Dose-Response Relationship, Drug; gamma- | 2009 |
The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzopyrans; Disability Evaluation; Dopamine Antagonists; Dose-Respon | 2010 |
Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Anim | 2010 |
Activation of the NMDA receptor involved in the alleviating after-effect of repeated stimulation of the subthalamic nucleus on motor deficits in hemiparkinsonian rats.
Topics: Animals; Deep Brain Stimulation; Dizocilpine Maleate; Dyskinesias; Excitatory Amino Acid Antagonists | 2010 |
The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; | 2010 |
Caffeine and CSC, adenosine A2A antagonists, offer neuroprotection against 6-OHDA-induced neurotoxicity in rat mesencephalic cells.
Topics: Adenosine A2 Receptor Agonists; Animals; Apoptosis; Caffeine; Cells, Cultured; Encephalitis; Female; | 2010 |
Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Ascorbic Acid; Brain; Central Nervous System | 2009 |
Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease.
Topics: Animals; Colon; Disease Models, Animal; Enteric Nervous System; Gastrointestinal Diseases; Gastroint | 2009 |
Effect of exercise on dopamine neuron survival in prenatally stressed rats.
Topics: Animals; Cell Survival; Denervation; Disease Models, Animal; Dopamine; Exercise Therapy; Female; For | 2009 |
Kinetics of microglial activation and degeneration of dopamine-containing neurons in a rat model of Parkinson disease induced by 6-hydroxydopamine.
Topics: Animals; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Kinetics; Male; Mesencephalo | 2009 |
L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation.
Topics: Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Electrochemistry; Levodopa; Male; Mi | 2010 |
Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinson's disease.
Topics: Animals; Apomorphine; Brain; Cell Membrane; Disease Models, Animal; Dopamine; Dopamine Agonists; Fat | 2010 |
Biochemical alteration in cerebrospinal fluid precedes behavioral deficits in Parkinsonian rats induced by 6-hydroxydopamine.
Topics: Animals; Biomarkers; Cell Count; Cell Death; Disease Models, Animal; Dopamine; Homovanillic Acid; Hy | 2009 |
Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Female; gamma-Aminobutyric Acid; Heparin; Male; Mast Cells; | 2010 |
Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Line; Corpus Striatum; Dopamine; Female; Gene Expressi | 2009 |
In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson's disease.
Topics: Animals; Brain; Brain Mapping; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; | 2010 |
Behavioral and electrophysiological effects of 5-HT in globus pallidus of 6-hydroxydopamine lesioned rats.
Topics: Action Potentials; Animals; Behavior, Animal; Dopamine Agents; Drug Combinations; Functional Lateral | 2010 |
Different striatal D2-like receptor function in an early stage after unilateral striatal lesion and medial forebrain bundle lesion in rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Prote | 2010 |
Therapeutic effect of human amniotic epithelial cell transplantation into the lateral ventricle of hemiparkinsonian rats.
Topics: Amnion; Animals; Apomorphine; Chromatography, High Pressure Liquid; Epithelial Cells; Female; Homova | 2009 |
MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dyskinesia, Drug-Induced | 2010 |
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Death; Cycloheximi | 2010 |
Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.
Topics: 5,7-Dihydroxytryptamine; Animals; Antiparkinson Agents; Brain; Citalopram; Cobra Neurotoxin Proteins | 2010 |
Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.
Topics: Adrenergic Agents; Animals; Axons; Corpus Striatum; Disease Models, Animal; Gene Expression; Male; M | 2010 |
Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Excitatory Amino Acid | 2010 |
Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cerebral Cortex; Corpus | 2010 |
Effect of deep brain stimulation in the pedunculopontine nucleus on motor function in the rat 6-hydroxydopamine Parkinson model.
Topics: Animals; Deep Brain Stimulation; Disease Models, Animal; Electrodes, Implanted; Forelimb; Male; Moto | 2010 |
Changes in firing rate and pattern of GABAergic neurons in subregions of the substantia nigra pars reticulata in rat models of Parkinson's disease.
Topics: Action Potentials; Animals; Cell Count; Disease Models, Animal; gamma-Aminobutyric Acid; Male; Media | 2010 |
Noradrenergic lesion of the locus coeruleus increases the firing activity of the medial prefrontal cortex pyramidal neurons and the role of alpha2-adrenoceptors in normal and medial forebrain bundle lesioned rats.
Topics: Action Potentials; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Ad | 2010 |
Locomotion analysis of Sprague-Dawley rats before and after injecting 6-OHDA.
Topics: Amyotrophic Lateral Sclerosis; Animals; Biomechanical Phenomena; Disease Models, Animal; Locomotion; | 2010 |
Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease.
Topics: Animals; Antioxidants; Disease Models, Animal; Dopamine; Enzymes; Free Radicals; Glutathione; Lipid | 2010 |
Morphologic and functional changes in the unilateral 6-hydroxydopamine lesion rat model for Parkinson's disease discerned with microSPECT and quantitative MRI.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Female; Magnetic Resonance Imaging; Oxidopamine; P | 2010 |
Voluntary exercise reduces the neurotoxic effects of 6-hydroxydopamine in maternally separated rats.
Topics: Analysis of Variance; Animals; Cell Death; Cell Survival; Choice Behavior; Disease Models, Animal; D | 2010 |
Skin-derived precursors differentiating into dopaminergic neuronal cells in the brains of Parkinson disease model rats.
Topics: Animals; Cell Differentiation; Cells, Cultured; Corpus Striatum; Dopamine; Extracellular Space; Male | 2010 |
Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo.
Topics: Animals; Brain Tissue Transplantation; Cell Survival; Cells, Cultured; Dopamine; Dyskinesia, Drug-In | 2010 |
Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Conditioning, | 2010 |
Graft-mediated functional recovery on a skilled forelimb use paradigm in a rodent model of Parkinson's disease is dependent on reward contingency.
Topics: Animals; Brain Tissue Transplantation; Cell Transplantation; Disability Evaluation; Disease Models, | 2010 |
Acupuncture inhibits oxidative stress and rotational behavior in 6-hydroxydopamine lesioned rat.
Topics: Acupuncture Therapy; Adrenergic Agents; Animals; Brain; Brain Chemistry; Catalase; Glutathione Perox | 2010 |
Proteomic analysis of expression and protein interactions in a 6-hydroxydopamine-induced rat brain lesion model.
Topics: Animals; Brain; Cell Line, Tumor; Disease Models, Animal; Gene Regulatory Networks; Gene Silencing; | 2010 |
Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Dose- | 2010 |
Involvement of astroglial fibroblast growth factor-2 and microglia in the nigral 6-OHDA parkinsonism and a possible role of glucocorticoid hormone on the glial mediated local trophism and wound repair.
Topics: Adrenalectomy; Animals; CD11b Antigen; Corpus Striatum; Disease Models, Animal; Fibroblast Growth Fa | 2009 |
Creating a ventral midbrain stem cell niche in an animal model for Parkinson's disease.
Topics: Animals; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Fluorescent Ant | 2010 |
Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha.
Topics: Amphetamine; Animals; Biomarkers; Chemokine CXCL12; Corpus Striatum; Cytoprotection; Disease Models, | 2010 |
Locus coeruleus and dorsal raphe neuron activity and response to acute antidepressant administration in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antidepressive Agents; Disease Models, Animal; Electrophysiological Phen | 2011 |
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-I | 2010 |
An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
Topics: Animals; Apomorphine; Benzoxazoles; Callithrix; Dopamine Agonists; Female; Male; Mice; Motor Activit | 2010 |
Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Bezafibrat | 2010 |
Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2010 |
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparasitic Agents; Corpus Striatum; Cyclin-Dependent Kinase 5; Disease Models, Animal; D | 2010 |
Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism.
Topics: Administration, Oral; Animals; Anthocyanins; Antiparkinson Agents; Apomorphine; Cell Count; Disease | 2010 |
A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Disease Models, Anima | 2010 |
Protective effects of octacosanol on 6-hydroxydopamine-induced Parkinsonism in rats via regulation of ProNGF and NGF signaling.
Topics: Animals; Antiparkinson Agents; Blotting, Western; Dose-Response Relationship, Drug; Fatty Alcohols; | 2010 |
The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra.
Topics: Animals; Antigens; Biomarkers; Corpus Striatum; Cytoprotection; Disease Models, Animal; Microglia; N | 2010 |
Effects of simvastatin and 6-hydroxydopamine on histaminergic H1 receptor binding density in rat brains.
Topics: Animals; Brain; Male; Oxidopamine; Parkinsonian Disorders; Protein Binding; Rats; Rats, Sprague-Dawl | 2010 |
Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; L | 2011 |
L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.
Topics: Adenylyl Cyclases; Animals; Dyskinesia, Drug-Induced; Enzyme Inhibitors; gamma-Aminobutyric Acid; Le | 2011 |
Effects of berberine on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and a rat model of Parkinson's disease.
Topics: Animals; Berberine; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Rel | 2010 |
Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Cytoprotection; Disease Models, Animal; Glutamic Acid; Male; Mice; Mice, Inbred C57BL; Mice | 2010 |
Progressive changes of orexin system in a rat model of 6-hydroxydopamine-induced Parkinson's disease.
Topics: Animals; Disease Models, Animal; Disease Progression; Intracellular Signaling Peptides and Proteins; | 2010 |
Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?
Topics: Acetylcysteine; Animals; Catalase; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Humans; | 2011 |
Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Basal Ganglia; Behavior, Animal; Biomarkers; Brain; Deoxyguano | 2011 |
Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease.
Topics: Animals; Axons; Botulinum Toxins, Type A; Corpus Striatum; Disease Models, Animal; Dyskinesias; Grow | 2011 |
Methanolic extract of Hibiscus asper leaves improves spatial memory deficits in the 6-hydroxydopamine-lesion rodent model of Parkinson's disease.
Topics: Animals; Antioxidants; Ethnopharmacology; Hibiscus; Male; Maze Learning; Medicine, African Tradition | 2011 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Bens | 2011 |
Neuroprotective effects of SCM198 on 6-hydroxydopamine-induced behavioral deficit in rats and cytotoxicity in neuronal SH-SY5Y cells.
Topics: Animals; Behavior, Animal; Cell Line, Tumor; Cell Survival; Gallic Acid; Humans; Leonurus; Male; Ner | 2011 |
BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Area Under Curve; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; | 2011 |
Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat.
Topics: Animals; Axons; Corpus Striatum; Disease Models, Animal; Inflammation; Male; Nerve Degeneration; Ner | 2011 |
Effects of unilateral 6-OHDA lesions on [3H]-N-propylnorapomorphine binding in striatum ex vivo and vulnerability to amphetamine-evoked dopamine release in rat.
Topics: Amphetamine; Animals; Apomorphine; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Do | 2011 |
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
Topics: Animals; Corpus Striatum; Cyclic GMP; Dyskinesia, Drug-Induced; Levodopa; Long-Term Synaptic Depress | 2011 |
Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.
Topics: Animals; Humans; Infusion Pumps; Male; Nerve Growth Factors; Neuroprotective Agents; Oxidopamine; Pa | 2011 |
Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats.
Topics: Analysis of Variance; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Indu | 2011 |
Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat.
Topics: Animals; Conditioning, Psychological; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dysk | 2011 |
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dose-R | 2011 |
Detoxification of 6-hydroxydopamine-induced Parkinsonian neurodegeneration by G-CYPMPO, a novel radical trapper.
Topics: Animals; Electron Spin Resonance Spectroscopy; Free Radical Scavengers; Immunohistochemistry; Male; | 2011 |
Progressive impairment in motor skill learning at 12 and 20 weeks post 6-OHDA- SNc lesion in rats.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Disease Progression; Learning; Male; Motor Activi | 2011 |
Cathepsin L is involved in 6-hydroxydopamine induced apoptosis of SH-SY5Y neuroblastoma cells.
Topics: Adrenergic Agents; Apoptosis; Blotting, Western; Cathepsin L; Cell Line, Tumor; Fluorescent Antibody | 2011 |
Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
Topics: Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Benzoxazines; Corpus Striatum; Disease M | 2011 |
In vivo magnetic resonance imaging characterization of bilateral structural changes in experimental Parkinson's disease: a T2 relaxometry study combined with longitudinal diffusion tensor imaging and manganese-enhanced magnetic resonance imaging in the 6-
Topics: Animals; Basal Ganglia; Behavior, Animal; Chlorides; Diffusion Tensor Imaging; Dopamine Plasma Membr | 2011 |
Time-course gait analysis of hemiparkinsonian rats following 6-hydroxydopamine lesion.
Topics: Analysis of Variance; Animals; Apomorphine; Disease Models, Animal; Disease Progression; Functional | 2011 |
Protective and restorative effects of magnolol on neurotoxicity in mice with 6-hydroxydopamine-induced hemiparkinsonism.
Topics: Animals; Biphenyl Compounds; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; | 2011 |
PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.
Topics: Animals; Cyclic AMP; Cyclic GMP; Disease Models, Animal; Dopamine; Gene Expression Regulation; Male; | 2011 |
Reduction of an afterhyperpolarization current increases excitability in striatal cholinergic interneurons in rat parkinsonism.
Topics: Acetylcholine; Action Potentials; Analysis of Variance; Animals; Anthracenes; Apamin; Ascorbic Acid; | 2011 |
Commentary on chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Merja H. Voutilainen et al.
Topics: Animals; Disease Models, Animal; Nerve Growth Factors; Oxidopamine; Parkinsonian Disorders; Rats | 2011 |
Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Disease Models, An | 2012 |
Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cell Count; Combined Modality Therapy; Dopamine; Dy | 2011 |
Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat.
Topics: alpha-Synuclein; Animals; Dopamine; Fetal Tissue Transplantation; Graft Survival; Humans; Lewy Bodie | 2011 |
Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease.
Topics: Absorbable Implants; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Female; Fu | 2011 |
Spatial memory deficits and oxidative stress damage following exposure to lipopolysaccharide in a rodent model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Lipopolysaccharides; Male; Memory Disorders; Neurotoxins; Oxidative | 2011 |
Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cells, Cultured; Docosahexaenoic A | 2012 |
Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiology of Parkinson's disease.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Male; Nerve Degeneration; Oxidopa | 2012 |
High frequency stimulation of the subthalamic nucleus acutely rescues motor deficits and neocortical movement representations following 6-hydroxydopamine administration in rats.
Topics: Animals; Deep Brain Stimulation; Electrodes, Implanted; Male; Movement Disorders; Neocortex; Neuroto | 2011 |
Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease.
Topics: Animals; Cell Adhesion Molecules; Corpus Striatum; Disease Models, Animal; Freund's Adjuvant; Interc | 2011 |
GDNF-pretreatment enhances the survival of neural stem cells following transplantation in a rat model of Parkinson's disease.
Topics: Animals; Cell Survival; Cells, Cultured; Disease Models, Animal; Female; Glial Cell Line-Derived Neu | 2011 |
Neuroprotective effect of the methanolic extract of Hibiscus asper leaves in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Antioxidants; Apoptosis; Catalase; Disease Models, Animal; DNA Fragmentation; Dose-Response | 2011 |
Increased efficacy of the 6-hydroxydopamine lesion of the median forebrain bundle in small rats, by modification of the stereotaxic coordinates.
Topics: Animals; Denervation; Disease Models, Animal; Female; Medial Forebrain Bundle; Microinjections; Neur | 2011 |
Endogenous morphine-like compound immunoreactivity increases in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; alpha-Methyltyrosine; Analysis of Variance; Anim | 2011 |
Acute versus long-term effects of 6-hydroxydopamine on oxidative stress and dopamine depletion in the striatum of mice.
Topics: Acute Disease; Animals; Chronic Disease; Corpus Striatum; Dopamine; Female; Mice; Mice, Inbred C57BL | 2011 |
Functional reorganization of the presynaptic dopaminergic terminal in parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Analysis of Variance; Animals; Chromatography, Hi | 2011 |
Effects of chronic, systemic treatment with the dopamine receptor agonist R-apomorphine in partially lesioned rat model of Parkinson's disease: an electrophysiological study of substantia nigra dopamine neurons.
Topics: Action Potentials; Animals; Apomorphine; Cell Count; Disease Models, Animal; Dopamine Agonists; Male | 2011 |
Effects of dopamine depletion on information flow between the subthalamic nucleus and external globus pallidus.
Topics: Action Potentials; Animals; Dopamine; Dopamine Antagonists; Dopaminergic Neurons; Globus Pallidus; M | 2011 |
Effect of pre- and postnatal manganese exposure on brain histamine content in a rodent model of Parkinson's disease.
Topics: Animals; Animals, Newborn; Brain; Disease Models, Animal; Dopamine; Drinking Water; Female; Histamin | 2012 |
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; D | 2012 |
Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Disease Models, Animal; Dop | 2011 |
[The reduced antioxidation ability in the serum in the early Parkinson's disease rats].
Topics: Animals; Disease Progression; Dopaminergic Neurons; Free Radical Scavengers; Hydroxyl Radical; Male; | 2011 |
Modulation of the activity of globus pallidus by dopamine D1-like receptors in parkinsonian rats.
Topics: Action Potentials; Animals; Behavior, Animal; Disease Models, Animal; Electrophysiology; Globus Pall | 2011 |
Antioxidant and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum.
Topics: Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Female; Inhibitor of Apoptosis Prote | 2012 |
Alterations in brain connectivity underlying beta oscillations in Parkinsonism.
Topics: Animals; Beta Rhythm; Brain; Computational Biology; Dopamine; Male; Models, Neurological; Nerve Net; | 2011 |
c-Fos expression after deep brain stimulation of the pedunculopontine tegmental nucleus in the rat 6-hydroxydopamine Parkinson model.
Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Disease Models, Animal; Humans; Immunohistochemistry | 2011 |
Overhauser-enhanced magnetic resonance imaging characterization of mitochondria functional changes in the 6-hydroxydopamine rat model.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Energy Metabolism; Magnetic Resonance Imaging; Mal | 2011 |
Chronic progesterone treatment of male rats with unilateral 6-hydroxydopamine lesion of the dorsal striatum exacerbates [corrected] parkinsonian symptoms.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Res | 2011 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, | 2011 |
L-type Cav1.2 calcium channel is involved in 6-hydroxydopamine-induced neurotoxicity in rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Calcium Channel Blockers; Calcium Channels, L-Type; Dopa | 2012 |
Microarray expression profiling in 6-hydroxydopamine-induced dopaminergic neuronal cell death.
Topics: Animals; Cell Death; Cell Line; Disease Models, Animal; Dopaminergic Neurons; Gene Expression Profil | 2011 |
Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
Topics: Action Potentials; Animals; Antiparkinson Agents; Corpus Striatum; D-Aspartate Oxidase; D-Aspartic A | 2011 |
Effects of unilateral nigrostriatal dopamine depletion on peripheral glucose tolerance and insulin signaling in middle aged rats.
Topics: Aging; Animals; Corpus Striatum; Dopamine; Dopamine Antagonists; Eating; Glucose Intolerance; Glucos | 2011 |
Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Buspirone; Catalepsy; Dose-Response Relationship, Drug; Injections, I | 2011 |
A quantitative comparison of basal ganglia neuronal activities of normal and Parkinson's disease model rats.
Topics: Action Potentials; Animals; Globus Pallidus; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rat | 2011 |
The effects of pergolide on memory and oxidative stress in a rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Glutathione Peroxidase; Linear Models; Lipid Per | 2012 |
Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy.
Topics: Animals; Cell Count; Corpus Striatum; Dopamine; Gait; Humans; Levodopa; Male; Medial Forebrain Bundl | 2012 |
Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model.
Topics: Animals; Carrier Proteins; Corpus Striatum; Cytokines; Dependovirus; Disease Models, Animal; Gene Ex | 2012 |
Ether-à-go-go 1 (Eag1) potassium channel expression in dopaminergic neurons of basal ganglia is modulated by 6-hydroxydopamine lesion.
Topics: Animals; Basal Ganglia; Disease Models, Animal; Dopaminergic Neurons; Ether-A-Go-Go Potassium Channe | 2012 |
CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease.
Topics: Animals; Antibodies, Blocking; Antigens, CD; Behavior, Animal; Disease Models, Animal; Dopamine; Dop | 2011 |
Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Amphetamine; Analysis of Variance; Anima | 2012 |
Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Disease Models, Animal; Dopaminergic Neurons; Gait Disorders, Neurologic | 2012 |
Neurorescue effect of rosmarinic acid on 6-hydroxydopamine-lesioned nigral dopamine neurons in rat model of Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cinnamates; Depsides; Disease Models, Animal; Fema | 2012 |
Mild dopaminergic lesions are accompanied by robust changes in subthalamic nucleus activity.
Topics: Action Potentials; Animals; Brain; Gait; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; | 2012 |
Striatal NTS1 , dopamine D2 and NMDA receptor regulation of pallidal GABA and glutamate release--a dual-probe microdialysis study in the intranigral 6-hydroxydopamine unilaterally lesioned rat.
Topics: Adrenergic Agents; Animals; Corpus Striatum; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid | 2012 |
Exercise improves motor deficits and alters striatal GFAP expression in a 6-OHDA-induced rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Glial Fibrillary Acidic Protein; Immunohistochemistry; | 2012 |
Motor disorders and impaired electrical power of pallidal EEG improved by gallic acid in animal model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antioxidants; Disease Models, Animal; Electroencephalography; Gallic Aci | 2011 |
Immunohistochemical changes of nigrostriatal tyrosine hydroxylase and dopamine transporter in the golden hamster after a single intrastriatal injection of 6-hydroxydopamine.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Cricetinae; Disease Models, Animal; Dopamine Plasma Mem | 2013 |
Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Mice, Inbred C57BL; Motor Activit | 2012 |
Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Allosteric Regulation; Anilides; Animals; Biomarkers; Cyclohexanecarboxylic Acids; Dopamine; Inflamm | 2012 |
Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Drug Synergism; Dyskinesias; Exenatide; Glucag | 2012 |
Antiparkinsonian properties of a nerve growth factor dipeptide mimetic GK-2 in in vivo experiments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catalepsy; Dipeptides; | 2011 |
Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Growth Inhibitors; Male; Matrix Metalloprotei | 2012 |
Vasoactive intestinal peptide enhances striatal plasticity and prevents dopaminergic cell loss in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Cell Count; Corpus Striatum; Dendrites; Dopaminergic Neurons; Drug Ev | 2012 |
Positive allosteric modulation of α4β2 nAChR agonist induced behaviour.
Topics: Allosteric Regulation; Animals; Azepines; Corpus Striatum; Female; Male; Nicotinic Agonists; Oxadiaz | 2012 |
High intake of folic acid or complex of B vitamins provides anti-Parkinsonism effect: no role for serum level of homocysteine.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Area Under Curve; Disease Models, Ani | 2012 |
Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson's disease.
Topics: Adenoviridae; Animals; Antiparkinson Agents; Apomorphine; Apoptosis; Cell Line; Corpus Striatum; Dop | 2012 |
L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients.
Topics: Animals; Brain; Dopaminergic Neurons; Humans; Levodopa; Models, Neurological; Neurodegenerative Dise | 2012 |
L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Anxiety; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; | 2012 |
DJ-1 protein protects dopaminergic neurons against 6-OHDA/MG-132-induced neurotoxicity in rats.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Apomorphine; Corpus Striatum; Dopamine; Dopaminergic | 2012 |
The effects of short-term nicotine administration on behavioral and oxidative stress deficiencies induced in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Disease Models, Animal; Ganglionic Stimulants; Glutath | 2012 |
An in vivo ultrahigh field 14.1 T (1) H-MRS study on 6-OHDA and α-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker.
Topics: alpha-Synuclein; Animals; Biomarkers; Brain; Early Diagnosis; Female; gamma-Aminobutyric Acid; Magne | 2013 |
Prolonged hyperoxia preconditioning attenuates behavioral symptoms of 6-hydroxydopamine-induced Parkinsonism.
Topics: Animals; Behavior, Animal; Behavioral Symptoms; Hyperoxia; Ischemic Preconditioning; Male; Oxidopami | 2012 |
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
Topics: Amphetamine; Analysis of Variance; Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; D | 2012 |
Dopaminergic imaging of nonmotor manifestations in a rat model of Parkinson's disease by fMRI.
Topics: Animals; Blood Volume; Blood Volume Determination; Brain; Cerebrovascular Circulation; Dopamine; Dop | 2013 |
Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Topics: Animals; Basal Ganglia; Calcium-Binding Proteins; Cyclooxygenase 2; Disease Models, Animal; Dopamine | 2012 |
Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Behavior, Animal; Blotting, Western; Brain; Ceftriaxone; Dopaminergic Neurons; Female; Moto | 2012 |
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
Topics: Amantadine; Animals; Antiparkinson Agents; Cycloserine; Dextromethorphan; Dopamine Agents; Dyskinesi | 2012 |
In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Fluorine Radiois | 2013 |
Reinforcing properties of Pramipexole in normal and parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Corpus Striatum; Dopamine Agonists; Drug-Seeking Beha | 2013 |
The C-terminal domain of the heavy chain of tetanus toxin given by intramuscular injection causes neuroprotection and improves the motor behavior in rats treated with 6-hydroxydopamine.
Topics: Animals; Apoptosis; Astrocytes; Catecholamines; Chromatography, High Pressure Liquid; Corpus Striatu | 2012 |
Unilateral lesion of the nigrostriatal pathway decreases the response of GABA interneurons in the dorsal raphe nucleus to 5-HT(1A) receptor stimulation in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Cell Count; Corpus Striatum; Dop | 2012 |
Subthalamic discharges as a causal determinant of parkinsonian motor deficits.
Topics: Action Potentials; Animals; Animals, Newborn; Biophysics; Deep Brain Stimulation; Disease Models, An | 2012 |
Proliferation of external globus pallidus-subthalamic nucleus synapses following degeneration of midbrain dopamine neurons.
Topics: Animals; Carrier Proteins; Dopamine; Dopaminergic Neurons; Exploratory Behavior; Globus Pallidus; In | 2012 |
Evaluation of dopamine transporters and D2 receptors in hemiparkinsonian rat brains in vivo using consecutive PET scans of [18F]FPCIT and [18F]fallypride.
Topics: Animals; Benzamides; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Down-Regulation; | 2012 |
Eppendorf finalist. Striatal interneurons: causes of or cures for movement disorders?
Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Humans; Int | 2012 |
Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson's disease.
Topics: Animals; Antioxidants; Avoidance Learning; Behavior, Animal; Cell Line, Tumor; Cognition; Cytoprotec | 2013 |
Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.
Topics: Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-In | 2013 |
Transplantation of neural stem cells co-transfected with Nurr1 and Brn4 for treatment of Parkinsonian rats.
Topics: Adrenergic Agents; Animals; Apomorphine; Cells, Cultured; Corpus Striatum; Disease Models, Animal; D | 2013 |
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease | 2012 |
Pharmacological blockade of TRPV1 receptors modulates the effects of 6-OHDA on motor and cognitive functions in a rat model of Parkinson's disease.
Topics: Acrylamides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cognition; Disease Models, Animal; Ma | 2013 |
Therapeutic deep brain stimulation in Parkinsonian rats directly influences motor cortex.
Topics: Action Potentials; Adrenergic Agents; Afferent Pathways; Animals; Antiparkinson Agents; Apomorphine; | 2012 |
Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.
Topics: Animals; Benzothiazoles; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Dyski | 2012 |
Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration.
Topics: Allantoin; Analysis of Variance; Animals; Blotting, Western; Brain; Dopamine; Dopaminergic Neurons; | 2013 |
Endogenous repair by the activation of cell survival signalling cascades during the early stages of rat Parkinsonism.
Topics: Animals; Blotting, Western; Cell Survival; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody T | 2012 |
Adaptive gene expression changes on the healthy side of parkinsonian rats.
Topics: Adaptation, Physiological; Adrenergic Agents; Animals; Cerebral Cortex; Disease Models, Animal; Dopa | 2013 |
Caffeic acid phenethyl ester protects against the dopaminergic neuronal loss induced by 6-hydroxydopamine in rats.
Topics: Adrenergic Agents; Animals; Antioxidants; Caffeic Acids; Cell Death; Disease Models, Animal; Dopamin | 2013 |
Caffeine has greater potency and efficacy than theophylline to reverse the motor impairment caused by chronic but not acute interruption of striatal dopaminergic transmission in rats.
Topics: Animals; Caffeine; Catalepsy; Corpus Striatum; Dopaminergic Neurons; Dose-Response Relationship, Dru | 2013 |
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Blotting, Western; Dyskinesia, Drug-Induced; Immun | 2013 |
Behavioral performance at early (4 weeks) and later (6 months) stages in rats with unilateral medial forebrain bundle and striatal 6-hydroxydopamine lesions.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Bromocriptine; Corpus Striatum; Injections; Male; Medi | 2013 |
PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: old switch, new target.
Topics: Animals; Apomorphine; Dinoprostone; Dopamine Agonists; Dopaminergic Neurons; Injections; Medial Fore | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, | 2013 |
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Topics: Afferent Pathways; Animals; Bacterial Proteins; Behavior, Animal; Biomarkers; Brain Mapping; Caudate | 2002 |
Deep brain stimulation of subthalamic neurons increases striatal dopamine metabolism and induces contralateral circling in freely moving 6-hydroxydopamine-lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Death; Disease Models, Animal; Dopamine; Electric Stim | 2002 |
Therapeutic effects of astrocytes expressing both tyrosine hydroxylase and brain-derived neurotrophic factor on a rat model of Parkinson's disease.
Topics: Animals; Apoptosis; Astrocytes; Behavior, Animal; Blotting, Western; Brain-Derived Neurotrophic Fact | 2002 |
The adult substantia nigra contains progenitor cells with neurogenic potential.
Topics: Animals; Antigens, Differentiation; Astrocytes; Bromodeoxyuridine; Cell Count; Cell Differentiation; | 2002 |
Forced nonuse in unilateral parkinsonian rats exacerbates injury.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Casts, Surg | 2002 |
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.
Topics: Amidohydrolases; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Carrier | 2002 |
Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons.
Topics: Animals; Astrocytes; Behavior, Animal; Cell Survival; Cells, Cultured; Denervation; Disease Models, | 2002 |
Dopamine depletion causes fragmented clustering of neurons in the sensorimotor striatum: evidence of lasting reorganization of corticostriatal input.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Corpus Striatum; Dopamine; Electrophysiology; Male; Ne | 2002 |
Effect of glutamatergic systems on in vivo binding of [(125)I]beta-CIT in the brain of a rat model of Parkinson's disease.
Topics: Animals; Autoradiography; Binding, Competitive; Cocaine; Disease Models, Animal; Dizocilpine Maleate | 2002 |
Experimental parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum.
Topics: Animals; Corpus Striatum; Denervation; Dopamine; Gene Expression Regulation; Male; Oligonucleotide A | 2002 |
Consequences of dopaminergic denervation on the metabolic activity of the cortical neurons projecting to the subthalamic nucleus in the rat.
Topics: Animals; Axons; Cerebral Cortex; Denervation; Disease Models, Animal; Dopamine; Electron Transport C | 2002 |
Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats.
Topics: Adult; Animals; Disease Models, Animal; Humans; Immunoenzyme Techniques; Middle Aged; Nerve Growth F | 2002 |
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; En | 2002 |
Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration.
Topics: Age Factors; Animals; Animals, Newborn; Antiparkinson Agents; Antipsychotic Agents; Excitatory Amino | 2002 |
Subthalamic GAD gene therapy in a Parkinson's disease rat model.
Topics: Animals; Dependovirus; Disease Models, Animal; Dopamine; Electric Stimulation; Electrophysiology; ga | 2002 |
Radiation and regeneration: behavioral improvement and GDNF expression after Gamma Knife radiosurgery in the 6-OHDA rodent model of hemi-parkinsonism.
Topics: Animals; Caudate Nucleus; Dominance, Cerebral; Glial Cell Line-Derived Neurotrophic Factor; Immunoen | 2002 |
Distribution of adenosine A(2A) receptor antagonist KW-6002 and its effect on gene expression in the rat brain.
Topics: Administration, Oral; Adrenergic Antagonists; Animals; Carbon Radioisotopes; Corpus Striatum; Enkeph | 2002 |
Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopamine D2 Recept | 2002 |
Diffusion parameters in the striatum of rats with 6-hydroxydopamine-induced lesions and with fetal mesencephalic grafts.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Corpus Striatum; Denervation; Diffusion; Fe | 2002 |
Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer.
Topics: Animals; Axons; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal; Down-Regulati | 2002 |
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Diben | 2002 |
Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system.
Topics: Animals; Corpus Striatum; Dyskinesias; Genes, fos; Injections, Intraventricular; Levodopa; Male; Oxi | 2002 |
Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment.
Topics: Animals; Corpus Striatum; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; In Vit | 2002 |
Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Blood-Brain Barrier; Bradykinin; Calcineurin; Corpus S | 2002 |
Comparison of the efficacy of cell preparations from embryonic ventral mesencephalon of various prenatal age transplanted intrastriatally to rats with 6-OHDA-induced Parkinsonism.
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Dopamine; Fetal Tissue Transplantation; Male; Me | 2002 |
Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Catecholamines; Cells, Cultured; Corpus Striatum; Dis | 2002 |
Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Cytoplasm; Drug Combinations; Indoles; Le | 2002 |
Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat.
Topics: Animals; Apoptosis; Cell Count; Cell Nucleus; Disease Models, Animal; DNA Fragmentation; Dopamine; I | 2002 |
AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport P | 2002 |
99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Macaca; Metabolic Clearance Rate; Models, Animal; | 2003 |
Ectopic expression of cell cycle markers in models of induced programmed cell death in dopamine neurons of the rat substantia nigra pars compacta.
Topics: Animals; Apoptosis; Biomarkers; Bromodeoxyuridine; CDC2 Protein Kinase; Cell Count; Cell Cycle Prote | 2003 |
Effects of antioxidant pretreatment on the survival of embryonic dopaminergic neurons in vitro and following grafting in an animal model of Parkinson's disease.
Topics: Acetylcysteine; Animals; Antioxidants; Cells, Cultured; Chromans; Disease Models, Animal; Dopamine; | 2002 |
A novel skilled-reaching impairment in paw supination on the "good" side of the hemi-Parkinson rat improved with rehabilitation.
Topics: Animals; Apomorphine; Behavior Control; Behavior, Animal; Corpus Striatum; Disease Models, Animal; F | 2003 |
Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chlorides; Diestrus; Dopamine; Dopamine Plasma Membrane Tra | 2003 |
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dyski | 2003 |
Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET.
Topics: Adaptation, Physiological; Animals; Benperidol; Feasibility Studies; Fluorine Radioisotopes; Male; N | 2003 |
Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Death; Disease Models, Animal; Dopamine; Female; Functi | 2003 |
Spreading of slow cortical rhythms to the basal ganglia output nuclei in rats with nigrostriatal lesions.
Topics: Action Potentials; Adrenergic Agents; Animals; Basal Ganglia; Cortical Synchronization; Disease Mode | 2003 |
Intranigral infusion of interleukin-1beta activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity.
Topics: Animals; Astrocytes; Body Temperature; Body Weight; Cell Count; Corpus Striatum; Disease Models, Ani | 2003 |
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Binding, Competitive; Cannabinoid | 2003 |
Convulsive and postural effects of lesioning the mid-substantia nigra pars reticulata in naïve and 6-hydroxydopamine lesioned rats.
Topics: Animals; Apomorphine; Behavior, Animal; Cortical Synchronization; Disease Models, Animal; Dopamine A | 2003 |
Regulation of neuropeptide mRNA expression in the basal ganglia by intrastriatal and intranigral transplants in the rat Parkinson model.
Topics: Adrenergic Agents; Animals; Autoradiography; Basal Ganglia; Brain Mapping; Disease Models, Animal; E | 2003 |
Distinct forelimb and hind limb stepping impairments in unilateral dopamine-depleted rats: use of the rotorod as a method for the qualitative analysis of skilled walking.
Topics: Animals; Dopamine; Exercise Test; Female; Forelimb; Hindlimb; Lameness, Animal; Motor Skills; Moveme | 2003 |
Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2003 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps | 2003 |
Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study.
Topics: Afferent Pathways; Amphetamine; Animals; Apomorphine; Binding, Competitive; Carrier Proteins; Denerv | 2003 |
Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Electron Transport Complex IV; Enke | 2003 |
Transfer of the von Hippel-Lindau gene to neuronal progenitor cells in treatment for Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Cell Differentiation; Cells, Cultured; Corpus Striatum; Dopam | 2003 |
Effect of acute and chronic administration of U50,488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; A | 2003 |
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Benzothi | 2003 |
Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine.
Topics: Animals; Dopamine; Estrogens; Female; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Dis | 2003 |
Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats.
Topics: Animals; Basal Ganglia; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Electron Transpor | 2003 |
Effect of subthalamic lesion with kainic acid on the neuronal activities of the basal ganglia of rat parkinsonian models with 6-hydroxydopamine.
Topics: Action Potentials; Animals; Basal Ganglia; Globus Pallidus; Kainic Acid; Male; Neural Pathways; Neur | 2003 |
Primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Corpus Striatum; Disease Models, Anima | 2003 |
Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys.
Topics: Animals; Behavior, Animal; Callithrix; Cell Count; Corpus Striatum; Disability Evaluation; Disease M | 2003 |
Survival and differentiation of adult rat-derived neural progenitor cells transplanted to the striatum of hemiparkinsonian rats.
Topics: Animals; Antigens; Cell Differentiation; Cell Movement; Cell Survival; Corpus Striatum; Disease Mode | 2003 |
Effect of ipsilateral subthalamic nucleus lesioning in a rat parkinsonian model: study of behavior correlated with neuronal activity in the pedunculopontine nucleus.
Topics: Adrenergic Agents; Animals; Basal Ganglia; Behavior, Animal; Corpus Striatum; Excitatory Amino Acid | 2003 |
Effect of glial cell line-derived neurotrophic factor (GDNF) co-transplantation with fetal ventral mesencephalic cells (VMC) on functional restoration in 6-hydroxydopamine (6-OHDA) lesioned rat model of Parkinson's disease: neurobehavioral, neurochemical
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Line; Chemotherapy, Adjuvant; Female; Glial Cell Line- | 2003 |
"Hydrocephalus-parkinsonism complex": progressive hydrocephalus as a factor affecting extrapyramidal tract disorder-an experimental study.
Topics: Animals; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Disease Models | 2004 |
Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease.
Topics: Absorbable Implants; Animals; Coated Materials, Biocompatible; Corpus Striatum; Drug Carriers; Drug | 2004 |
Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, | 2004 |
"Passive stabilization" of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson's disease: a voltammetric study in the 6-OHDA-lesioned rat.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Disease Progression; Dopamine; Electric Stimulatio | 2003 |
Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Female; Immun | 2003 |
Effects of electrolytic and 6-hydroxydopamine lesions of rat nigrostriatal pathway on nitric oxide synthase and nicotinamide adenine dinucleotide phosphate diaphorase.
Topics: Adrenergic Agents; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2003 |
[Wakefulness and central basal nuclei: experimental observations and possible implications in Parkinson's disease].
Topics: Animals; Humans; Iontophoresis; Neurons; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Pa | 2003 |
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; D | 2003 |
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Dis | 2003 |
Genetically modified human embryonic stem cells relieve symptomatic motor behavior in a rat model of Parkinson's disease.
Topics: Animals; Blotting, Western; Cells, Cultured; Disease Models, Animal; Embryo, Mammalian; Genetic Ther | 2003 |
Gene expression profiling in the midbrain of striatal 6-hydroxydopamine-injected mice.
Topics: Animals; Brain Chemistry; Cell Survival; Gene Expression Profiling; Male; Mesencephalon; Mice; Oxido | 2004 |
Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine-treated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations.
Topics: Animals; Apomorphine; Corpus Striatum; Glutamic Acid; Male; Oxidopamine; Parkinsonian Disorders; Rat | 2004 |
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine A | 2004 |
6-Hydroxydopamine increases the level of TNFalpha and bax mRNA in the striatum and induces apoptosis of dopaminergic neurons in hemiparkinsonian rats.
Topics: Adrenergic Agents; Animals; Apoptosis; bcl-2-Associated X Protein; Corpus Striatum; Dopamine; Functi | 2004 |
High-frequency stimulation of both zona incerta and subthalamic nucleus induces a similar normalization of basal ganglia metabolic activity in experimental parkinsonism.
Topics: Animals; Diencephalon; Electric Stimulation Therapy; Electron Transport Complex I; Globus Pallidus; | 2004 |
Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Clinical Trials as Topic; Corpus | 2004 |
Intralaminar thalamic nuclei lesions: widespread impact on dopamine denervation-mediated cellular defects in the rat basal ganglia.
Topics: Adrenergic Agents; Animals; Autoradiography; Basal Ganglia; Carrier Proteins; Dopamine; Female; Gene | 2004 |
Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function.
Topics: Acyltransferases; Amidohydrolases; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; | 2004 |
L-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease.
Topics: Animals; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders | 2004 |
An in vitro interval before transplantation of mesencephalic reaggregates does not compromise survival or functionality.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Cell Count; Cell Survival; Cells, Cultured; Dise | 2004 |
Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cyclic AMP-Dependent Protein Kinases; Disease | 2004 |
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Callithrix; Disease Models, Animal; Dopamine Agonists; D | 2004 |
Selective knockdown of gene expression of N-methyl-D-aspartate receptor one ameliorates parkinsonian motor symptom in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Female; Gene Expression Regulation; Gene Silencing; Motor Activity; Neostriatum; Oligonucle | 2004 |
The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?
Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Anima | 2004 |
Beneficial effects of intraventricularly administered BMP-7 following a striatal 6-hydroxydopamine lesion.
Topics: Animals; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Corpus Striatum; Disease Models, | 2004 |
Pedunculopontine nucleus.
Topics: Animals; Corpus Striatum; Dominance, Cerebral; Dopamine; Electric Stimulation Therapy; Humans; Kaini | 2004 |
Behavioral changes in unilaterally 6-hydroxy-dopamine lesioned rats after transplantation of differentiated mouse embryonic stem cells without morphological integration.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Differentiation; Corpus Striatum; Huma | 2004 |
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism.
Topics: Animals; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Depend | 2004 |
Voluntary running provides neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle.
Topics: Animals; Antiparkinson Agents; Apomorphine; Corpus Striatum; Dopamine; Male; Medial Forebrain Bundle | 2004 |
Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Basal Ganglia; Denervation; Disease Models, Animal; Effe | 2004 |
Increased dopamine release in vivo by estradiol benzoate from the central amygdaloid nucleus of Parkinson's disease model rats.
Topics: Amygdala; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Electric Stim | 2004 |
Functional improvement with low-dose dopaminergic grafts in hemiparkinsonian rats.
Topics: Animals; Brain Tissue Transplantation; Cell Survival; Corpus Striatum; Dopamine; Dose-Response Relat | 2004 |
6-hydroxydopamine lesions in anuran amphibians: a new model system for Parkinson's disease?
Topics: Acoustic Stimulation; Animals; Anura; Attention; Brain; Disease Models, Animal; Dopamine; Down-Regul | 2004 |
Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Brain Chemistry; Catalepsy; Disease Mod | 2004 |
Alterations in the cellular distribution of bcl-2, bcl-x and bax in the adult rat substantia nigra following striatal 6-hydroxydopamine lesions.
Topics: Animals; Apoptosis; Astrocytes; bcl-2-Associated X Protein; bcl-X Protein; Disease Models, Animal; D | 2004 |
Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration.
Topics: Animals; Cell Death; Cell Differentiation; Cells, Cultured; Corpus Striatum; DNA-Binding Proteins; D | 2004 |
Neurotrophic factor in the treatment of Parkinson disease.
Topics: Animals; Apomorphine; Astrocytes; Cell Differentiation; Cell Division; Cells, Cultured; Female; Fibr | 2003 |
Co-transplantation of carotid body and ventral mesencephalic cells as an alternative approach towards functional restoration in 6-hydroxydopamine-lesioned rats: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Binding, Competitive; Brain Tissue Transplantation; Carotid | 2004 |
Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson's disease.
Topics: Animals; Cell Count; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Fib | 2005 |
Intrastriatal transforming growth factor alpha delivery to a model of Parkinson's disease induces proliferation and migration of endogenous adult neural progenitor cells without differentiation into dopaminergic neurons.
Topics: Animals; Behavior, Animal; beta Catenin; Bromodeoxyuridine; Cell Movement; Cell Proliferation; Corpu | 2004 |
Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats.
Topics: Animals; Behavior, Animal; Male; Motor Activity; Nerve Growth Factors; Neuropeptides; Neurotransmitt | 2004 |
Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor.
Topics: 5-Methoxytryptamine; Animals; Male; Melatonin; Naphthalenes; Oxidopamine; Parkinsonian Disorders; Ra | 2004 |
Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy).
Topics: Animals; Biomarkers; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine and cAMP-Regulat | 2005 |
3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy.
Topics: Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Denervatio | 2005 |
Serotonergic influence on the potentiation of D-amphetamine and apomorphine-induced rotational behavior by the alpha2-adrenoceptor antagonist 2-methoxy idazoxan in hemiparkinsonian rats.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; A | 2005 |
A tetracycline-regulated adenovirus encoding dominant-negative caspase-9 is regulated in rat brain and protects against neurotoxin-induced cell death in vitro, but not in vivo.
Topics: Adenoviridae; Animals; Apoptosis; Brain; Caspase 9; Caspases; Cell Line; Gene Expression Regulation; | 2005 |
Cerebral glutamate metabolism in Parkinson's disease: an in vivo dynamic (13)C NMS study in the rat.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Carbon Isotopes; Disease Models, Animal; Dopamine; Glu | 2005 |
Testing forelimb placing "across the midline" reveals distinct, lesion-dependent patterns of recovery in rats.
Topics: Animals; Behavior, Animal; Cerebral Decortication; Chronic Disease; Diagnosis, Differential; Disease | 2005 |
RA410/Sly1 suppresses MPP+ and 6-hydroxydopamine-induced cell death in SH-SY5Y cells.
Topics: 1-Methyl-4-phenylpyridinium; Adaptation, Physiological; Animals; Apoptosis; Carrier Proteins; Caspas | 2005 |
Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies.
Topics: Animals; Astrocytes; Cell Survival; Cells, Cultured; Cystatin C; Cystatins; Cysteine Proteinase Inhi | 2005 |
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Topics: Animals; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catecho | 2005 |
6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson's disease monitored by magnetic resonance imaging.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interaction | 2005 |
Aminopeptidase activity in the nigrostriatal system and prefrontal cortex of rats with experimental hemiparkinsonism.
Topics: Aminopeptidases; Animals; CD13 Antigens; Cystinyl Aminopeptidase; Functional Laterality; Glutamyl Am | 2005 |
Reductions in spontaneous locomotor activity in aged male, but not female, rats in a model of early Parkinson's disease.
Topics: Adaptation, Physiological; Adrenergic Agents; Age Factors; Aging; Animals; Corpus Striatum; Disease | 2005 |
A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease.
Topics: Animals; Antioxidants; Biological Transport; Blood-Brain Barrier; Cell Line, Tumor; Cells, Cultured; | 2005 |
Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Catecholamines; Disease Models | 2005 |
Assessment of recovery in the hemiparkinson rat: drug-induced rotation is inadequate.
Topics: Animals; Apomorphine; Astrocytes; Behavioral Research; Brain Tissue Transplantation; Corpus Striatum | 2005 |
Comparison of the effects of nicotine and epibatidine given in combination with nomifensine on rotational behaviour in rats.
Topics: Adrenergic Agents; Animals; Brain; Bridged Bicyclo Compounds, Heterocyclic; Dopamine Uptake Inhibito | 2005 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal | 2005 |
Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats.
Topics: Animals; Behavior, Animal; Brain; Disease Models, Animal; Male; Neuroprotective Agents; Oxidopamine; | 2005 |
Fate of pre-differentiated mouse embryonic stem cells transplanted in unilaterally 6-hydroxydopamine lesioned rats: histological characterization of the grafted cells.
Topics: Animals; Biomarkers; Brain Neoplasms; Cell Count; Cell Differentiation; Cell Lineage; Cell Prolifera | 2005 |
Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Down-Regulation; Hydroxymethylglutaryl-CoA Red | 2005 |
Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Analysis of Variance; Animals; Brai | 2005 |
In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system.
Topics: Adenoviridae; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship | 2005 |
Bilateral control of brain activity by dopamine D1 receptors: evidence from induction patterns of regulator of G protein signaling 2 and c-fos mRNA in D1-challenged hemiparkinsonian rats.
Topics: Animals; Benzazepines; Brain; Dopamine Agonists; Functional Laterality; Gene Expression Regulation; | 2005 |
Behavioural effects of parafascicular thalamic lesions in an animal model of parkinsonism.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Choice Behavior; Disease Models, Anima | 2005 |
Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
Topics: Adrenergic Agents; Amphetamine; Animals; Dopamine; Electron Transport Complex I; Enzyme Inhibitors; | 2005 |
Pig xenografts to the immunocompetent rat brain: Survival rates using distinct neurotoxic lesions in the nigrostriatal pathway and two rat strains.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain Tissue Transplantation; Cell Size; Cells, Cultured; Corp | 2005 |
Transplantation of mouse embryonic stem cell-derived neurons into the striatum, subthalamic nucleus and substantia nigra, and behavioral recovery in hemiparkinsonian rats.
Topics: Animals; Basal Ganglia; Behavior, Animal; Brain Tissue Transplantation; Cell Count; Corpus Striatum; | 2005 |
In vivo models of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Corpus Striatum; Levodopa; Macaca fascicularis; Mice | 2005 |
Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Benzazepines; Brain; Corpus Striatum; Disease Models, Animal | 2005 |
CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Apoptosis; Axotomy; Behavio | 2005 |
Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
Topics: Adrenergic Agents; Aldehydes; alpha-Synuclein; Animals; Behavior, Animal; Blotting, Western; CD11b A | 2005 |
Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in rats using a lateralised nose-poking task with low stimulus-response compatibility.
Topics: Animals; Conditioning, Operant; Corpus Striatum; Disease Models, Animal; Dopamine; Exploratory Behav | 2005 |
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Blotting, Western; Corpus Striatum; Disease Models, | 2006 |
Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson's disease.
Topics: Active Transport, Cell Nucleus; Animals; Autonomic Nervous System; Cell Line; Cell Survival; Corpus | 2005 |
Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease.
Topics: Analysis of Variance; Animals; Apomorphine; Dopamine; Dopamine Agonists; Functional Laterality; Male | 2005 |
Partial dopamine loss enhances activated caspase-3 activity: differential outcomes in striatal projection systems.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Corpus Striatum; Disease Models, Animal; Disease Progressio | 2005 |
Cell survival patterns in the pedunculopontine tegmental nucleus of methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys and 6OHDA-lesioned rats: evidence for differences to idiopathic Parkinson disease patients?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Survival; Disease Mode | 2005 |
Gene expression profiles of reactive astrocytes cultured from dopamine-depleted striatum.
Topics: Animals; Antibodies; Astrocytes; Corpus Striatum; Disease Models, Animal; Dopamine; Down-Regulation; | 2005 |
Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine-depleted rat.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Agonists; | 2006 |
Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
Topics: Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Electron Trans | 2006 |
Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Autoradiography; Behavior, Animal; Dopamine; Dopamine Agents; Dopamine Plasma | 2005 |
Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease.
Topics: Animals; Behavior, Animal; Cell Line, Transformed; Corpus Striatum; Denervation; Disease Models, Ani | 2006 |
Modulation of torsinA expression in the globus pallidus internus is associated with levodopa-induced dyskinesia in hemiparkinsonian rats.
Topics: Animals; Cell Count; Disease Models, Animal; Dopamine Agents; Down-Regulation; Dyskinesia, Drug-Indu | 2006 |
In vivo PET measurements with [11C]PE2I to evaluate fetal mesencephalic transplantations to unilateral 6-OHDA-lesioned rats.
Topics: Analysis of Variance; Animals; Autoradiography; Behavior, Animal; Cell Transplantation; Corpus Stria | 2005 |
Effects of pallidotomy on motor symptoms in an animal model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Female; Functional Laterality; Globus Pallidu | 2006 |
The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamin | 2006 |
Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions.
Topics: Analysis of Variance; Animals; Cell Death; Diagnosis; Disease Models, Animal; Disease Progression; D | 2006 |
Circadian distribution of motor-activity in unilaterally 6-hydroxy-dopamine lesioned rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Circadian Rhythm; Disease Models, Animal; Explorato | 2006 |
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Drug Therapy | 2006 |
Purified mouse dopamine neurons thrive and function after transplantation into brain but require novel glial factors for survival in culture.
Topics: Animals; Animals, Newborn; Brain Tissue Transplantation; Cell Culture Techniques; Cells, Cultured; D | 2005 |
Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Antioxidants; Brain; Cell Survival; Corpus Striatum; Cytoprotection; Disease Models, Animal | 2006 |
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine; | 2006 |
Basal ganglia neural responses during behaviorally effective deep brain stimulation of the subthalamic nucleus in rats performing a treadmill locomotion test.
Topics: Adrenergic Agents; Animals; Basal Ganglia; Brain Mapping; Deep Brain Stimulation; Exercise Test; Fun | 2006 |
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskin | 2006 |
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antiparkinson Agents; Calcium-Calmodulin-Dependent Pr | 2006 |
Subthalamic nucleus lesioning inhibits expression and phosphorylation of c-Jun in nigral neurons in the rat's 6-OHDA model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Apoptosis; Behavior, Animal; Disease Models, Animal; Immunohistochemistr | 2006 |
Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; L | 2006 |
Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Brain; Image Processing, Computer-Assisted; Immunohist | 2006 |
The stepping test and its learning process in different degrees of unilateral striatal lesions by 6-hydroxydopamine in rats.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dose-Response Relationship, | 2006 |
Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Blotting, Western; Cyclooxygenase 1; Cyclooxygenase | 2006 |
Control of dopamine-secretion by Tet-Off system in an in vivo model of parkinsonian rat.
Topics: Animals; Antiporters; Apomorphine; Bacterial Proteins; Behavior, Animal; Cell Transplantation; Disea | 2006 |
Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, | 2006 |
KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
Topics: Animals; Cell Count; Cell Death; Cytoprotection; Disease Models, Animal; Dopamine; Laminin; Male; Ne | 2006 |
MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dose-Respons | 2006 |
Proliferation of neural precursors in the subventricular zone after chemical lesions of the nigrostriatal pathway in rat brain.
Topics: Animals; Biomarkers; Bromodeoxyuridine; Cell Movement; Cell Proliferation; Corpus Striatum; Denervat | 2006 |
Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK 1/2 map kinase pathway.
Topics: Animals; Animals, Newborn; Corpus Striatum; Disease Models, Animal; Dopamine; Enzyme Activation; MAP | 2006 |
CGP 56999A, a GABA(B) receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Denerva | 2006 |
Reduction in parvalbumin expression in the zona incerta after 6OHDA lesion in rats.
Topics: Animals; Biomarkers; Calcium; Cell Count; Disease Models, Animal; Dopamine; Down-Regulation; Immunoh | 2005 |
Erythropoietin and GDNF enhance ventral mesencephalic fiber outgrowth and capillary proliferation following neural transplantation in a rodent model of Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Capillaries; Cell Survival; Cells, Cultured; Drug Synergism; | 2006 |
Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
Topics: Amphetamine; Animals; Cell Death; Cells, Cultured; Coculture Techniques; Disease Models, Animal; Dop | 2006 |
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
Topics: Animals; Antibodies, Monoclonal; Antigens; Basal Ganglia; Biomarkers; Blood-Brain Barrier; Bromodeox | 2006 |
Oxidative stress-triggered unfolded protein response is upstream of intrinsic cell death evoked by parkinsonian mimetics.
Topics: Animals; Cell Death; Cell Line; Cell Survival; Cells, Cultured; Disease Models, Animal; Immunohistoc | 2006 |
Improvements in motor behavioral tests during deep brain stimulation of the subthalamic nucleus in rats with different degrees of unilateral parkinsonism.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Central Nervous System Stimulants; Dee | 2006 |
Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, | 2006 |
RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Camptothecin; DNA-Binding Proteins; Gene E | 2006 |
Fos immunoreactivity in some locomotor neural centres of 6OHDA-lesioned rats.
Topics: Animals; Cell Count; Immunohistochemistry; Locomotion; Male; Medial Forebrain Bundle; Mesencephalon; | 2006 |
Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease.
Topics: Adjuvants, Immunologic; Analysis of Variance; Animals; Disease Models, Animal; Freund's Adjuvant; Ma | 2006 |
Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agents; Drug Administration Schedule; gamma-Aminob | 2006 |
Dopamine stimulation via infusion in the lateral ventricle.
Topics: Animals; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Inter | 2006 |
Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease.
Topics: Age Factors; Aging; Aldehydes; Animals; Corpus Striatum; Dopamine; Male; Oxidative Stress; Oxidopami | 2007 |
Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition.
Topics: Anastrozole; Animals; Aromatase; Aromatase Inhibitors; Cell Survival; Corpus Striatum; Dopamine; Dop | 2007 |
A protocol for the differentiation of human embryonic stem cells into dopaminergic neurons using only chemically defined human additives: Studies in vitro and in vivo.
Topics: Biomarkers; Bucladesine; Cell Culture Techniques; Cell Differentiation; Cell Line; Cells, Cultured; | 2007 |
Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Functional Lat | 2007 |
Running wheel exercise enhances recovery from nigrostriatal dopamine injury without inducing neuroprotection.
Topics: Animals; Binding, Competitive; Cell Survival; Cocaine; Corpus Striatum; Cytoprotection; Dopamine; Do | 2007 |
Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat.
Topics: Animals; Dopamine; Female; Melatonin; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Dis | 2006 |
Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Ketones; Lipid Peroxidation; Male; Mesencephalon; Oxidative Stress; Oxidop | 2007 |
Transplanted human neural precursor cells migrate widely but show no lesion-specific tropism in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Cell Death; Cell Differentiation; Cell Movement; Disease Models, Animal; | 2006 |
The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Combined Modality Therapy; Corpus Striatum; | 2007 |
Increased 8-OHdG levels in the urine, serum, and substantia nigra of hemiparkinsonian rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Biomarkers; Deoxyguanosine; Disease Progression; Neurotoxins; | 2007 |
Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, In | 2006 |
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
Topics: Animals; Antioxidants; Arachidonic Acids; Benzoxazines; Cannabinoid Receptor Agonists; Cannabinoid R | 2007 |
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopam | 2007 |
Transplantation of immortalized mesencephalic progenitors (CSM14.1 cells) into the neonatal parkinsonian rat caudate putamen.
Topics: Animals; Animals, Newborn; Behavior, Animal; Cell Differentiation; Cell Line; Cell Movement; Disease | 2007 |
Unilateral 6-hydroxydopamine lesion of dopamine neurons and subchronic L-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulata.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Down-Regulation; Drug Administration Sched | 2007 |
Effect of subthalamic nucleus lesions in a 6-hydroxydopamine-induced rat parkinsonian model: behavioral and biochemical studies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dominance, Cerebral; Dopamine; Globus Pall | 2006 |
Deep brain stimulation in a rat model modulates TH, CaMKIIa and Homer1 gene expression.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Ki | 2007 |
In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD.
Topics: Adrenergic Agents; Animals; Brain; Carbon Radioisotopes; Image Processing, Computer-Assisted; Male; | 2007 |
Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Benzodiazepines; Corpus Striatum; Dop | 2007 |
Effects of desensitized nicotinic receptors on rotational behavior in a 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain; Disease Models, Animal; Dopamine Agonists; D | 2007 |
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Bicuculline; Drug Synergism; Drug Therapy, Combinatio | 2007 |
Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain; Brain Mapping; Disease Models, Animal; Dopam | 2007 |
Evaluation of four pyridine analogs to characterize 6-OHDA-induced modulation of mGluR5 function in rat brain using microPET studies.
Topics: Adrenergic Agents; Animals; Brain; Cocaine; Functional Laterality; Image Processing, Computer-Assist | 2007 |
Intracerebral co-transplantation of liposomal tacrolimus improves xenograft survival and reduces graft rejection in the hemiparkinsonian rat.
Topics: Analysis of Variance; Animals; Antigens, CD; Behavior, Animal; Cell Transplantation; Disease Models, | 2007 |
Early inhibition of TNFalpha increases 6-hydroxydopamine-induced striatal degeneration.
Topics: Animals; Immunohistochemistry; Male; Neostriatum; Nerve Degeneration; Oligodeoxyribonucleotides, Ant | 2007 |
Combination of bFGF, heparin and laminin induce the generation of dopaminergic neurons from rat neural stem cells both in vitro and in vivo.
Topics: Animals; Animals, Newborn; Brain Tissue Transplantation; Cell Differentiation; Cell Movement; Cells, | 2007 |
NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Benzothiazoles; DNA Fragmentation; Dopamine; Mal | 2007 |
Alterations in dendritic morphology of the prefrontal cortical and striatum neurons in the unilateral 6-OHDA-rat model of Parkinson's disease.
Topics: Animals; Cell Shape; Corpus Striatum; Dendrites; Dendritic Spines; Disease Models, Animal; Male; Neu | 2007 |
Repetitive vibrissae-elicited forelimb placing before and immediately after unilateral 6-hydroxydopamine improves outcome in a model of Parkinson's disease.
Topics: Animals; Conditioning, Classical; Disease Models, Animal; Exercise Therapy; Exploratory Behavior; Fo | 2007 |
Implantation of pure cultured olfactory ensheathing cells in an animal model of parkinsonism.
Topics: Animals; Brain Tissue Transplantation; Cell Differentiation; Cells, Cultured; Corpus Striatum; Dopam | 2007 |
Neural-tube-derived neuroepithelial stem cells: a new transplant resource for Parkinson's disease.
Topics: Animals; Behavior, Animal; Cell Differentiation; Cell Survival; Corpus Striatum; Embryonic Stem Cell | 2007 |
Modification of L-DOPA pharmacological activity by MAO inhibitors.
Topics: Animals; Basal Ganglia; Brain; Denervation; Dopamine; Drug Interactions; Levodopa; Monoamine Oxidase | 2007 |
Changes in the firing activity of serotonergic neurons in the dorsal raphe nucleus in a rat model of Parkinson's disease.
Topics: Action Potentials; Animals; Disease Models, Animal; Male; Neurons; Oxidopamine; Parkinsonian Disorde | 2007 |
Nicotine induces tyrosine hydroxylase plasticity in the neurodegenerating striatum.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Axons; | 2007 |
Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats.
Topics: Animals; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Electroconvulsive Therapy; M | 2007 |
The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agon | 2007 |
Differential effects on forelimb grasping behavior induced by fetal dopaminergic grafts in hemiparkinsonian rats.
Topics: Animals; Brain Tissue Transplantation; Cell Count; Disease Models, Animal; Dopamine; Female; Fetal T | 2007 |
AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease.
Topics: Adenoviridae; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Female; | 2007 |
Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats.
Topics: Animals; Cation Transport Proteins; Cell Death; Dopamine Agonists; Female; Fluorescent Antibody Tech | 2007 |
Striatal dysfunction increases basal ganglia output during motor cortex activation in parkinsonian rats.
Topics: Action Potentials; Animals; Biological Clocks; Corpus Striatum; Dopamine; Dopamine Agonists; Electri | 2007 |
Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.
Topics: Animals; Carbon Radioisotopes; Cocaine; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins | 2007 |
Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model.
Topics: Animals; Cell Death; Disease Models, Animal; Dopamine; Gene Expression Regulation; Male; Neostriatum | 2007 |
Effect of ventrolateral thalamic nucleus lesions in the unilateral 6-hydroxydopamine rat model.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Efferent Pathways; Exploratory Behavior; Fema | 2007 |
The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; Catecholamines; Disease Models, An | 2007 |
High frequency stimulation of the subthalamic nucleus improves speed of locomotion but impairs forelimb movement in Parkinsonian rats.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Electric Stimulation Therap | 2007 |
Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Topics: Animals; Benzoates; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Excitatory Amino Ac | 2007 |
Distinct changes in evoked and resting globus pallidus activity in early and late Parkinson's disease experimental models.
Topics: Action Potentials; Animals; Behavior, Animal; Brain Mapping; Disease Models, Animal; Disease Progres | 2007 |
Progressive degeneration of dopamine neurons in 6-hydroxydopamine rat model of Parkinson's disease does not involve activation of caspase-9 and caspase-3.
Topics: Adrenergic Agents; Animals; Apoptosis; Brain; Caspase 3; Caspase 9; Caspases; Dopamine; Enzyme Activ | 2008 |
Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Behavior, Animal; Electrophysiolog | 2007 |
Increased striatal mRNA and protein levels of the immunophilin FKBP-12 in experimental Parkinson's disease and identification of FKBP-12-binding proteins.
Topics: Amino Acid Sequence; Animals; Chromatography, Liquid; Corpus Striatum; Electrophoresis, Gel, Two-Dim | 2007 |
Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa.
Topics: Amino Acid Sequence; Animals; Basal Ganglia; Brain Chemistry; Dopamine; Dopamine and cAMP-Regulated | 2007 |
Pael receptor is involved in dopamine metabolism in the nigrostriatal system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2007 |
Reversible unilateral nigrostriatal pathway inhibition induced through expression of adenovirus-mediated clostridial light chain gene in the substantia nigra.
Topics: Adenoviridae; Animals; Clostridium; Disease Models, Animal; Dopamine; Male; Metalloendopeptidases; O | 2007 |
Expression of FasL and its interaction with Fas are mediated by c-Jun N-terminal kinase (JNK) pathway in 6-OHDA-induced rat model of Parkinson disease.
Topics: Animals; Apoptosis; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Fas Ligand Protein; fa | 2007 |
Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice.
Topics: Animals; Cell Count; Disease Models, Animal; Disease Progression; Dopamine; Dose-Response Relationsh | 2008 |
Effects of substance P on neuronal firing of pallidal neurons in parkinsonian rats.
Topics: Action Potentials; Adrenergic Agents; Analysis of Variance; Animals; Behavior, Animal; Compulsive Be | 2008 |
Bilateral changes in neuronal activity of the basal ganglia in the unilateral 6-hydroxydopamine rat model.
Topics: Adrenergic Agents; Animals; Basal Ganglia; Electroencephalography; Functional Laterality; Immunohist | 2008 |
Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration
Topics: Animals; Antiparkinson Agents; Cell Line; Cricetinae; Cricetulus; Humans; Naphthols; Oxidopamine; Pa | 2008 |
Antiapoptotic and trophic effects of dominant-negative forms of dual leucine zipper kinase in dopamine neurons of the substantia nigra in vivo.
Topics: Analysis of Variance; Animals; Apoptosis; Carbazoles; Dependovirus; Disease Models, Animal; Enzyme I | 2008 |
Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Dr | 2008 |
Survival and functional recovery of transplanted human dopaminergic neurons into hemiparkinsonian rats depend on the cannula size of the implantation instrument.
Topics: Animals; Brain Tissue Transplantation; Catheterization; Cell Survival; Denervation; Disease Models, | 2008 |
Specific induction of PAG608 in cranial and spinal motor neurons of L-DOPA-treated parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; DNA-Binding Prot | 2008 |
Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Chlorobenzenes; Corpus Striatum; | 2008 |
Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
Topics: Animals; Astrocytes; Biomarkers; Calcium-Binding Proteins; Corpus Striatum; Disease Models, Animal; | 2008 |
Zuckerkandl's organ improves long-term survival and function of neural stem cell derived dopaminergic neurons in Parkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromodeoxyuridine; Cell Differentiation; Coculture Techniqu | 2008 |
Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model.
Topics: Aminobutyrates; Animals; Brain; Cytoprotection; Disease Models, Animal; Drug Therapy, Combination; E | 2008 |
Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease.
Topics: Animals; Antirheumatic Agents; Disease Models, Animal; Disease Susceptibility; Dopamine; Female; Int | 2008 |
Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmission.
Topics: Analysis of Variance; Animals; Apomorphine; Brain Damage, Chronic; Disease Models, Animal; Dopamine; | 2008 |
Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Male; Maze Learning; Motor Activity; Oxidopamine; | 2008 |
In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adamantane; Amidines; Animals; Antiparkinson Agents; Basal Ganglia; | 2008 |
Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
Topics: Animals; Biomarkers; Blotting, Western; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane T | 2008 |
Preclinical models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Injections, Intra-Arterial; Injec | 2001 |
Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxi | 2007 |
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Corpus St | 2008 |
Activation of the extracellular signal-regulated kinases 1 and 2 by glial cell line-derived neurotrophic factor and its relation to neuroprotection in a mouse model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Enzyme Activation; Glial Cell Line-Derived Neurotrophic Factor; Imm | 2008 |
Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Analysis of Variance; Aniline Compo | 2008 |
Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats.
Topics: Animals; Corpus Striatum; Dose-Response Relationship, Drug; Drug Resistance; Extracellular Fluid; Gl | 2008 |
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine; Drug Evalua | 2008 |
Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS.
Topics: Adrenergic Agents; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Re | 2008 |
Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists.
Topics: Animals; Disease Models, Animal; Imidazoles; Levodopa; Ligands; Molecular Structure; Oxidopamine; Pa | 1999 |
Subchronic toluene exposure in low concentrations produces signs of reduced dysfunction in the 6-hydroxydopamine lesioned nigrostriatal dopaminergic system of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Denervation; Dopamine; Injec | 1999 |
Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment.
Topics: Animals; Corpus Striatum; Denervation; Dopamine; Drug Administration Schedule; Exploratory Behavior; | 1999 |
The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Ani | 1999 |
Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Catalepsy; Dopamine Agonists; Indoles; Macaca fascicul | 2000 |
CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury.
Topics: Animals; Behavior, Animal; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Brain Ischemia | 2000 |
Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion.
Topics: Animals; Apomorphine; Denervation; Dopamine Agonists; Dopamine Antagonists; Glutamic Acid; Haloperid | 2000 |
The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
Topics: Animals; Apomorphine; Axons; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; | 2000 |
Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease.
Topics: Animals; Axonal Transport; Disease Models, Animal; Energy Metabolism; Excitatory Postsynaptic Potent | 2000 |
Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Denervation; Dizocilpine Maleate; Functional Laterality; Glutamic Acid; Ma | 2000 |
Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.
Topics: Animals; Benzazepines; Corpus Striatum; Dependovirus; Dopamine Agonists; Female; Gene Transfer Techn | 2000 |
Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine.
Topics: Animals; Benzothiazoles; Cell Count; Cell Death; Dopamine; Dopamine Agonists; Male; Neostriatum; Ner | 2000 |
Effects of sub-chronic combined treatment with pergolide and caffeine on contralateral rotational behavior in unilateral 6-hydroxydopamine-denervated rats.
Topics: Animals; Bromocriptine; Caffeine; Denervation; Drug Administration Schedule; Drug Combinations; Drug | 2000 |
Axonal sprouting following lesions of the rat substantia nigra.
Topics: Adrenergic Agents; Animals; Axons; Carrier Proteins; Dopamine; Dopamine Plasma Membrane Transport Pr | 2000 |
Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506.
Topics: Animals; Dopamine; Functional Laterality; Immunosuppressive Agents; Male; Neostriatum; Neural Pathwa | 2000 |
Simultaneous intrastriatal and intranigral dopaminergic grafts in the parkinsonian rat model: role of the intranigral graft.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Denervation; Disease Models, Animal; Dopamine; F | 2000 |
Depletion of brain glutathione potentiates the effect of 6-hydroxydopamine in a rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Brain Chemistry; Corpus Striatum; Glutathione; Glutathione Transferase; L | 2000 |
Effects of nigrostriatal dopamine denervation on ionotropic glutamate receptors in rat caudate-putamen.
Topics: Adrenergic Agents; Animals; Caudate Nucleus; Denervation; Oxidopamine; Parkinsonian Disorders; Putam | 2000 |
Ipsilateral and contralateral subthalamic activity after unilateral dopaminergic lesion.
Topics: Action Potentials; Animals; Carrier Proteins; Denervation; Dopamine; Dopamine Plasma Membrane Transp | 2000 |
Differential expression of mRNAs of GDNF family in the striatum following 6-OHDA-induced lesion.
Topics: Animals; Dopamine; Female; Gene Expression Regulation; Glial Cell Line-Derived Neurotrophic Factor; | 2000 |
Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion.
Topics: Animals; Cell Death; Dopamine; Fluorescent Dyes; Immunohistochemistry; In Situ Nick-End Labeling; Lo | 2000 |
Expression of metallothionein-III mRNA and its regulation by levodopa in the basal ganglia of hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Levodopa; Male; Metallothionein 3; Ne | 2000 |
MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dizocilpine Maleate; Dopamine; Ex | 2000 |
Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine.
Topics: Animals; Cell Count; Disease Models, Animal; Dopamine; GAP-43 Protein; Male; Neostriatum; Nerve Dege | 2001 |
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration S | 2000 |
CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Brain; Cell Culture Techniques; Cell Dea | 2000 |
Intranigral transplantation of solid tissue ventral mesencephalon or striatal grafts induces behavioral recovery in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Brain Tissue Transplantation; Corpus S | 2001 |
IGF-I and bFGF improve dopamine neuron survival and behavioral outcome in parkinsonian rats receiving cultured human fetal tissue strands.
Topics: Abortion, Induced; Animals; Apomorphine; Brain; Brain Tissue Transplantation; Cell Survival; Cells, | 2001 |
Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence.
Topics: Amphetamine; Animals; Apomorphine; Atrophy; Axonal Transport; Corpus Striatum; Disease Models, Anima | 2001 |
Catecholamines and their metabolites in the brain and urine of rats with experimental Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catecholamines; Dihydroxyphenylalanine; Dopamine; Ep | 2000 |
Dopaminergic regulation of synaptotagmin I and IV mRNAs in hemiparkinsonian rats.
Topics: Animals; Benzazepines; Calcium-Binding Proteins; Denervation; Dopamine; Dopamine Agonists; Down-Regu | 2000 |
cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Gene Expres | 2000 |
The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.
Topics: Adrenergic Agents; Animals; Clorgyline; Corpus Striatum; Dopamine Agents; Dopamine Uptake Inhibitors | 2000 |
Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Dopamine; Enzyme Inhibitors; Glutathione; | 2001 |
Unilateral dopamine depletion increases expression of the 2A subunit of the N-methyl-D-aspartate receptor in enkephalin-positive and enkephalin-negative neurons.
Topics: Animals; Autoradiography; Corpus Striatum; Dopamine; Enkephalins; Gene Expression; In Situ Hybridiza | 2001 |
Partial, graded losses of dopamine terminals in the rat caudate-putamen: an animal model for the study of compensatory adaptation in preclinical parkinsonism.
Topics: Adrenergic Agents; Animals; Caudate Nucleus; Disease Models, Animal; Dopamine; Electric Stimulation; | 2001 |
Complex analysis of efficiency of transplantation of embryonic nerve tissue to rats with hemiparkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Tissue Transplantation; Dopamine; Fetal Tissue Transp | 2000 |
Entopeduncular lesions facilitate and thalamic lesions depress spontaneous and drug-evoked motor behavior in the hemiparkinsonian rat.
Topics: Amphetamine; Animals; Apomorphine; Denervation; Disease Models, Animal; Dopamine Agonists; Dyskinesi | 2001 |
Time-course of changes in firing rates and firing patterns of subthalamic nucleus neuronal activity after 6-OHDA-induced dopamine depletion in rats.
Topics: Action Potentials; Adrenergic Agents; Animals; Dopamine; Male; Neurons; Oxidopamine; Parkinsonian Di | 2001 |
Intrapallidal dopamine restores motor deficits induced by 6-hydroxydopamine in the rat.
Topics: Animals; Apomorphine; Benzazepines; Dopamine; Dopamine Agonists; Dopamine Antagonists; gamma-Aminobu | 2001 |
Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Electric Stimulation Therapy; Extracellular Space | 2001 |
Enhancement of sensorimotor behavioral recovery in hemiparkinsonian rats with intrastriatal, intranigral, and intrasubthalamic nucleus dopaminergic transplants.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Count; Corpus Striatum; Disease Models | 2001 |
Generation of dopaminergic neurons in the adult brain from mesencephalic precursor cells labeled with a nestin-GFP transgene.
Topics: AC133 Antigen; Animals; Animals, Genetically Modified; Antigens, CD; Brain; Brain Tissue Transplanta | 2001 |
Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain Injuries; Cells, Cultured; Dopamine; Immunophilins; Immu | 2001 |
Toxic effects of MPP(+) and MPTP in PC12 cells independent of reactive oxygen species formation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Differentia | 2001 |
Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum.
Topics: Animals; Anti-Bacterial Agents; Cell Death; Disease Models, Animal; Gliosis; Immunohistochemistry; M | 2001 |
Validity of a quantitative technique to study striatal dopaminergic neurodegeneration by in vivo microdialysis.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Chromatography, High Pressure Liquid; Dopamine; Dose-Response | 2001 |
Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions.
Topics: Amphetamine; Animals; Dizocilpine Maleate; Energy Metabolism; Excitatory Amino Acid Antagonists; Fun | 2001 |
Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dopamine Agonists; Down-Regulat | 2001 |
Role of striatal acetylcholine on dopamine D1 receptor agonist-induced turning behavior in 6-hydroxydopamine lesioned rats: a microdialysis-behavioral study.
Topics: Acetylcholine; Animals; Behavior, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug | 2001 |
Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Denervation; Dopamine; Dose-Response Relationship, Drug; Drug Adminis | 2001 |
Chronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6-OHDA dopamine-depleted (hemi-Parkinson analogue) rats.
Topics: Animals; Antiparkinson Agents; Arm; Cell Count; Drug Administration Schedule; Female; Immunohistoche | 2001 |
Involvement of GDNF in neuronal protection against 6-OHDA-induced parkinsonism following intracerebral transplantation of fetal kidney tissues in adult rats.
Topics: Age Factors; Animals; Behavior, Animal; Corpus Striatum; Dopamine; Enzyme-Linked Immunosorbent Assay | 2001 |
In vitro generation and transplantation of precursor-derived human dopamine neurons.
Topics: Animals; Brain Tissue Transplantation; Cell Culture Techniques; Cell Differentiation; Cell Survival; | 2001 |
Cultured human foetal cerebral cortex, transfected with tyrosine hydroxylase cDNA, as a source of neural transplant material.
Topics: Adrenergic Agents; Animals; Brain Tissue Transplantation; Cells, Cultured; Cerebral Cortex; Corpus S | 2001 |
A clonal line of mesencephalic progenitor cells converted to dopamine neurons by hematopoietic cytokines: a source of cells for transplantation in Parkinson's disease.
Topics: Animals; Cell Differentiation; Cells, Cultured; Clone Cells; Corpus Striatum; Cryopreservation; Cyto | 2001 |
Effect of microiontophoretic application of dopamine on subthalamic nucleus neuronal activity in normal rats and in rats with unilateral lesion of the nigrostriatal pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Apomorphine; | 2001 |
NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease.
Topics: Amphetamine; Amyloid beta-Protein Precursor; Animals; Antibodies; Caspase 3; Caspases; Cell Survival | 2001 |
Increased burst firing in substantia nigra pars reticulata neurons and enhanced response to selective D2 agonist in hemiparkinsonian rats after repeated administration of apomorphine.
Topics: Animals; Apomorphine; Dopamine Agonists; Male; MPTP Poisoning; Oxidopamine; Parkinsonian Disorders; | 2001 |
LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Isoquinolines; Levodopa; Male; Motor Activity; Oxi | 2001 |
Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment.
Topics: Animals; Apomorphine; Chromogranins; DNA, Complementary; Dopamine Agonists; Drug Administration Sche | 2001 |
Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease.
Topics: Animals; Bromocriptine; Denervation; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dru | 2001 |
The role of dopamine transporter imaging agent [99mTc]TRODAT-1 in hemi-parkinsonism rat brain.
Topics: Animals; Autoradiography; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopam | 2001 |
Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease.
Topics: Animals; Blood-Brain Barrier; Brain; Cell Count; Cell Survival; Disease Models, Animal; Dopamine; Fl | 2001 |
Prevention of neurotoxin damage of 6-OHDA to dopaminergic nigral neuron by subthalamic nucleus lesions.
Topics: Afferent Pathways; Animals; Biomarkers; Dopamine; Excitatory Amino Acid Agonists; Glutamic Acid; Kai | 2000 |
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocil | 2002 |
MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dizocilpine Maleate; Excitatory Amino Acid Antagonis | 2002 |
Bilateral overactivation of the sensorimotor cortex in the unilateral rodent model of Parkinson's disease - a functional magnetic resonance imaging study.
Topics: Animals; Basal Ganglia; Denervation; Disease Models, Animal; Functional Laterality; Magnetic Resonan | 2002 |
Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antineoplastic A | 2002 |
Activation and differentiation of endogenous neural stem cell progeny in the rat Parkinson animal model.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Dopamine; Ependyma; Epidermal Growth Factor; | 2002 |
Induction of tyrosine hydroxylase expression in rat fetal striatal precursor cells following transplantation.
Topics: Animals; Biomarkers; Brain; Brain Tissue Transplantation; Cell Communication; Cell Differentiation; | 2002 |
Morphological changes in immunopositive cells of ionotropic glutamate receptor subunits during the development of transplanted fetal ventral mesencephalic neurons.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Differentiation; Disease Models, Anima | 2002 |
Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats.
Topics: Animals; Apomorphine; Autoradiography; Behavior, Animal; Binding, Competitive; Corpus Striatum; Dise | 2002 |
A sequential intrastriatal dopaminergic graft strategy in the rodent model for Parkinson's disease: implications for graft survival and targeting.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Transplantation; Corpus Striatum; Dise | 2002 |
Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Line; Corpus Striatum; Dependovirus; Disease Models, An | 2002 |
Striatal xenotransplantation of human retinal pigment epithelial cells attached to microcarriers in hemiparkinsonian rats ameliorates behavioral deficits without provoking a host immune response.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Transplantation; Corpus Striatum; Dextrans; Dopamine; F | 2002 |
Dual SPECT of dopamine system using [99mTc]TRODAT-1 and [123I]IBZM in normal and 6-OHDA-lesioned formosan rock monkeys.
Topics: Animals; Benzamides; Brain; Dopamine; Macaca; Organotechnetium Compounds; Oxidopamine; Parkinsonian | 2002 |
Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.
Topics: Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Excitatory Amino Acid Antagonists; Kinetics; | 2002 |
Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Corpus Striatum; Cotinine; Disease Models, Animal; | 2002 |